WO2014093640A1 - Hydroxy-polmer-drug-protein conjugates - Google Patents

Hydroxy-polmer-drug-protein conjugates Download PDF

Info

Publication number
WO2014093640A1
WO2014093640A1 PCT/US2013/074703 US2013074703W WO2014093640A1 WO 2014093640 A1 WO2014093640 A1 WO 2014093640A1 US 2013074703 W US2013074703 W US 2013074703W WO 2014093640 A1 WO2014093640 A1 WO 2014093640A1
Authority
WO
WIPO (PCT)
Prior art keywords
kda
integer
polymer
pbrm
drug
Prior art date
Application number
PCT/US2013/074703
Other languages
French (fr)
Inventor
Aleksander V. YURKOVETSKIY
Original Assignee
Mersana Therapeutics,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mersana Therapeutics,Inc. filed Critical Mersana Therapeutics,Inc.
Priority to EP13814764.0A priority Critical patent/EP2931316B1/en
Priority to US14/651,640 priority patent/US9872918B2/en
Publication of WO2014093640A1 publication Critical patent/WO2014093640A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Definitions

  • One objective in the field of drug delivery systems is to deliver medications intact to specifically targeted areas of the body through a system that can stabilize the drug and control the in vivo transfer of the therapeutic agent utilizing either physiological or chemical mechanisms, or both.
  • Antibody-drug conjugates have been developed as target-specific therapeutic agents. Antibodies against various cancer cell-surface antigens have been conjugated with different cytotoxic agents that inhibit various essential cellular targets such as microtubules (maytansinoids, auristatins, taxanes: U.S. Patent Nos. 5,208,020; 5,416,064; 6,333,410;
  • the present invention relates to a protein-hydroxyl polymer-drug conjugate that is biodegradable, biocompatible and exhibits high drug load as well as strong binding to target antigen.
  • the present invention also relates to a polymeric scaffold useful to conjugate with a protein based recognition-molecule (PBRM) so as to obtain the protein-hydroxyl polymer-drug conjugate.
  • PBRM protein based recognition-molecule
  • the invention features a polymeric scaffold useful to conjugate with a PBRM.
  • the scaffold includes a linear, branched or cyclic polymer having one or more -OH
  • the polymer is a hydroxyl polymer
  • each occurrence of D is independently a therapeutic agent having a molecular weight ⁇ 5 kDa;
  • L D1 is a carbonyl-containing moiety
  • each u independently is a first linker that contains a biodegradable bond so that when the bond is broken, D is released in an active form for its intended therapeutic effect; in which each u
  • D denotes direct or indirect attachment of D to L D1 ; and each occurrence of is independently a second linker not yet connected to PBRM in which L is a moiety containing a functional group that is capable of forming a covalent bond with a functional roup of a PBRM, each u independently is an integer 0 or 1, and the ⁇ in denotes direct or indirect attachment of L p2 to L D1 , and each occurrence of the second linker is distinct from each occurrence of the first linker.
  • the polymeric scaffold can include one or more of the following features:
  • the hydroxyl polymer has a molecular weight ranging from 2 kDa to 300 kDa.
  • the polymeric carrier e.g., hydroxyl polymer
  • the polymeric carrier is not a polyacetal or a polyketal.
  • the polymeric carrier is not poly(l-hydroxymethylethylene hydroxymethyl-formal, PHF).
  • the polymeric carrier is not a polysaccharide, carbohydrate, or oligosaccharide.
  • the polymeric carrier is not a naturally-occurring polymer selected from polysaccharide, carbohydrate, and oligosaccharide.
  • the polymeric carrier is selected from hydroxyalkyl starches, polyglycerols, PEG polymers, HPMA polymers, carboxymethyl dextrans (CM dextrans), polyvinyl alcohols, poly(acrylic acid), and dendrimers, copolymers and mixtures thereof.
  • the polymeric carrier has at least four -OH groups before modification.
  • L D1 is a carbonyl-containing moiety.
  • L p2 contains a biodegradable bond.
  • the functional group of L p2 is selected from -SR P , -S-S-LG, maleimido, and halo, in which LG is a leaving group and R p is H or a sulfur protecting group.
  • the polymer of the scaffold of the invention is a linear, branched or cyclic hydroxyl polymeric carrier having a molecular weight ranging from 2 kDa to 300 kDa. (i.e., MW of the unmodified hydroxyl polymer) and the hydroxyl polymer is not a polyacetal or polyketal.
  • the polymer of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 40 kDa (e.g., about 6-20 kDa or about 8- 15 kDa).
  • the hydroxyl polymer of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about ranging from about 20 kDa to about 300 kDa. (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30-100 kDa, or about 50-100 kDa).
  • the scaffold is of Formula (Ibb):
  • n 1 to 2200
  • mi is an integer from 1 to 660
  • n 2 is an integer from 1 to 300
  • n 3 is an integer from 1 to 1 10, and
  • the sum of m, m l s m 2 and m 3 ranges from 4 to about 2200 .
  • the scaffold of (Ibb) can include one or more of the following features:
  • the hydroxyl polymeric carrier (i.e. hydroxyl polymer) in Formula (Ibb) has a molecular weight ranging from about 2 kDa to about 40 kDa
  • the sum of m, m l 5 m 2 , and m 3 ranges from about 4 to about 300 (e.g., from about 45 to about 140; or from about 60 to about 1 10)
  • m 2 is an integer from 1 to about 40
  • m 3 is an integer from 1 to about 18
  • mi is an integer from 1 to about 140 (e.g., mi being about 1-90).
  • the sum of mi and m 2 is an integer from 1 to 140.
  • the hydroxyl polymeric carrier in Formula (Ibb) has a molecular weight ranging from 20 kDa to 300 kDa
  • the sum of m, mi, n3 ⁇ 4, and m 3 ranges from about 4 to about 2200 (e.g., from about 150 to about 1100; or from about 220 to about 740)
  • m 2 is an integer from 1 to about 300
  • m 3 is an integer from 1 to about 110
  • mi is an integer from 1 to about 660 (e.g., mi being about 10-250).
  • the sum of mi and m 2 is an integer from 1 to 660.
  • the polymer of the scaffold of the invention is a hydroxyl polymer having a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 40 kDa (e.g., from about 6 kDa to about 20 kDa; or from about 8 kDa to about 15 kDa) and the hydroxyl polymeric carrier is not a polyacetal or a polyketal.
  • the polymeric carrier of the scaffold of the invention is a hydroxyl polymer having a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about ranging from about 20 kDa to about 300 kDa (e.g., from about 20 kDa to about 150 kDa; or from about 30 kDa to about 100 kDa) and the hydroxyl polymeric carrier is not a polyacetal or a polyketal.
  • a molecular weight i.e., MW of the unmodified hydroxyl polymer
  • the scaffold of Formula (Ibb) further comprises a PBRM connected to the polymeric carrier via L p .
  • One or more PBRMs are connected to one drug-carrying hydroxyl polymeric carrier.
  • the scaffold e.g., a PBRM-polymer-drug-conjugate
  • the scaffold e.g., a PBRM-polymer-drug-conjugate of Formula (Ibb) is of
  • m between ⁇ ⁇ and PBRM denotes direct or indirect attachment of PBRM to L p2 ,
  • each occurrence of PBRM independently has a molecular weight of less than 200 kDa (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa),
  • n 1 to 2200
  • ⁇ is an integer from 1 to 660
  • n 2 is an integer from 1 to 300
  • n 1 to 110
  • n 4 is an integer from 1 to 60;
  • the sum of m, mi, m 2 , m 3 and m 4 ranges from 4 to 2200.
  • the hydroxyl polymeric carrier in Formula (Ice) has a molecular weight ranging from 20 kDa to 300 kDa
  • the sum of m, mi, m 2 , m 3 , and ni 4 ranges from about 4 to about 2200 (e.g., from about 150 to about 1 100; or from about 220 to about 740)
  • m 2 is an integer from 1 to about 300
  • m 3 is an integer from 1 to about 1 10
  • m 4 is an integer from 1 to about 60
  • ⁇ is an integer from 1 to about 660 (e.g., mi being about 10-330 or about 15-100).
  • the sum of mi and m 2 is an integer from 1 to 660, and the sum of m 3 and m 4 is an integer from 1 to 110.
  • one or more drug-carrying polymeric carriers are connected to one PBRM.
  • the scaffold (e.g., a PBRM-polymer-drug conjugate) comprises a PBRM with a molecular weight of greater than 40 kDa (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa) and one or more D-carrying polymeric carriers connected to the PBRM, in which each of the D-carrying polymeric carrier independently is of Formula (Idd):
  • a PBRM with a molecular weight of greater than 40 kDa e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about
  • terminal in attached to L denotes direct or indirect attachment of L to PBRM such that the D-carrying polymeric carrier is connected to the PBRM,
  • n 1 to 300
  • mi is an integer from 1 to 140
  • n 2 is an integer from 1 to 40
  • n 3 is an integer from 0 to 18,
  • n 4 is an integer from 1 to 10;
  • the sum of m, mj, m 2 , m 3 , and m 4 ranges from 4 to 300; provided that the total number of L P2 attached to the PBRM is 10 or less.
  • the hydroxyl polymeric carrier in Formula (Idd) has a molecular weight ranging from 2 kDa to 40 kDa
  • the sum of m, mi, m 2 , m 3 , and m 4 ranges from about 4 to about 300 (e.g., from about 45 to about 140; or from about 60 to about 1 10)
  • m 2 is an integer from 1 to about 40
  • m 3 is an integer from 1 to about 18
  • m 4 is an integer from 1 to about 10
  • mj is an integer from 1 to about 140 (e.g., mi being about 10-330 or about 15-100).
  • the sum of mi and m 2 is an integer from 1 to 140
  • the sum of m 3 and m 4 is an integer from 1 to 18.
  • the ratio of D to PBRM is between 5: 1 and 40:1 (e.g., 30: 1,
  • Each occurrence of D independently is selected from vinca alkaloids
  • calicheamicins SN38, non-natural camptothecins, pyrrolobenodiazepines, auristatins, tubulysins, duocarmycins, kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogs or prodrugs thereof.
  • scaffold of Formula (Ibb), (Ice) or (Idd) include those described herein where applicable.
  • the invention features a hydroxyl polymeric scaffold useful to conjugate with a PBRM.
  • the scaffold comprises a polymeric carrier (e.g., a polymer), one or more -L D -D connected to the polymeric carrier, and one or more L p connected to the polymeric carrier which is suitable for connecting a PBRM to the polymeric carrier but not yet connected to the PBRM, wherein:
  • each occurrence of D is independently a therapeutic agent having a molecular weight ⁇ 5 kDa;
  • the polymeric carrier is a hydroxyl polymer containing one or more -OH and the polymer is not a polyacetal or a polyketal,
  • each occurrence of L D is independently a first linker having the structure:
  • L D! is a carbonyl-containing moiety
  • each L pl is independently a moiety containing a functional group that is capable of forming a covalent bond with a functional group of a PBRM but not yet connected to PBRM.
  • the hydroxyl polymeric scaffold can include one or more of the features of scaffold of Formula (Ibb), (Ice) or (Idd) described herein where applicable and one or more of the following features:
  • each of R L1 independently is absent, alkyl, heteroalkyl, cycloalkyl, or heterocycloalkyl;
  • each occurrence of R 2 , R 3 , and R 4 independently is hydrogen or an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety, or each occurrence of -NR 2 - or -NR 2 NR 3 - is a heterocycloalkyl moiety;
  • each L D1 at least one of X D , Y D , Z D , and Q D is not absent.
  • R 1K is a leaving group (e.g., halide or RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety)
  • R 1A is a sulfur protecting group
  • ring A is cycloalkyl or heterocycloalkyl
  • R ,J is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
  • Each R 1A independently is , , or , in which r is 1 or 2 and each of R sl , R s2 , and R s3 is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
  • Each L p is independently a linker having the structure:
  • ⁇ denotes direct or indirect attachment of L to L .
  • Each when connected to PBRM, independently is -X P -M P1 -
  • each occurrence of R 2 , R 3 , and R 4 independently is hydrogen or an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety, or each occurrence of-NR 2 - or -NR 2 NR 3 - is a heterocycloalkyl moiety;
  • the functional group of L or L P2 is selected from -SR P , -S-S-LG, maleimido, and halo, in which LG is a leaving group and R p is H or a sulfur protecting group.
  • L P1 or L P2 contains a biodegradable bond.
  • R L! and R L2 are absent.
  • the oxygen atom of the hydroxyl polymeric earner R and R is connected to the oxygen atom from the one or more -OH groups of the polymeric carrier.
  • Each of M D1 and M P1 independently is C ]-6 alkyl or Ci -6 heteroalkyl.
  • Each of M D2 , M D3 , M D4 , M P2 , M P3 , and M p4 independently is absent, C ]-6 alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, or a combination thereof.
  • the invention encompasses a conjugate comprising a polymeric carrier, one or more -L D -D connected to the polymeric carrier, and a protein based recognition-molecule (PBRM) connected to the polymeric carrier via L P , wherein:
  • each occurrence of D is independently a therapeutic agent (e.g., a drug) having a molecular weight ⁇ 5 kDa;
  • the polymeric carrier is a hydroxyl polymeric carrier and the polymeric carrier is not a polyacetal or polyketal,
  • each of R L1 and R L2 independently is absent, alkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl;
  • each L D at least one of X D , Y D , Z D , and Q D is not absent, and for each L p , at least one of X p , Y p , Z p , and Q p is not absent.
  • the conjugate can include one or more of the features of scaffold of Formula
  • the polymeric carrier can be a linear, branched or cyclic hydroxyl polymer, and the hydroxyl polymer is not a polyacetal or polyketal.
  • the oxygen atoms of the hydroxyl polymeric carrier that R L1 and R L2 are connected to are each an oxygen atom from the one or more -OH groups of the polymeric carrier.
  • M D1 is not absent when X D is absent.
  • M P1 is not absent when X p is absent.
  • R 1A is a sulfur protecting group
  • each of ring A and B independently, is cycloalkyl or heterocycloaikyl
  • R w is an aliphatic, heteroaliphatic, carbocyclic or heterocycloaikyl moiety
  • ring D is heterocycloaikyl
  • R 1J is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or
  • R 1K is a leaving group (e.g., halide or RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloaikyl moiety).
  • R is a leaving group (e.g., halide or RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety), R 1A is a sulfur protecting group, and ring A is cycloalkyl or heterocycloalkyl, and R 1J is hydrogen, an aliphatic, heteroaliphatic,
  • R is a leaving group (e.g., halide or RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety)
  • R 1A is a sulfur protecting group
  • ring A is cycloalkyl or heterocycloalkyl
  • R 1J is hydrogen, an aliphatic, heteroaliphatic
  • R 1A is
  • R sl , R s2 , and R s is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
  • Ring A can be C 3-8 cycloalkyl or 5-19 membered heterocycloalkyl.
  • Ring A can be [0063]
  • Ring B can be C 3-8 cycloalkyl or 3-12 membered heterocycloalkyl.
  • Ring D can be piperazinyl or piperidinyl.
  • Each of R sl , R s2 , and R s3 can be hydrogen or Ci -6 alkyl.
  • Each PBRM independently can be a peptide, a peptide mimetic, an antibody, or an antibody fragment.
  • Each of M D1 and M P1 independently can be C 1-6 alkyl or C 1-6 heteroalkyl.
  • Each of M D2 , M D3 , M D4 , M p2 , M P3 , and M p4 independently can be absent, Ci -6 alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, or a combination thereof.
  • each L at most one of M and M can have one of the following
  • q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3.
  • M p2 and M p3 can have one of the following structures:
  • q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3.
  • ring A or B independently is cycloalkyl or heterocycloalkyl;
  • R is an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety;
  • R 1J is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety; and
  • ring D is heterocycloalkyl.
  • each of-M p2 -Z p -, -Z P -M P3 -, -Z P -M P2 -, and -M p3 -Z p - can have one of the following structures:
  • ring A is cycloalkyl or heterocycloalkyl and R is hydrogen, an aliphatic
  • heteroaliphatic, carbocyclic, or heterocycloalkyl moiety is heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
  • Each of X D and X p independently can be absent.
  • Each of X D and X p independently can be O or NH.
  • Each of Y D and Y p independently can be -S-S-, -OCO-, -COO-, -CONH-, -NHCO
  • Each of Q D and Q p independently can be absent, -S-S-, -OCO-, -COO-, -CONH- -NHCO-, -OCONHNH- or -NHNHCOO-.
  • this invention features a conjugate of Formula (I):
  • each D can be the same or different moiety and each PBRM can be the same or different moiety.
  • the ratio between n 2 and i1 ⁇ 4 can be greater than 1 :1 , and up to 200: 1 (e.g., up to
  • 100: 1) e.g., between 2: 1 and 40:1 ; between 5:1 and 20: 1 ; between 10:1 and 50: 1 , between 25: 1 and 50: 1 , or between 30: 1 and 50: 1.
  • the ratio between n 2 and i1 ⁇ 4 can be about 50: 1 , 40: 1 , 30: 1 , 25 : 1 , 20: 1 , 10: 1 , 5: 1 or
  • the ratio between D and PBRM can be greater than 1 : 1, and up to
  • PBRM PBRM
  • PBRM PBRM
  • IgG and IgM full length antibodies
  • antibody fragments such as Fabs, scFv, scFvFc, camelids, Fab2, and the like, small proteins, and peptides.
  • the ratio between D and PBRM can be about 50: 1 , 40: 1 , 30: 1 ,
  • the ratio between D and PBRM can be about 25: 1 , 20:1,
  • the invention provides compositions comprising the conjugates, methods for their preparation, and methods of use thereof in the treatment of various disorders, including, but not limited to cancer.
  • the invention also features a drug-polymer conjugate (e.g., therapeutic agent- polymer conjugate) that is similar to the protein-polymer-drug conjugate described above except that drug-polymer conjugate does not contain a PBRM.
  • the polymer-drug conjugate may comprise a plurality of drug moieties in which each D can be the same or different.
  • r is 0 in the conjugate of Formula (I).
  • the invention also features a protein-polymer conjugate (e.g., PBRM-polymer conjugate) that is similar to the protein-polymer-drug conjugate described above except that protein-polymer conjugate does not contain a drug.
  • the protein-polymer conjugate may comprise a plurality of protein moieties in which each PBRM can be the same or different.
  • n 2 is 0 in the conjugate of Formula (I).
  • the target cancer can be anal, astrocytoma, leukemia, lymphoma, head and neck, liver, testicular, cervical, sarcoma, hemangioma, esophageal, eye, laryngeal, mouth, mesothelioma, skin, myeloma, oral, rectal, throat, bladder, breast, uterus, ovary, prostate, lung, colon, pancreas, renal, or gastric cancer.
  • the invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a polymeric scaffold or conjugate described herein and a pharmaceutically acceptable carrier.
  • the invention relates to a method of diagnosing a disorder in a subject suspected of having the disorder.
  • the method comprises administering an effective amount of the conjugate described herein to the subject suspected of having the disorder or performing an assay to detect a target antigen/receptor in a sample from the subject so as to determine whether the subject expresses target antigen or receptor.
  • the method comprises providing a polymer that is substituted with one or more
  • hydroxyl polymer As used herein the terms "hydroxyl polymer,” “polymer,” “hydroxyl polymeric carrier,” and “polymeric carrier” are used interchangeably when the polymer or polymeric carrier contains one or more -OH groups (i.e., hydroxyl of an alcohol or a carboxylic acid) connected to the polymer or polymeric carrier. As used herein the above terms do not include a polyacetal or polyketal. “Alcohol” refers to primary, secondary (sec), and tertiary (tert) alcohols. [0094] As used herein, the terms “polymeric scaffold” or simply “scaffold” and
  • conjugates are used interchangeably when the scaffold comprises one or more PBRM and one or more D molecules.
  • the scaffold comprises a linear, branched or cyclic hydroxyl polymeric carrier and the hydroxyl polymeric carrier is not a polyacetal or polyketal.
  • the appending groups of the polymeric carrier described herein such as the appending groups containing D, PBRM, L D1 , and L P2 , etc., are randomly distributed along the polymer backbone.
  • the protein-polymer-drug conjugates or the polymeric scaffolds described herein greatly enhances the bioavailability of the drugs to be delivered and/or enhances the bioavailability of the protein attached to the polymeric carrier.
  • Another advantage of the present invention is that the efficacy of the protein-polymer- drug conjugates described herein increases or at least remains substantially the same with increases in the drug load of the conjugates.
  • Yet another advantage of the present invention is that the protein-polymer conjugates via thiol conjugation to the cysteine moiety of the protein exhibits substantially improved stability.
  • Figure 1 is a group of tables listing "m" values per hydroxyl polymeric scaffold and polymer/PBRM ratios of embodiments of the invention.
  • Table 1 relates to PBRM-drug polymer conjugates in which the PBRMs have a molecular weight of 40 kDa or greater (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa) and one or more hydroxyl polymer-Drug scaffolds are attached to one PBRM.
  • 40 kDa or greater e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200
  • Table 2 relates to PBRM- drug polymer conjugates in which the PBRMs have a molecular weight of 200 kDa or less (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa), and one or more PBRMs are attached to one hydroxyl polymer-Drug scaffold, wherein the polymer is a linear, branched or cyclic hydroxyl polymer.
  • the PBRMs have a molecular weight of 200 kDa or less (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa)
  • the polymer is a linear, branched or cyclic hydroxyl polymer.
  • the present invention provides novel protein-polymer-drug conjugates, polymeric scaffolds for making the conjugates, synthetic methods for making the conjugates or polymeric scaffolds, pharmaceutical compositions containing them and various uses of the conjugates.
  • the present invention also provides novel polymer-drug conjugates, synthetic methods for making the conjugates, pharmaceutical compositions containing them and various uses of the conjugates.
  • the present invention further provides novel drug derivatives, synthetic methods for making the derivatives, pharmaceutical compositions containing them and various uses of the drug derivatives.
  • “about X” includes a range of values that are ⁇ 20%, ⁇ 10%, ⁇ 5%, ⁇ 2%, ⁇ 1%, ⁇ 0.5%, ⁇ 0.2%, or ⁇ 0.1% of X, where X is a numerical value.
  • the term “about” refers to a range of values which are 5% more or less than the specified value.
  • the term “about” refers to a range of values which are 2% more or less than the specified value.
  • the term “about” refers to a range of values which are 1% more or less than the specified value.
  • protecting group means that a particular functional moiety, e.g. , O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound.
  • a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group must be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the other functional groups; the protecting group forms an easily separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction.
  • oxygen, sulfur, nitrogen and carbon protecting groups may be utilized.
  • oxygen protecting groups include, but are not limited to methyl ethers, substituted methyl ethers (e.g., MOM (methoxymethyl ether), MTM (methylthiomethyl ether), BOM (benzyloxymethyl ether), and PMBM (p- methoxybenzyloxymethyl ether)), substituted ethyl ethers, substituted benzyl ethers, silyl ethers (e.g., TMS (trimethylsilyl ether), TES (triethylsilyl ether), TIPS (triisopropylsilyl ether), TBDMS (t-butyldimethylsilyl ether), tribenzyl silyl ether, and TBDPS (t-butyldiphenyl silyl ether), esters (e.g., formate, acetate, benzoate (Bz), trifluoroacetate, and dichloroacetate), carbon
  • nitrogen protecting groups are utilized.
  • Nitrogen protecting groups as well as protection and deprotection methods are known in the art.
  • Nitrogen protecting groups include, but are not limited to, carbamates (including methyl, ethyl and substituted ethyl carbamates (e.g., Troc), amides, cyclic imide derivatives, N- Alkyl and N-Aryl amines, imine derivatives, and enamine derivatives.
  • certain exemplary sulfur protecting groups may be utilized.
  • the sulfur protecting groups include, but are not limited to those oxygen protecting group describe above as well as aliphatic carboxylic acid (e.g., acrylic acid), maleimide, vinyl sulfonyl, and optionally substituted maleic acid.
  • Certain other exemplary protecting groups are detailed herein, however, it will be appreciated that the present invention is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the present invention. Additionally, a variety of protecting groups are described in "Protective Groups in Organic Synthesis" Third Ed. Greene, T.W. and Wuts, P.G., Eds., John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.
  • Leaving group refers to a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage. Leaving groups can be anions or neutral molecules. Leaving groups include, but are not limited to halides such as CF, Br ⁇ , and ⁇ , sulfonate esters, such as ⁇ ra-toluenesulfonate ("tosylate", TsO ⁇ ), and RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety. [00109] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
  • Antibody refers to a full-length antibody or functional fragment of an antibody comprising an immunoglobulin.
  • a “functional fragment” it is meant a sufficient portion of the immunoglobulin or antibody is provided that the moiety effectively binds or complexes with the cell surface molecule for its target cell population.
  • An immunoglobulin may be purified, generated recombinantly, generated synthetically, or combinations thereof, using techniques known to those of skill in the art. While immunoglobulins within or derived from IgG antibodies are particularly well-suited for use in this invention, immunoglobulins from any of the classes or subclasses may be selected, e.g., IgG, IgA, IgM, IgD and IgE. Suitably, the immunoglobulin is_of the class IgG including but not limited to IgG subclasses (IgGl, 2, 3 and 4) or class IgM which is able to specifically bind to a specific epitope on an antigen. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact
  • Antibodies may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, camelized single domain antibodies, intracellular antibodies (“intrabodies”), recombinant antibodies, anti-idiotypic antibodies, domain antibodies, linear antibody, multispecific antibody, antibody fragments, such as, Fv, Fab, F(ab) 2 , F(ab) 3 , Fab', Fab'-SH, F(ab') 2 , single chain variable fragment antibodies (scFv), tandem/bis-scFv, Fc, pFc', scFvFc, (or scFv-Fc), disulfide Fv (dsfv), bispecific antibodies (bc-scFv) such as BiTE antibodies; camelid antibodies, resurfaced antibodies, humanized antibodies, fully human antibodies, single-domain antibody (sdAb, also known as NANOBODY®), chimeric antibodies, chimeric antibodies comprising at least one human constant region, dual immunoglobulins
  • Antibody fragment refers to at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region.
  • antibody refers to both the full-length antibody and antibody fragments unless otherwise specified.
  • PBRM Protein based recognition-molecule
  • PBRM protein based recognition-molecule
  • examples of PBRMs include but are not limited to, antibodies (e.g., Trastuzumab, Cetuximab, Rituximab, Bevacizumab, Epratuzumab,
  • Veltuzumab Labetuzumab, B7-H4, B7-H3, CA125, CD33, CXCR2, EGFR, FGFR1, FGFR2, FGFR3, FGFR4, HER2, PD-L1 and anti-5T4) or peptides (LHRH receptor targeting peptides, EC-1 peptide), lipocalins, such as, for example, anticalins, proteins such as, for example, interferons, lymphokines, growth factors, colony stimulating factors, and the like, peptides or peptide mimics, and the like.
  • lipocalins such as, for example, anticalins, proteins such as, for example, interferons, lymphokines, growth factors, colony stimulating factors, and the like, peptides or peptide mimics, and the like.
  • the protein based recognition molecule in addition to targeting the modified polymer conjugate to a specific cell, tissue or location, may also have certain therapeutic effect such as antiproliferative (cytostatic and/or cytotoxic) activity against a target cell or pathway.
  • the protein based recognition molecule comprises or may be engineered to comprise at least one chemically reactive group such as, -CO OH, primary amine, secondary amine -NHR, -SH, or a chemically reactive amino acid moiety or side chains such as, for example, tyrosine, histidine, cysteine, or lysine.
  • a PBRM may be a ligand (LG) or targeting moiety which specifically binds or complexes with a cell surface molecule, such as a cell surface receptor or antigen, for a given target cell population. Following specific binding or complexing of the ligand with its receptor, the cell is permissive for uptake of the ligand or ligand-drug-conjugate, which is then internalized into the cell.
  • a ligand that "specifically binds or complexes with” or "targets" a cell surface molecule preferentially associates with a cell surface molecule via intermolecular forces.
  • the ligand can preferentially associate with the cell surface molecule with a d of less than about 50 nM, less than about 5 nM, or less than 500 pM.
  • a d of less than about 50 nM, less than about 5 nM, or less than 500 pM.
  • Techniques for measuring binding affinity of a ligand to a cell surface molecule are well-known; for example, one suitable technique, is termed surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • the ligand is used for targeting and has no detectable therapeutic effect as separate from the drug which it delivers.
  • the ligand functions both as a targeting moiety and as a therapeutic or immunomodulatory agent (e.g., to enhance the activity of the active drug or prodrug).
  • Biocompatible as used herein is intended to describe compounds that exert minimal destructive or host response effects while in contact with body fluids or living cells or tissues.
  • a biocompatible group refers to an aliphatic, cycloalkyl, heteroaliphatic, heterocycloalkyl, aryl, or heteroaryl moiety, which falls within the definition of the term biocompatible, as defined above and herein.
  • Biocompatibility as used herein, is also taken to mean that the compounds exhibit minimal interactions with recognition proteins, e.g., naturally occurring antibodies, cell proteins, cells and other components of biological systems, unless such interactions are specifically desirable.
  • substances and functional groups specifically intended to cause the above minimal interactions are considered to be biocompatible.
  • compounds intended to be cytotoxic such as, e.g., antineoplastic agents
  • compounds are "biocompatible" if their addition to normal cells in vitro, at concentrations similar to the intended systemic in vivo concentrations, results in less than or equal to 1% cell death during the time equivalent to the half-life of the compound in vivo ⁇ e.g. , the period of time required for 50% of the compound administered in vivo to be eliminated/cleared), and their administration in vivo induces minimal and medically acceptable inflammation, foreign body reaction, immunotoxicity, chemical toxicity and/or other such adverse effects.
  • the term "normal cells” refers to cells that are not intended to be destroyed or otherwise significantly affected by the compound being tested.
  • Biodegradable As used herein, “biodegradable” polymers are polymers that are susceptible to biological processing in vivo. As used herein, “biodegradable” compounds or moieties are those that, when taken up by cells, can be broken down by the lysosomal or other chemical machinery or by hydrolysis into components that the cells can either reuse or dispose of without significant toxic effect on the cells.
  • biocleavable as used herein has the same meaning of “biodegradable”. The degradation fragments preferably induce little or no organ or cell overload or pathological processes caused by such overload or other adverse effects in vivo. Examples of biodegradation processes include enzymatic and non-enzymatic hydrolysis, oxidation and reduction.
  • Suitable conditions for non-enzymatic hydrolysis of the biodegradable protein-polymer-drug conjugates (or their components, e.g., the biodegradable polymeric carrier and the linkers between the carrier and the antibody or the drug molecule) described herein, for example, include exposure of the biodegradable conjugates to water at a temperature and a pH of lysosomal intracellular compartment.
  • Biodegradation of some protein-polymer-drug conjugates can also be enhanced extracellularly, e.g., in low pH regions of the animal body, e.g., an inflamed area, in the close vicinity of activated macrophages or other cells releasing degradation facilitating factors.
  • the effective size of the polymer carrier at pH ⁇ 7.5 does not detectably change over 1 to 7 days, and remains within 50% of the original polymer size for at least several weeks.
  • the polymer carrier preferably detectably degrades over 1 to 5 days, and is completely transformed into low molecular weight fragments within a two-week to several- month time frame. Polymer integrity in such tests can be measured, for example, by size exclusion HPLC. Although faster degradation may be in some cases preferable, in general it may be more desirable that the polymer degrades in cells with the rate that does not exceed the rate of metabolization or excretion of polymer fragments by the cells. In preferred embodiments, the polymers and polymer biodegradation byproducts are biocompatible.
  • Bioavailability refers to the systemic availability (i.e., blood/plasma levels) of a given amount of drug or compound administered to a subject. Bioavailability is an absolute term that indicates measurement of both the time (rate) and total amount (extent) of drug or compound that reaches the general circulation from an administered dosage form.
  • Hydrophilic The term “hydrophilic” as it relates to substituents, e.g., on the polymer monomeric units does not essentially differ from the common meaning of this term in the art, and denotes chemical moieties which contain ionizable, polar, or polarizable atoms, or which otherwise may be solvated by water molecules.
  • a hydrophilic group refers to an aliphatic, cycloalkyl, heteroaliphatic, heterocycloalkyl, aryl or heteroaryl moiety, which falls within the definition of the term hydrophilic, as defined above.
  • hydrophilic organic moieties which are suitable include, without limitation, aliphatic or heteroaliphatic groups comprising a chain of atoms in a range of between about one and twelve atoms, hydroxyl, hydroxyalkyl, amine, carboxyl, amide, carboxylic ester, thioester, aldehyde, nitryl, isonitryl, nitroso, hydroxylamine, mercaptoalkyl, heterocycle, carbamates, carboxylic acids and their salts, sulfonic acids and their salts, sulfonic acid esters, phosphoric acids and their salts, phosphate esters, polyglycol ethers, polyamines, polycarboxylates, polyesters and polythioesters.
  • hydrophilic substituents comprise a carboxyl group (COOH), an aldehyde group (CHO), a ketone group (COCi -4 alkyl), a methylol (CH 2 OH) or a glycol (for example, CHOH-CH 2 OH or CH-(CH 2 OH) 2 ), NH 2 , F, cyano, S0 3 H, PO 3 H, and the like.
  • hydrophilic as it relates to the polymers of the invention generally does not differ from usage of this term in the art, and denotes polymers comprising hydrophilic functional groups as defined above.
  • hydrophilic polymer is a water- soluble polymer. Hydrophilicity of the polymer can be directly measured through determination of hydration energy, or determined through investigation between two liquid phases, or by chromatography on solid phases with known hydrophobicity, such as, for example, C4 or CI 8.
  • Polymeric Carrier refers to a hydroxyl polymer or a modified hydroxyl polymer, which is suitable for covalently attaching to or can be covalently attached to one or more drug molecules with a designated linker and/or one or more PBRMs with a designated linker.
  • the unmodified hydroxyl polymer of the invention has four or more -OH groups connected to the polymer.
  • the "-OH group” as used herein refers to either an alcohol hydroxyl group or a hydroxyl group from a carboxylic acid, unless otherwise specified.
  • Hydroxyalkyl starch refers to a starch derivative that has been substituted by one or more hydroxyalkyl groups.
  • the hydroxyalkyl group comprises 2 to 4 carbon atoms, such as, for example, hydroxyethyl starch, hydroxypropyl starch and
  • the hydroxyalkyl starch is hydroxyethyl starch (HES).
  • Polyglycerol refers to a polymer obtained by condensation of glycerol or by anionic ring-opening polymerization of glycidol (l,2-epoxy-3-hydroxypropane). Polyglycerol polymers additionally can be modified by derivatization with other hydroxy containing compounds, such as, for example, polyethylene glycol (PEG) or carboxylic acids (such as, for example, propionic acid) to improve their polyglycerol solubility or biocompatibility.
  • PEG polyethylene glycol
  • carboxylic acids such as, for example, propionic acid
  • PEG polymer refers to a linear or branched polyethyleneglycol (PEG) derivative (including but not limited to, multi-arm PEG) comprising terminal one or more hydroxy or carboxy groups.
  • Branched PEGs are typically prepared by pegylation of hydroxy, carboxy or amino groups of multi-functional scaffolds selected from, but not limited to, pentaerithritol; sorbitol; amino-(trioxymethyl methane); di-, tri- and tetra-glycerol, and polyglycerol; poly(alpha-glutamic acid), poly(gamma-glutamic acid), poly(glutamic acid) dendrimers, and polylysine, polyethyleneimine.
  • HPMA polymer refers to polymers of N-(2-hydroxypropyl)methacylamide (HPMA) and/or HPMA copolymers with methacrylic acid and/or methacrylic acid ester or amide derivatives obtained by free radical polymerization thereof.
  • CM dextran refers to a dextran derivative that has up to 20% by weight of carboxymethyl groups.
  • the dextrans are typically prepared by carboxymethylation of dextran hydroxyl groups with bromoacetic acid in basic conditions, and are available as CM dextran sodium salt.
  • Polyvinyl alcohol refers to the polymers prepared by exhaustive or partial hydrolysis of polyvinyl acetate. Polyvinyl alcohol additionally can be modified by derivatization with other hydroxy containing compounds such as, for example, polyethylene glycol (PEG) or carboxylic acids (such as, for example, propionic acid) to improve their polyglycerol solubility or biocompatibility.
  • PEG polyethylene glycol
  • carboxylic acids such as, for example, propionic acid
  • Poly(acrylic acid) refers to homopolymers of acrylic acid, and/or polyacrylic acid obtained by partially crosslinked via a suitable crosslinking agent selected from but not limited to allyl ether, pentaerythritol allyl ether, sucrose allyl ether.
  • Dendrimers refers to neutral or acidic polyhydroxylated dendrimers comprising a surface layer of hydroxyl or carboxy functional groups resulting in polyglycerol dendrimers, poly(alpha-glutamic acid) and poly(gamma-polyglutamic acid) dendrimers, poly(2,2-bis(hydroxymethyl)propionic acid) dendrimers, poly(glycerol succinate) dendrimers, carboxylated and/or hydroxylated polylysine dendrimers, carboxylated and/or hydroxylated polyaminoamide (PAMAM) dendrimers, surface glycosylated dendrimers and combinations thereof.
  • PAMAM hydroxylated polyaminoamide
  • physiological conditions The phrase “physiological conditions”, as used herein, relates to the range of chemical (e.g., pH, ionic strength) and biochemical (e.g., enzyme concentrations) conditions likely to be encountered in the extracellular fluids of living tissues.
  • chemical e.g., pH, ionic strength
  • biochemical e.g., enzyme concentrations
  • the physiological pH ranges from about 7.0 to 7.4. Circulating blood plasma and normal interstitial liquid represent typical examples of normal physiological conditions.
  • Polysaccharide "carbohydrate” or “oligosaccharide”: The terms
  • polysaccharide “carbohydrate”, or “oligosaccharide” are known in the art and refer, generally, to substances having chemical formula (CH 2 0) n , where generally n>2, and their derivatives.
  • Carbohydrates are polyhydroxyaldehydes or polyhydroxyketones, or change to such substances on simple chemical transformations, such as hydrolysis, oxidation or reduction.
  • carbohydrates are present in the form of cyclic acetals or ketals (such as, glucose or fructose). These cyclic units (monosaccharides) may be connected to each other to form molecules with few (oligosaccharides) or several (polysaccharides) monosaccharide units. Often, carbohydrates with well-defined number, types and positioning of monosaccharide units are called
  • polysaccharides consisting of mixtures of molecules of variable numbers and/or positioning of monosaccharide units
  • polysaccharides consisting of mixtures of molecules of variable numbers and/or positioning of monosaccharide units.
  • polysaccharide consisting of mixtures of molecules of variable numbers and/or positioning of monosaccharide units
  • polysaccharides consisting of mixtures of molecules of variable numbers and/or positioning of monosaccharide units.
  • polysaccharide may include natural sugars (e.g., glucose, fructose, galactose, mannose, arabinose, ribose, and xylose) and/or derivatives of naturally occurring sugars (e.g., - fluororibose, 2'-deoxyribose, and hexose).
  • natural sugars e.g., glucose, fructose, galactose, mannose, arabinose, ribose, and xylose
  • drug refers to a compound which is biologically active and provides a desired physiological effect following administration to a subject in need thereof (e.g., an active pharmaceutical ingredient).
  • Prodrug refers to a precursor of an active drug, that is, a compound that can be transformed to an active drug. Typically such a prodrug is subject to processing in vivo, which converts the drug to a physiologically active form. In some instances, a prodrug may itself have a desired physiologic effect. A desired physiologic effect may be, e.g., therapeutic, cytotoxic, immunomodulatory, or the like.
  • Cytotoxic means toxic to cells or a selected cell population (e.g., cancer cells). The toxic effect may result in cell death and/or lysis. In certain instances, the toxic effect may be a sublethal destructive effect on the cell, e.g., slowing or arresting cell growth. In order to achieve a cytotoxic effect, the drug or prodrug may be selected from a group consisting of a DNA damaging agent, a microtubule disrupting agent, or a cytotoxic protein or polypeptide, amongst others.
  • Cytostatic As used herein the term “cytostatic” refers to a drug or other compound which inhibits or stops cell growth and/or multiplication.
  • Small molecule As used herein, the term “small molecule” refers to molecules, whether naturally-occurring or artificially created (e.g. , via chemical synthesis) that have a relatively low molecular weight. Preferred small molecules are biologically active in that they produce a local or systemic effect in animals, preferably mammals, more preferably humans. In certain preferred embodiments, the small molecule is a drug and the small molecule is referred to as “drug molecule” or “drug” or "therapeutic agent”.
  • the drug molecule has MW less than or equal to about 5 kDa. In other embodiments, the drug molecule has MW less than or equal to about 1.5 kDa.
  • the drug molecule is selected from vinca alkaloids, auristatins, tubulysins, duocarmycins, kinase inhibitors, MEK inhibitors, KSP inhibitors, calicheamicins, SN38, pyrrolobenodiazepines, and analogs thereof.
  • the drug is one that has already been deemed safe and effective for use by an appropriate governmental agency or body, e.g., the FDA. For example, drugs for human use listed by the FDA under 21 C.F.R.
  • Classes of drug molecules that can be used in the practice of the present invention include, but are not limited to, anti-cancer substances, radionuclides, vitamins, anti-AIDS substances, antibiotics, immunosuppressants, anti- viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal anti-inflammatory agents, anti-angiogenic factors, anti -secretory factors, anticoagulants and
  • prostaglandins are also drugs and such large molecules may be used in the conjugates and other constructs described herein.
  • suitable large molecules include, e.g., amino acid based molecules.
  • Amino acid based molecules may encompass, e.g., peptides, polypeptides, enzymes, antibodies, immunoglobulins, or functional fragments thereof, among others.
  • the drug may have a chemically reactive group such as, for example, -COOH, primary amine, secondary amine -NHR, -OH, -SH, -C(0)H, -C(0)R, -C(0)NHR 2b , C(S)OH, -S(0) 2 OR 2b , -P(0) 2 OR 2b , - CN, -NC or -ONO, in which R is an aliphatic, heteroaliphatic, carbocyclic or heterocycloalkyl moiety and R 2b is a hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety.
  • a chemically reactive group such as, for example, -COOH, primary amine, secondary amine -NHR, -OH, -SH, -C(0)H, -C(0)R, -C(0)NHR 2b , C(S)OH, -S(0) 2 OR 2b , -P(0) 2 OR 2b , - CN
  • drug derivative or “modified drug” or the like as used herein, refers to a compound that comprises the drug molecule intended to be delivered by the conjugate of the invention and a functional group capable of attaching the drug molecule to the polymeric carrier.
  • active form refers to a form of a compound that exhibits intended pharmaceutical efficacy in vivo or in vitro.
  • the active form can be the drug itself or its derivatives, which exhibit the intended therapeutic properties.
  • the release of the drug from the conjugate can be achieved by cleavage of a biodegradable bond of the linker which attaches the drug to the polymeric carrier.
  • the active drug derivatives accordingly can comprise a portion of the linker.
  • Diagnostic label refers to an atom, group of atoms, moiety or functional group, a nanocrystal, or other discrete element of a composition of matter, that can be detected in vivo or ex vivo using analytical methods known in the art. When associated with a conjugate of the present invention, such diagnostic labels permit the monitoring of the conjugate in vivo. Alternatively or additionally, constructs and
  • compositions that include diagnostic labels can be used to monitor biological functions or structures.
  • diagnostic labels include, without limitation, labels that can be used in medical diagnostic procedures, such as, radioactive isotopes (radionuclides) for gamma scintigraphy and Positron Emission Tomography (PET), contrast agents for Magnetic Resonance Imaging (MRI) (for example paramagnetic atoms and superparamagnetic nanocrystals), contrast agents for computed tomography and other X-ray-based imaging methods, agents for ultrasound- based diagnostic methods (sonography), agents for neutron activation (e.g., boron, gadolinium), fluorophores for various optical procedures, and, in general moieties which can emit, reflect, absorb, scatter or otherwise affect electromagnetic fields or waves (e.g., gamma-rays, X-rays, radiowaves, microwaves, light), particles (e.g., alpha particles, electrons, positrons, neutrons, protons) or other forms of radiation, e
  • aliphatic in general, includes both saturated and unsaturated, straight chain ⁇ i.e., unbranched) or branched aliphatic hydrocarbons, which are optionally substituted with one or more functional groups.
  • aliphatic is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl moieties.
  • alkyl includes straight and branched alkyl groups.
  • lower alkyl is used to indicate those alkyl groups (substituted, unsubstituted, branched or unbranched) having about 1 -6 carbon atoms.
  • Substituted alkyl refers to alkyl groups that are substituted with one or more functional groups. Substituents include, but are not limited to, any of the substituents mentioned below, i.e. , the substituents recited below resulting in the formation of a stable compound.
  • alkenyl the term alkenyl denotes a monovalent group derived from a hydrocarbon moiety having at least one carbon-carbon double bond by the removal of a single hydrogen atom.
  • substituted alkenyl groups are substituted with one or more functional groups. Substituents include, but are not limited to, any of the substituents mentioned below, i.e., the substituents recited below resulting in the formation of a stable compound.
  • Alkenyl groups include, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l -yl, and the like.
  • alkynyl the term alkynyl as used herein refers to a monovalent group derived from a hydrocarbon having at least one carbon-carbon triple bond by the removal of a single hydrogen atom.
  • Substituted alkenyl groups are substituted with one or more functional groups. Substituents include, but are not limited to, any of the substituents mentioned below, i.e. , the substituents recited below resulting in the formation of a stable compound.
  • alkynyl groups include ethynyl, 2-propynyl (propargyl), 1 -propynyl, and the like.
  • the alkyl, alkenyl and alkynyl groups employed in the invention contain about 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-8 aliphatic carbon atoms.
  • the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-4 carbon atoms.
  • Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- pentyl, sec-pentyl, isopentyl, tert-pentyl, n-hexyl, sec-hexyl, moieties and the like, which again, may bear one or more substituents.
  • Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, and the like.
  • Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like.
  • Alkylene as used herein, the term alkylene by itself or part of another term refers to a saturated, branched or straight chain having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
  • Alkylene radicals include, but are not limited to, methylene, 1 ,2, ethylene, 1 ,3-propyl, and the like.
  • Suitable alkylenes include, but are not limited to methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, ocytylene, nonylene, decalene, and the like.
  • Cycloalkylene similarly refers to bivalent cycloalkyl.
  • Cycloalkylene radicals include, but are not limited to, 1 ,1-cyclopentylene, 1,2-cyclopentylene, 1,1-cyclobutylene, 1,3- cyclobutylene, etc.
  • Heteroaliphatic refers to aliphatic moieties in which one or more carbon atoms in the main chain have been substituted with a heteroatom.
  • a heteroaliphatic group refers to an aliphatic chain which contains one or more oxygen, sulfur, nitrogen, phosphorus or silicon atoms, e.g. , in place of carbon atoms.
  • Heteroaliphatic moieties may be branched or linear unbranched.
  • heteroaliphatic moieties are substituted ("substituted heteroaliphatic") by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; heteroaliphatic; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;
  • Cycloalkyl refers to a saturated or unsaturated nonaromatic hydrocarbon mono-or multi-ring system having 3 to 30 carbon atoms (e.g., C 3 -C 10 ).
  • Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloheptynyl, adamantyl, and the like.
  • Heterocycloalkyl refers to a saturated or unsaturated
  • heterocycloalkyl refers to a non-aromatic 5-, 6-, 7- or 8- membered ring or a polycyclic group, including, but not limited to a bi- or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5 -membered ring has 0 to 2 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocycloalkyl; rings may be fused to an aryl or heteroaryl
  • heterocycloalkyl groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, tetrahydrothienyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1,2,3, 6-tetrahy drop yridinyl, tetrahydro-2H-pyranyl, 3,6- dihydro-2H-pyranyl, morpholinyl, and the like.
  • Aryl refers to groups with aromaticity, including “conjugated,” or multicyclic systems with at least one aromatic ring and do not contain any heteroatom in the ring structure. Examples include phenyl, benzyl, 1 ,2,3,4-tetrahydronaphthalenyl, etc.
  • Heteroaryl refers to aryl groups, as defined above, except having from one to four heteroatoms in the ring structure, and may also be referred to as “aryl heterocycles” or “heteroaromatics.”
  • heteroaryl is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 1 1- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g. ⁇ , 2, 3, 4, 5, or 6 heteroatoms,
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or other substituents, as defined).
  • heteroaryl examples include pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, tetrazolyl, pyridazinyl, quinazolinyl, dihydroquinazolyl, and tetrahydroquinazolyl and the like.
  • aryl and heteroaryl include multicyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
  • multicyclic aryl and heteroaryl groups e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran,
  • Carbocycle or “carbocyclic moiety” as used herein, is intended to include any stable monocyclic, bicyclic or tricyclic ring having the specified number of carbons, any of which may be saturated, unsaturated, or aromatic.
  • Carbocycle includes cycloalkyl and aryl.
  • a C 3 -Q carbocycle is intended to include a monocyclic, bicyclic or tricyclic ring having 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13 or 14 carbon atoms.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, fluorenyl, phenyl, naphthyl, indanyl, adamantyl and tetrahydronaphthyl.
  • Bridged rings are also included in the definition of carbocycle, including, for example,
  • a bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms.
  • bridge rings are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge. Fused (e.g., naphthyl, tetrahydronaphthyl) and spiro rings are also included.
  • Heterocycle or “heterocyclic moiety” as used herein, includes any ring structure (saturated, unsaturated, or aromatic) which contains at least one ring heteroatom (e.g. , N, O or S). Heterocycle includes heterocycloalkyl and heteroaryl. Examples of heterocycles include, but are not limited to, morpholine, pyrrolidine, tetrahydrothiophene, piperidine, piperazine and tetrahydrofuran.
  • heterocyclic groups include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3-6]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl,
  • the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring (or the carbocyclic or heterocyclic group) can be substituted at one or more ring positions (e.g., the ring-forming carbon or heteroatom such as N) with such substituents as described above, for example, aliphatic; heteroaliphatic; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; alkylaryl;
  • alkylheteroaryl alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio;
  • alkoxy refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom (“alkoxy")-
  • alkoxy oxygen atom
  • the alkyl group contains about 1-20 aliphatic carbon atoms.
  • the alkyl group contains about 1-10 aliphatic carbon atoms.
  • the alkyl group contains about 1-8 aliphatic carbon atoms.
  • the alkyl group contains about 1 -6 aliphatic carbon atoms.
  • the alkyl group contains about 1-4 aliphatic carbon atoms.
  • alkoxy groups include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert- butoxy, neopentoxy and n-hexoxy.
  • aryloxy refers to an aryl group, as defined herein, attached to the parent molecular moiety through an oxygen atom.
  • aryloxy groups include but are not limited to phenoxy and napthyloxy.
  • heteroaryloxy refers to a heteroaryl group, as defined herein, attached to the parent molecular moiety through an oxygen atom.
  • heteroaryloxy groups include but are not limited to, quinolyloxy and
  • amine refers to a group having the structure -N(R) 2 wherein each occurrence of R is independently hydrogen, or an aliphatic or heteroaliphatic moiety, or the R groups, taken together, may form a heterocyclic moiety.
  • an amine group can be charged (protonized) or quarternized, e.g., -HN + (R) 2 or -N + (R) 3 .
  • alkylamino refers to a group having the structure -NHR' wherein R' is alkyl, as defined herein.
  • aminoalkyl refers to a group having the structure NH 2 R'-, wherein R' is alkyl, as defined herein.
  • the alkyl group contains about 1-20 aliphatic carbon atoms.
  • the alkyl group contains about 1-10 aliphatic carbon atoms.
  • the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-8 aliphatic carbon atoms.
  • the alkyl group contains about 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains about 1-4 aliphatic carbon atoms.
  • alkylamino include, but are not limited to, methylamino, ethylamino, iso-propylamino and the like.
  • Alkylthio (or “thioalkyl”) means an alkyl group as defined herein with the indicated number of carbon atoms attached through a sulfur atom.
  • C 1-6 alkylthio is intended to include C], C 2 , C 3 , C 4 , C 5 , and C 6 alkylthio groups.
  • Ci -8 alkylthio is intended to include C l s C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , and C 8 alkylthio groups.
  • the thioalkyl groups can be substituted with groups such as alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, amino (including alkylamino, dialkylamino, arylamino, diarylamino and
  • alkylarylamino examples include alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl alkylaryl, or an aryl or heteroaryl moieties.
  • Thiocarbonyl or “thiocarboxy” includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.
  • Thioether includes moieties which contain a sulfur atom bonded to two carbon atoms or heteroatoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls and alkthioalkynyls. The term "alkthioalkyls" include moieties with an alkyl, alkenyl or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group.
  • alkthioalkenyls refers to moieties wherein an alkyl, alkenyl or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkenyl group
  • alkthioalkynyls refers to moieties wherein an alkyl, alkenyl or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.
  • Arylthio (or “thioaryl”) means an aryl group as defined herein with the indicated number of carbon atoms attached through a sulfur atom.
  • Carboxylic acid refers to a compound comprising a group of formula -C0 2 H.
  • Dicarboxylic acid refers to a compound comprising two groups of formula - C0 2 H.
  • Halo, halide and halogen refer to an atom selected from fluorine, chlorine, bromine, and iodine.
  • methylol refers to an alcohol group of the structure -CH 2 OH.
  • hydroxyalkyl refers to an alkyl group, as defined above, bearing at least one OH group.
  • mercaptoalkyl refers to an alkyl group, as defined above, bearing at least one SH group.
  • acyl includes moieties that contain the acyl radical (-C(O)-) or a carbonyl group.
  • “Substituted acyl” includes acyl groups where one or more of the hydrogen atoms are replaced by, for example, alkyl groups, alkynyl groups, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including
  • Hydrocarbon refers to any chemical group comprising hydrogen and carbon.
  • the hydrocarbon may be substituted or unsubstituted.
  • the hydrocarbon may be unsaturated, saturated, branched, unbranched, cyclic, polycyclic, or heterocyclic.
  • Illustrative hydrocarbons include, for example, methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, allyl, vinyl, n-butyl, tert-butyl, ethynyl, cyclohexyl, methoxy, diethylamino, heterocycloalkyl, aryl, heteroaryl, thioalkyl, and the like. As would be known to one skilled in this art, all valencies must be satisfied in making any substitutions.
  • Alkylaryl refers to an aryl group substituted with one or more alkyl groups ⁇ e.g., methylphenyl).
  • Alkylarylamino refers to -N R G4 R G5 , wherein R G4 is alkyl, as defined herein, and R G5 is an aryl, as defined herein, or at least one of R G4 and R G5 is an alkylaryl as defined herein.
  • substituted refers to the replacement of a hydrogen radical in a given structure with the radical of a specified substituent. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • substituted is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
  • Heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.
  • substituents include, but are not limited to aliphatic; heteroaliphatic; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy;
  • Animal refers to humans as well as non- human animals, at any stage of development, including, for example, mammals, birds, reptiles, amphibians, fish, worms and single cells. Cell cultures and live tissue samples are considered to be pluralities of animals.
  • the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig).
  • An animal may be a transgenic animal or a human clone.
  • subject encompasses animals.
  • “Efficient amount” In general, as it refers to an active agent or drug delivery device, the term “efficient amount” refers to the amount necessary to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the efficient amount of an agent or device may vary depending on such factors as the desired biological endpoint, the agent to be delivered, the composition of the encapsulating matrix, the target tissue, etc. For example, the efficient amount of microparticles containing an antigen to be delivered to immunize an individual is the amount that results in an immune response sufficient to prevent infection with an organism having the administered antigen.
  • Natural amino acid refers to any one of the common, naturally occurring L-amino acids found in naturally occurring proteins: glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (He), lysine (Lys), arginine (Arg), histidine (His), proline (Pro), serine (Ser), threonine (Thr), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Tip), aspartic acid (Asp), glutamic acid (Glu), asparagine (Asn), glutamine (Gin), cysteine (Cys) and methionine (Met).
  • Unnatural amino acid refers to any amino acid which is not a natural amino acid. This includes, for example, amino acids that comprise ⁇ -, ⁇ -, ⁇ -, D-, L- amino acyl residues. More generally, the unnatural amino acid comprises a residue of the general formula wherein the side chain R is other than the amino acid side chains occurring in nature. Exemplary unnatural amino acids, include, but are not limited to, sarcosine (N-methylglycine) , citrulline (cit), homocitrulline, ⁇ -ureidoalanine, thiocitrulline,
  • amino acyl More generally, the term amino acyl, as used herein, encompasses natural amino acid and unnatural amino acids.
  • Polyamide refers to homo- or hetero- polymers of natural amino acid and unnatural amino acids.
  • Illustrative homo-polymers include, but are not limited to, poly-lysine, poly-arginine, poly-y-glutaric acid, and the like.
  • Illustrative hetero- polymers include, but are not limited to, polymers comprising peptides fragments selected from peptidases, lysozymes, metalloproteinases, and the like.
  • PEF poly(l -hydroxymethylethylene hydroxymethyl-formal).
  • polymer unit As used herein, the terms "polymer unit”, “monomeric unit”, “monomer”, “monomer unit”, “unit” all refer to a repeatable structural unit in a polymer.
  • molecular weight or “MW” of a polymer or polymeric carrier/scaffold or polymer conjugates refers to the weight average molecular weight unless otherwise specified.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • isotopes of carbon include C-13 and C-14.
  • the present invention is intended to include all isomers of the compound, which refers to and includes, optical isomers, and tautomeric isomers, where optical isomers include enantiomers and diastereomers, chiral isomers and non-chiral isomers, and the optical isomers include isolated optical isomers as well as mixtures of optical isomers including racemic and non-racemic mixtures; where an isomer may be in isolated form or in a mixture with one or more other isomers.
  • the conjugates of the invention find use in biomedical applications, such as drug delivery and tissue engineering, and the polymeric carriers of the conjugates are biocompatible and biodegradable.
  • the polymeric carrier is a soluble hydroxyl polymer, in the form of, e.g., a nanoparticle, gel, liposome, micelle, suture, or an implant, etc.
  • the carrier is a fully synthetic, semi-synthetic or naturally-occurring polymer.
  • the carrier is hydrophilic.
  • the carriers used in the present invention are biodegradable biocompatible polymers having at least four -OH groups connected to the polymer wherein the hydroxyl polymer of the invention is not a polyacetal or a polyketal.
  • the four or more -OH groups are the hydroxyl groups of four or more - COOH groups connected to the polymer.
  • the four or more -OH groups are the alcohol hydroxyl groups (i.e., not those of-COOH groups) connected to the polymer.
  • the four or more -OH groups are a combination of alcohol hydroxyl groups and hydroxyl groups of-COOH.
  • the properties (e.g. , solubility, bioadhesivity and hydrophilicity) of biodegradable biocompatible polymer conjugates can be modified by subsequent substitution of additional hydrophilic or hydrophobic groups.
  • the conjugates of this invention are hydrophilic, hydrolysable and comprise drug molecules (e.g. , vinca alkaloids or derivatives, non-natural camptothecin compounds or derivatives, auristatins, tubulysins, duocarmycins, PI3 kinases, MEK inhibitors, KSP inhibitors, calicheamicins, SN38, non-natural camptothecins, pyrrolobenodiazepines and analogs or prodrugs thereof) and antibodies (e.g., Trastuzumab, Cetuximab, Rituximab, Bevacizumab, Epratuzumab, Veltuzumab, Labetuzumab, B7-H4, B7-H3, CA125, CD33, CXCR2, EGFR, FGFR1 , FGFR2, FGFR3, FGFR4, HER2, PD-L1 and anti-5T4) or peptides (LHRH receptor targeting peptides (
  • carriers suitable for practicing the present invention are polyals having at least one acetal/ketal oxygen atom in each monomer unit positioned within the main chain.
  • biodegradable biocompatible hydroxyl polymer carriers, used for preparation of polymer conjugates of the invention are any -OH group-containing polymer known in the art except polyacetals and polyketals, such as, for example, hydroxyalkyl starches, polyglycerols, PEG polymers, HPMA polymers, carboxymethyl dextrans (CM dextran), polyvinyl alcohols, poly(acrylic acid), dendrimers and products of their oxidation,
  • the polymeric carrier is a hydrophilic biodegradable polymer selected from the group consisting of hydroxyalkyl starches, polyglycerols, PEG polymers, HPMA polymers, carboxymethyl dextrans (CM dextran), polyvinyl alcohols, poly(acrylic acid), dendrimers, and derivatives thereof.
  • the unmodified hydroxyl polymers having -OH groups connected to the polymer backbone are of Formula (III):
  • the molar fraction, n, of unmodified polymer units is the molar fraction available to promote biocompatibility, solubility and increase half-life, based on the total number of polymer units in the modified polymer.
  • the molar fraction n may be the minimal fraction of unmodified monomer polymer units needed to provide biocompatibility, solubility, stability, or a particular half-life, or can be some larger fraction.
  • the most desirable degree of cytotoxicity is substantially none, i.e., the modified polymer is substantially inert to the subject. However, as is understood by those of ordinary skill in the art, some degree of cytotoxicity can be tolerated depending on the severity of disease or symptom being treated, the efficacy of the treatment, the type and degree of immune response, and like considerations.
  • biodegradable biocompatible hydroxyl polymers suitable for practicing the present invention have a molecular weight of between about 0.5 and about 300 kDa.
  • the biodegradable biocompatible hydroxyl polymers have a molecular weight of between about 1 and about 300 kDa (e.g., between about 1 and about 200 kDa, between about 2 and about 300 kDa, between about 2 and about 200 kDa, between about 5 and about 100 kDa, between about 10 and about 70 kDa, between about 20 and about 50 kDa, between about 20 and about 300 kDa, between about 40 and about 150 kDa, between about 50 and about 100 kDa, between about 2 and about 40 kDa, between about 6 and about 20 kDa, or between about 8 and about 15 kDa).
  • the biodegradable biocompatible hydroxyl polymers suitable for practicing the present invention are modified before conjugating with a drug or a PBRM.
  • the therapeutic agent is a small molecule having a molecular weight preferably ⁇ about 5 kDa, more preferably ⁇ about 4 kDa, more preferably ⁇ about 3 kDa, most preferably ⁇ about 1.5 kDa or ⁇ about 1 kDa.
  • the therapeutic agent has an IC 5 o of about less than 1 nM.
  • the therapeutic agent has an IC 5 o of about greater than 1 nM, for example, the therapeutic agent has an IC 5 o of about 1 to 50 nM.
  • Some therapeutic agents having an IC 5 o of greater than about 1 nM are unsuitable for conjugation with a PBRM using art-recognized conjugation techniques.
  • such therapeutic agents have a potency that is insufficient for use in targeted PBRM-drug conjugates using conventional techniques as sufficient copies of the drug (i.e., more than 8) cannot be conjugated using art-recognized techniques without resulting in diminished pharmacokinetic and physiochemical properties of the conjugate.
  • sufficiently high loadings of these less potent drugs can be achieved using the conjugation strategies described herein thereby resulting in high loadings of the therapeutic agent while maintaining the desirable pharmacokinetic and physiochemical properties.
  • the invention also relates to a PBRM-drug conjugate which includes a PBRM, hydroxyl polymer and at least eight therapeutic agent moieties, wherein the therapeutic agent has an IC 5 o of greater than about 1 nM.
  • about 0.1 to about 25 % monomers comprise a therapeutic agent, more preferably about 0.5 to about 20%, more preferably about 1 to about 15%, and even more preferably about 2 to about 10%.
  • the small molecule therapeutic agents used in this invention e.g.,
  • antiproliferative (cytotoxic and cytostatic) agents capable of being linked to a polymer carrier) include cytotoxic compounds (e.g., broad spectrum), angiogenesis inhibitors, cell cycle progression inhibitors, PBK/m-TOR/AKT pathway inhibitors, MAPK signaling pathway inhibitors, kinase inhibitors, protein chaperones inhibitors, HDAC inhibitors, PARP inhibitors, Wnt/Hedgehog signaling pathway inhibitors and RNA polymerase inhibitors.
  • Broad spectrum cytotoxins include, but are not limited to, DNA-binding or alkylating drugs, microtubule stabilizing and destabilizing agents, platinum compounds, and topoisomerase I inhibitors.
  • Exemplary DNA-binding or alkylating drugs include, CC-1065 and its analogs, anthracyclines (doxorubicin, epirubicin, idarubicin, daunorubicin) and its analogs, alkylating agents, such as calicheamicins, dactinomycines, mitromycines, pyrrolobenzodiazepines, and the like.
  • anthracyclines doxorubicin, epirubicin, idarubicin, daunorubicin
  • alkylating agents such as calicheamicins, dactinomycines, mitromycines, pyrrolobenzodiazepines, and the like.
  • Exemplary CC-1065 analogs include duocarmycin SA, duocarmycin A, duocarmycin CI , duocarmycin C2, duocarmycin Bl, duocarmycin B2, duocarmycin D, DU-86, KW-2189, adozelesin, bizelesin, carzelesin, seco-adozelesin, related analogs and prodrug forms, examples of which are described in U.S. Patent Nos. 5,475,092; 5,595,499; 5,846,545;
  • Doxorubicin and its analogs include those described in U.S. Patent No. 6,630,579.
  • Calicheamicins include those described in U.S. Patent Nos. 5,714,586 and 5,739,1 16.
  • Duocarmycins include those described in U.S. Patent
  • microtubule stabilizing and destabilizing agents include taxane compounds, such as paclitaxel, docetaxel, tesetaxel and carbazitaxel; maytansinoids, auristatins and analogs thereof, tubulysin A and B derivatives, vinca alkaloid derivatives, epothilones and cryptophycins.
  • Exemplary maytansinoids or maytansinoid analogs include maytansinol and maytansinol analogs, maytansine or DM-1 and DM-4 are those described in U.S. Patent Nos. 5,208,020; 5,416,064; 6,333.410; 6,441 ,163; 6,716,821 ; RE39,151 and 7,276,497.
  • the cytotoxic agent is a maytansinoid, another group of anti-tubulin agents (ImmunoGen, Inc.; see also Chari et al., 1992, Cancer Res. 52: 127-131), maytansinoids or maytansinoid analogs.
  • suitable maytansinoids include maytansinol and
  • maytansinol analogs Suitable maytansinoids are disclosed in U.S. Patent Nos. 4,424,219;
  • Exemplary auristatins include auristatin E (also known as a derivative of dolastatin-10), auristatin EB (AEB), auristatin EFP (AEFP), mono methyl auristatin E (MMAE), monomethyl auristatin F (MMAF), auristatin F, auristatin F phenylenediamine (AFP), auristatin F HPA and dolastatin.
  • auristatin E also known as a derivative of dolastatin-10
  • AEB auristatin E
  • AEFP auristatin EFP
  • MMAE mono methyl auristatin E
  • MMAF monomethyl auristatin F
  • AFP auristatin F HPA and dolastatin
  • Suitable auristatins are also described in U.S. Publication Nos.
  • Exemplary tubulysin compounds include compounds described in U.S. Patent Nos. 7,816,377; 7,776,814; 7,754,885; U.S. Publication Nos. 2011/0021568; 2010/004784; 2010/0048490; 2010/00240701 ; 2008/0176958; and PCT Application Nos.
  • WO 98/13375 WO 2004/005269; WO 2008/138561; WO 2009/002993; WO 2009/055562; WO 2009/012958; WO 2009/026177; WO 2009/134279; WO 2010/033733; WO 2010/034724; WO 201 1/017249; WO 201 1/057805; the disclosures of which are incorporated by reference herein in their entirety.
  • Exemplary vinca alkaloids include vincristine, vinblastine, vindesine, and navelbine (vinorelbine).
  • Suitable Vinca alkaloids that can be used in the present invention are also disclosed in U.S. Publication Nos. 2002/0103136 and 2010/0305149, and in U.S. Patent No. 7,303,749 Bl , the disclosures of which are incorporated herein by reference in their entirety.
  • Exemplary epothilone compounds include epothilone A, B, C, D, E and F, and derivatives thereof. Suitable epothilone compounds and derivatives thereof are described, for example, in U.S. Patent Nos.
  • Exemplary platinum compounds include cisplatin (PLATINOL®), carboplatin
  • Exemplary topoisomerase I inhibitors include camptothecin, camptothecin, derivatives, camptothecin analogs and non- natural camptothecins, such as, for example, CPT-1 1 (irinotecan), SN-38, topotecan, 9-aminocamptothecin, rubitecan, gimatecan, karenitecin, silatecan, lurtotecan, exatecan, diflomotecan, belotecan, lurtotecan and S39625.
  • Other camptothecin compounds that can be used in the present invention include those described in, for example, J. Med. Chem., 29:2358-2363 (1986); J. Med. Chem., 23:554 (1980); J. Med. Chem., 30: 1774 (1987).
  • Angiogenesis inhibitors include, but are not limited, MetAP2 inhibitors, VEGF inhibitors, PIGF inhibitors, VGFR inhibitors, PDGFR inhibitors, MetAP2 inhibitors.
  • Exemplary VGFR and PDGFR inhibitors include sorafenib (Nexavar), sunitinib (Sutent) and vatalanib.
  • Exemplary MetAP2 inhibitors include fumagillol analogs, meaning any compound that includes the fumagillin core structure, including fumagillamine, that inhibits the ability of MetAP-2 to remove NH 2 -terminal methionines from proteins as described in Rodeschini et al., J. Org.
  • Exemplary cell cycle progression inhibitors include CDK inhibitors such as, for example, BMS-387032 and PD0332991 ; Rho-kinase inhibitors such as, for example
  • GSK429286 checkpoint kinase inhibitors such as, for example, AZD7762; aurora kinase inhibitors such as, for example, AZD1 152, MLN8054 and MLN8237; PLK inhibitors such as, for example, BI 2536, BI6727 (Volasertib), GSK461364, ON-01910 (Estybon); and KSP inhibitors such as, for example, SB 743921 , SB 715992 (ispinesib), MK-0731 , AZD8477, AZ3146 and ARRY-520.
  • checkpoint kinase inhibitors such as, for example, AZD7762
  • aurora kinase inhibitors such as, for example, AZD1 152, MLN8054 and MLN8237
  • PLK inhibitors such as, for example, BI 2536, BI6727 (Volasertib), GSK461364, ON-01910 (Estybon
  • Exemplary PI3K/m-TOR/AKT signaling pathway inhibitors include phosphoinositide 3-kinase (PI3K) inhibitors, GSK-3 inhibitors, ATM inhibitors, DNA-PK inhibitors and PDK-1 inhibitors.
  • PI3K phosphoinositide 3-kinase
  • Exemplary PI3 kinases are disclosed in U.S. Patent No. 6,608,053, and include BEZ235, BGT226, BKM120, CAL101, CAL263, demethoxyviridin, GDC-0941 , GSK615, IC87114, LY294002, Palomid 529, perifosine, PF-04691502, PX-866, SAR245408,
  • Exemplary AKT inhibitors include, but are not limited to AT7867.
  • Exemplary MAPK signaling pathway inhibitors include MEK, Ras, JNK, B-Raf and p38 MAPK inhibitors.
  • Exemplary MEK inhibitors are disclosed in U.S. Patent No. 7,517,994 and include GDC-0973, GSK1 120212, MSC1936369B, AS703026, R05126766 and R04987655, PD0325901, AZD6244, AZD 8330 and GDC-0973.
  • Exemplary B-raf inhibitors include CDC-0879, PLX-4032, and SB590885.
  • Exemplary B p38 MAPK inhibitors include BIRB 796, LY2228820 and SB 202190.
  • RTK Receptor tyrosine kinases
  • Exemplary inhibitors of ErbB2 receptor include but not limited to AEE788 (NVP-AEE 788), BIBW2992, (Afatinib), Lapatinib, Erlotinib (Tarceva), and Gefitinib (Iressa).
  • multitargeted kinase inhibitors include AP24534 (Ponatinib) that targets FGFR, FLT-3, VEGFR-PDGFR and Bcr-Abl receptors; ABT-869 (Linifanib) that targets FLT-3 and VEGFR- PDGFR receptors; AZD2171 that targets VEGFR-PDGFR, Flt-1 and VEGF receptors; CHR-258 (Dovitinib) that targets VEGFR-PDGFR, FGFR, Flt-3, and c-Kit receptors; Sunitinib (Sutent) that targets VEGFR, PDGFR, KIT, FLT-3 and CSF-IR; Sorafenib (Nexavar) and Vatalanib that target VEGFR, PDGFR as well as intracellular serine/threonine kinases in the Raf/Mek/Erk pathway.
  • Exemplary protein chaperon inhibitors include HSP90 inhibitors.
  • Exemplary amino acids include HSP90 inhibitors.
  • HSP90 inhibitors include 17AAG derivatives, BIIB021, BIIB028, SNX-5422, NVP-AUY-922 and KW-2478.
  • HDAC inhibitors include Belinostat (PXD101), CUDC-101,
  • Droxinostat ITF2357 (Givinostat, Gavinostat), JNJ-26481585, LAQ824 (NVP-LAQ824, Dacinostat), LBH-589 (Panobinostat), MCI 568, MGCD0103 (Mocetinostat), MS-275
  • Exemplary PARP inhibitors include iniparib (BSI 201 ), olaparib (AZD-2281 ),
  • ABT-888 (Veliparib), AG014699, CEP 9722, MK 4827, KU-0059436 (AZD2281), LT-673, 3- aminobenzamide, A-966492, and AZD2461.
  • Exemplary Wnt/Hedgehog signaling pathway inhibitors include vismodegib (RG3616/GDC-0449), cyclopamine (1 1-deoxojervine) (Hedgehog pathway inhibitors) and XAV-939 (Wnt pathway inhibitor)
  • Exemplary RNA polymerase inhibitors include amatoxins.
  • Exemplary amatoxins include a- amanitins, ⁇ - amanitins, ⁇ - amanitins, ⁇ -amanitins, amanullin, amanullic acid, amaninamide, amanin, and proamanullin.
  • the drug of the invention is a non-natural camptothecin compound, vinca alkaloid, kinase inhibitor (e.g., PI3 kinase inhibitor (GDC-0941 and PI-103)), MEK inhibitor, KSP inhibitor, RNA polymerase inhibitor, PARP inhibitor, docetaxel, paclitaxel, doxorubicin, duocarmycin, tubulysin, auristatin, dolastatin, calicheamicins, SN38,
  • kinase inhibitor e.g., PI3 kinase inhibitor (GDC-0941 and PI-103)
  • MEK inhibitor e.g., PI3 kinase inhibitor (GDC-0941 and PI-103)
  • KSP inhibitor e.g., PI3 kinase inhibitor (GDC-0941 and PI-103)
  • MEK inhibitor e.g., PI3 kinase inhibitor (GDC-0941 and PI-103)
  • the drug is a derivative of SN-38, vindesine, vinblastine, PI-103, AZD 8330, auristatin E, auristatin F, a duocarmycin compound, tubulysin compound, or ARRY-520.
  • the drug used in the invention is a combination of two or more drugs, such as, for example, PI3 kinases and MEK inhibitors; broad spectrum cytotoxic compounds and platinum compounds; PARP inhibitors and platinum compounds; broad spectrum cytotoxic compounds and PARP inhibitors.
  • the drug used in the invention is auristatin F- hydroxypropylamide-L-alanine.
  • Vinca alkaloid is a compound of Formula (V):
  • Ri 4 is hydrogen, -C(0)-Ci -3 alkyl or -C(0)-chloro substituted C 1-3 alkyl;
  • Ri5 is hydrogen, -CH 3 or -CHO
  • Rig is hydrogen, and either R] 6 or Ri 7 is ethyl and the other is hydroxyl;
  • Ri 7 and Rig are taken together with the carbon to which they are attached to form an oxiran ring, Ri 6 is ethyl;
  • Ri9 is hydrogen, OH, amino group, alkyl amino or -[C(R 2 oR 2 i)] a -R22;
  • each of R 20 and R 2] independently is hydrogen, Ci -6 alkyl, C 6- i 0 aryl, hydroxylated C 6- i 0 aryl, polyhydroxylated C 6- i 0 aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3-8 cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NH 2 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d -(0 CH 2 -CH 2 ) f -N(H)(R 23 ) or -Rg 2 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, Ci_ 6 alkyl, C 6- i 0 aryl, C 3-8 cycloalkyl, -COOH, or -COO-C, -6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R77 is hydrogen or X 2 and NR77 form a nitrogen containing heterocyclic moiety
  • R 82 is -NH or oxygen
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • Vinca alkaloids are described in, e.g., US 2010/0305149 and US 2002/0103136.
  • Vinca alkaloid of Formula (V) is a compound of Formula
  • R40 is hydrogen, -OH, -NH 2 , or any of the following structures:
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3.
  • R 0 is
  • R40 is
  • the compound of Formula (VI) is a compound of Formula (Via) or (VIb):
  • the non-natural camptothecin is a compound of Formula
  • R 24 is -H, -CI, -F, -OH or alkyl; or R 24 and R 25 , may be taken together to form an optionally substituted five- or six-membered ring;
  • R 29 is -NH 2 , -R 28 -Cj -6 alkyl-R 22 , 5 to 12-membered heterocycloalkyl, R 28 -C 5 -j 2 heterocycloalkyl-Ci -6 alkyl-R 22 or -R 28 -C[ -6 alkyl-C 6 -i 2 aryl-Ci -6 alkyl-R 22 ; or R 29 is R 47 as defined herein;
  • R 26 is -H, -CH 2 -N(CH 3 ) 2 , NH 2 , or N0 2 ;
  • R 27 is ethyl, N-methyl piperidine, cycloalkyl, -CH 2 CH 2 NHCH(CH 3 ) 2 , or
  • R 79 is -H or -C(0)-R 28 -[C(R 2 oR 2 i)]a-R 22 ;
  • each of R 2 o and R 2 i independently is hydrogen, Ci_ 6 alkyl, C -i 0 aryl, hydroxylated C 6- io aryl, polyhydroxylated C 6- io aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3-8 cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NH 2 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d -(0 CH 2 -CH 2 ) f -N(H)(R 23 ), or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, Ci -6 alkyl, C 6- io aryl, C 3-8 cycloalkyl, -COOH, or -COO-C 1-6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R 77 is a hydrogen or X 2 and NR 77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • R 28 is absent, NH or oxygen
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • u is an integer 0 or 1 ;
  • w is an integer 0 or 1 ;
  • non-natural camptothecin compound of Formula (VII) is a compound of Formula (VIII) or Formula (XXV):
  • R 30 is -NH 2 , -R 28 -Ci -6 alkyl-R 22 , 5 to 12-membered heterocycloalkyl, R 28 -C 5 -i 2 heterocycloalkyl-Ci-6 alkyl-R 22 or -R 28 -Ci -6 alkyl-C 6 -i 2 aryl-C 1 -6 alkyl-R 22 ;
  • R 28 is absent, NH or oxygen
  • R 22 is -OH, -NH 2 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d -(0 CH 2 -CH 2 ) f -N(H)(R 23 ) or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, C] -6 alkyl, C 6- io aryl, C 3-8 cycloalkyl, -COOH, or -COO-C 1 .6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R 77 is a hydrogen or X 2 and NR 77 form a nitrogen containing cyclic compound; R 82 is -NH or oxygen;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • R 30 is any one of the following structures:
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • g is an integer from 2 to 6.
  • PI3 kinase is a compound of Formula (IX):
  • R47 is an amino group, -R 9 -[C(R 2 oR 2 i)] a -Rio, -R9-C5-12 heterocycloalkyl-Ci -6 alkyl-Ri 0 , 5 to 12-membered heterocycloalkyl, or -R9-C 6- io aryl ;
  • each of R 2 o and R 2 i independently is hydrogen, Ci -6 alkyl, C 6- i 0 aryl, hydroxylated C 6- io aryl, polyhydroxylated C 6- i 0 aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3-8 cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • Rio is -OH, -NHR 83 , -N-(R 83 )R n , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 - C(0)(CH 2 ) d -(0 CH 2 -CH -N(H)(R 23 ), -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 or -R 82 -C(0)-
  • each R 23 independently is hydrogen, Ci -6 alkyl, C 6- io aryl, C 3-8 cycloalkyl, -COOH, or -COO-C 1-6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R 77 is a hydrogen or X 2 and NR 77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • R9 is absent, N-(R 83 ) or oxygen
  • R 83 is hydrogen or CH 3 ;
  • R11 is :
  • each Ri 2 independently is hydrogen, chloride, -CH 3 or -OCH 3 ;
  • Ri3 is hydrogen or -C(0)-(CH 2 ) d -(0-CH 2 -CH 2 ) r NH 2 ;
  • R 82 is -NH or oxygen
  • X 4 is the side chain of lysine, arginine, citrulline, alanine or glycine;
  • X 5 is the side chain of phenylalanine, valine, leucine, isoleucine or tryptophan; each of X 6 and X 7 is independently the side chain of glycine, alanine, serine, valine or proline;
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12;
  • each u independently is an integer 0 or 1 ;
  • R n is -Yu-W q -Rss
  • Y is any one of the following structures:
  • R 3 is hydrogen or CH 3
  • each W is an amino acid unit
  • each Ri 2 ' independently is halogen , -Ci- alkyl, -0-Ci- alkyl, nitro or cyano;
  • R is hydrogen or -C(0)-(CH 2 )f ⁇ (NH-C(0))aa-E j -(CH 2 ) bb -R 8 5
  • E is -CH 2 - or -CH 2 CH 2 0-;
  • u is an integer 0 or 1 ;
  • q is an integer from 0 to 12;
  • aa is an integer 0 or 1 ;
  • bb is an integer 0 or 2;
  • ff is an integer from 0 to 10;
  • R 83 is hydrogen or CH 3;
  • R 84 is C 1-6 alkyl or C 6- io aryl
  • each R1 2 ' independently is halogen , -C] -8 alkyl, -0-C] -8 alkyl, nitro or cyano;
  • h is an integer from 0 to 4.
  • u is an integer 0 or 1.
  • Rj 1 is:
  • each R 12 ' independently is chloride, -CH 3 or -OCH 3 ;
  • R 88 is hydrogen or -C(0)-(CH 2 ) f r(CH 2 -CH20) r CH2-CH2-NH 2 ;
  • R 82 is -NH or oxygen
  • X 4 is the side chain of lysine, arginine, citrulline, alanine or glycine;
  • X 5 is the side chain of phenylalanine, valine, leucine, isoleucine or tryptophan;
  • each of X 6 and X 7 is independently the side chain of glycine, alanine, serine, valine or proline;
  • ff is an integer from 1 to 3; j is an integer from 1 to 12
  • h is an integer from 0 to 4.
  • each u independently is an integer 0 or 1.
  • crtrulhne-valine is crtrulhne-valine; lysn phenylalanine; citrulline-phenylalanine; citralline-leucine; citralline-valine-glycine-glyc glycine-phenylalanine-glycine-glycine; valine; proline; leucine or isoleucine.
  • Rn is any one of the following structures:
  • 3 ⁇ 4 7 is any one of the following structures
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • g is an integer from 2 to 6.
  • auristatin is a com ound of Formula (X):
  • each of R31 and R 32 independently is hydrogen or CI -8 alkyl and at most one of R31 and R 32 is hydrogen;
  • R 33 is hydrogen, Cpg alkyl, C 3 - 8 carbocycle, C 6- io aryl, Cp 8 alkyl-C 6- i 0 aryl, X'-(C 3 -g carbocycle), C 3 -g heterocycle or X ! -(C 3 -g heterocycle);
  • R 34 is hydrogen, Cpg alkyl, C 3 -g carbocycle, C 6- io aryl, X'-C 6-10 aryl, X'-(C 3 -g carbocycle), C 3 -g heterocycle or X'-(C 3 -g heterocycle);
  • R 35 is hydrogen or methyl
  • R 3 4 and R 35> together with the carbon atom to which they attach form a carbocyclic ring having the formula -(CRssR ⁇ t,- wherein each of R55 and R41 independently is hydrogen or Cpg alkyl and b is an integer from 3 to 7;
  • R 36 is hydrogen or Cpg alkyl
  • R 37 is hydrogen, Cpg alkyl, C 3 -g carbocycle, C 6-i0 aryl, -X'-Ce-io aryl, -X ! -(C 3 -g carbocycle), C 3 - 8 heterocycle or -X' -(C 3 - 8 heterocycle);
  • each R 38 independently is hydrogen, OH, Cpg alkyl, C 3 -g carbocycle or 0-(Cpg alkyl);
  • R 53 is:
  • R 3 9 is H, Ci-g alkyl, C6-10 aryl, aryl, C 3- g carbocycle, C 3- g heterocycle, -X ] -C 3 -g heterocycle, -Ci -8 alkylene-NH 2 , or (CH 2 ) 2 SCH 3
  • each X 1 independently is Ci-10 alkylene or C 3 .i 0 cycloalkyl ene
  • R 4 is hydrogen or Cpg alkyl
  • R45 is X 3 -R4 2 or NH-Ri 9 ;
  • X 3 is O or S
  • R]9 is hydrogen, OH, amino group, alkyl amino or -[C(R 20 R2i)] a -R-22;
  • R4 2 is an amino group, Ci_ 6 alkyl amino or -[C(R 2 oR2i)] a -R22;
  • each of R 2 o and R 2 i independently is hydrogen, Ci -6 alkyl, C -io aryl, hydroxylated C 6 -io aryl, polyhydroxylated C 6 _io aryl, 5 to 12-membered heterocycle, C 3- g cycloalkyl, hydroxylated C 3- g cycloalkyl, polyhydroxylated C 3 _g cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NHR 23 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d - (O CH 2 -CH 2 ) f -N(H)(R 23 ) or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, C 1-6 alkyl, C 6- io aryl, C 3-8 cycloalkyl, -COOH, or -COO-Ci-6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R 77 is a hydrogen or X 2 and NR 77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • R 54 is -C(R 56 ) 2 -C(R 56 ) 2 -C 6- io aryl, -C(R 56 ) 2 -C(R 56 ) 2 -C 3-8 heterocycle or -C(R 56 ) 2 - C(R 56 ) 2 -C 3-8 carbocycle;
  • R 56 is independently selected from H, OH, C 1-8 alkyl, C 3-8 carbocycle, -0-Ci -8 alkyl, -O- C(0)-R 29 and -0-R 23 -0-Ci. 6 alkyl-NH 2 ;
  • R 29 is an amino group, 5 to 12-membered heterocycloalkyl, -R 28 -Ci -6 alkyl-R 22 , R 28 -C 5 -i 2 heterocycloalkyl-C 1-6 alkyl-R 22 , -[C(R 20 R 2 i)] a -R2 2 , or -R 28 -Ci -6 alkyl-C 6 - 12 aryl-C!. 6 alkyl-R 22 ; or R 29 is R4 7 as defined herein;
  • R 28 is absent, NH or oxygen
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • R4 4 is hydrogen
  • auristatin is a compound of Formula (Xa):
  • R 33 through R 38 , and R ⁇ are as defined herein,
  • R 3 i and R 32 is hydrogen or C 1-8 alkyl and the other is:
  • R 83 is hydrogen or CH 3;
  • R 84 is Ci -6 alkyl or C 6 -io aryl
  • each R 12 ' independently is halogen , -Ci -8 alkyl, -0-Ci -8 alkyl, nitro or cyano; h is an integer from 0 to 4.
  • u is an integer 0 or 1 ;
  • each X 1 independently is CMO alkylene or C 3- io cycloalkylene
  • R 45 is ⁇ 3 ⁇ 2 or NH-Ri 9 ;
  • X 3 is O or S
  • Ri9 is hydrogen, OH, amino group, alkyl amino or - ⁇ [C(R 2 oR 2 i)] a -R 2 2;
  • R 42 is H, an amino group, Ci -6 alkyl amino or -[C(R 2 oR 2 i)] a -R22; each of R 2 o and R21 independently is hydrogen, Ci -6 alkyl, C 6-10 aryl, hydroxylated C 6 .i 0 aryl, polyhydroxylated C 6-10 aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3 _g cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NHR 23 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d - (O CH 2 -CH 2 ) f -N(H)(R 23 ) or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, C 1-6 alkyl, C 6-10 aryl, C 3 . 8 cycloalkyl, -COOH, or -COO-Ci -6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R77 is a hydrogen or X 2 and NR77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • R 54 is -C(R 56 ) 2 -C(R 56 ) 2 -C 6-1 o aryl, -C(R 56 ) 2 -C(R 56 ) 2 -C 3-8 heterocycle or -C(R 56 ) 2 - C(R 56 ) 2 -C 3-8 carbocycle;
  • R 56 is independently selected from H, OH, Ci -8 alkyl, C 3-8 carbocycle, -O-Cj-g alkyl, -O- C(0)-R 29 and -0-R 23 -0-Ci -6 alkyl-NH 2 ;
  • R 2 9 is an amino group, 5 to 12-membered heterocycloalkyl, -R 28 -Ci -6 alkyl-R 22 , R 28 -C 5 -i 2 heterocycloalkyl-Ci -6 alkyl-R 22 , -[C(R 20 R 2 i)] a -R22, or -R 28 -Ci -6 alkyl-C 6 -i 2 aryl-Ci -6 alkyl-R 22 ; or R 2 9 is R 7 as defined herein;
  • R 28 is absent, NH or oxygen
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • the auristatin compound of Formula (Xa) is a compound of Formula (XIa) or Formula (Xlb):
  • R 83 is hydrogen or CH 3 .
  • the auristatin of Formula (X) is a compound of Formula (XI), Formula (XII) or Formula (XIII):
  • R42 is -CH 3 or any one of the following structures:
  • a is an integer from 1 to 6; and c is an integer from 0 to 3; wherein the compound of Formula (XII) is:
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • R 29 is an amino group, 5 to 12-membered heterocycloalkyl, -R 28 -Ci -6 alkyl-R 22 , R 28 -C 5 -i 2 heterocycloalkyl-Ci -6 alkyl-R 22 , -R 28 -[C(R 20 R 2 i)] a -R 22 , or -R 28 -Ci -6 alkyl-C 6 -i2 ar l-Ci. 6 alkyl-R 22 ; or R 29 is R4 7 as defined herein;
  • each of R 20 and R 21 independently is hydrogen, C 1-6 alkyl, C 6- io aryl, hydroxylated C 6- i o aryl, polyhydroxylated C 6 -io aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3 - 8 cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NHR 23 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d - (O CH 2 -CH 2 ) f -N(H)(R 23 ) or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ; each R 2 3 independently is hydrogen, Ci -6 alkyl, C 6 -io aryl, C 3-8 cycloalkyl, -COOH, -Ci-6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R77 is a hydrogen or X 2 and NR77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • R 28 is absent, NH or oxygen
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • R 40 is
  • the compound of Formula (XII) is a compound of
  • R29 is -NH 2 , 5 membered heterocycloalkyl, -R 28 -C ]-6 alkyl-R 22 , R 28 -C 5 -i 2 heterocycloalkyl-Ci -6 alkyl-R 22 or -R 28 -Ci -6 alkyl-C 6 - ]2 aryl-C ]-6 alkyl-R 22; ; or R 29 is R41 as defined herein;
  • R 28 is absent, NH or oxygen
  • R 22 is -OH, -NHR 23 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d - (O CH 2 -CH 2 ) f -N(H)(R 23 ) or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, C ]-6 alkyl, C 6- i 0 aryl, C 3-8 cycloalkyl, -COOH, or -COO-C.6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R 77 is a hydrogen or X 2 and NR 77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • R 29 is any one of the following structures:
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • g is an integer from 2 to 6.
  • R43 is H or -R 6 -R 7; each of R 20 and R 2 i independently is hydrogen, C 1-6 alkyl, C 6- i 0 aryl, hydroxylated C 6- i 0 aryl, polyhydroxylated C6-i 0 aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3-8 cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NH 2 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d -(0 CH 2 -CH 2 ) f -N(H)(R 23 ) or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 2 3 independently is hydrogen, Ci -6 alkyl, C 6 _io aryl, C 3-8 cycloalkyl, -COOH, or -COO-Ci -6 alkyl;
  • R 77 is a hydrogen or X and NR 77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • R46 is -C(O)-; -C(0)-0-, -C(0)-NH-, or absent;
  • R 47 is as defined herein;
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • R ⁇ is -C(0)-(CH 2 ) a -NH 2 , or -C(0)-C(H)(CH 3 )-(CH 2 ) c - NH 2 ; in which a is an integer from 1 to 6; and c is an integer from 0 to 3.
  • the duocarmycin compound is a compound of Formula
  • R4 7 is as defined herein;
  • R48 is hydrogen, -COOC, -6 alkyl, -COOH, -NH 2 or -CH 3 ;
  • R49 is CI, Br or -OH
  • R 5 o is hydrogen, -OCH 3 ,
  • each of R51 and R 52 independently is hydrogen or -OCH 3 ;
  • ring AA is either a phenyl or pyrrolyl ring.
  • duocarmycin compounds are disclosed in e.g., US 7,553,816.
  • duocarmycin compound of Formula (XV) is a compound of Formula (XVI),
  • R49 is CI, Br or -OH
  • R -7 is as defined herein.
  • the duocarmycin compound is a duocarmycin SA compound of Formula (XX), see, e.g., US 5101038; or (XXI):
  • R4 2 is Ci-6 alkyl amino or -[C(R 20 R 2 i)] a -R 22 ;
  • each of R 20 and R 2 i independently is hydrogen, C 1-6 alkyl, C 6- io aryl, hydroxylated C 6-1 o aryl, polyhydroxylated C 6- io aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3-8 cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NH 2 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d -(0 CH 2 -CH 2 ) f -N(H)(R 23 ), or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, Ci -6 alkyl, C 6-1 o aryl, C 3-8 cycloalkyl, -COOH, or -COO-C,. 6 alkyl;
  • X is a side chain of a natural or unnatural ammo acid
  • R 77 is a hydrogen or X 2 and NR 77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12.
  • ⁇ is any one of the following structures:
  • duocarmycin compound is Duocarmycin A
  • Duocarmycin Bl Duocarmycin B2, Duocarmycin CI, Duocarmycin C2, Duocarmycin 1065, Adozelesin, Bizelesin or Carzelesin
  • tubulysin is a compound of Formula (XXII):
  • R 57 is Ci- 4 alkyl or -C(0)R 58 ;
  • R-58 is Cj-6 alkyl, CF 3 or C 6-1 o aryl
  • R 59 is Ci -6 alkyl
  • R 60 is hydrogen, C r6 alkyl, C 2 - 7 alkenyl, -CH 2 -phenyl, CH 2 OR 65 or CH 2 OCOR 66 ;
  • R 65 is hydrogen, Ci- 6 alkyl, C 2 - 7 alkenyl, C 6 -io aryl or C(0)R 67 ;
  • R 67 is Ci-6 alkyl, C 2 - 6 alkenyl, C 6- io aryl or heteroaryl;
  • R 66 is Ci-6 alkyl, -C 6 H 5 or -CH 2 -phenyl
  • R 6 i is C 1 -6 alkyl
  • R 62 is hydrogen, OH, 0-C,- 4 alkyl or 0-C(0)-C, -4 alkyl;
  • R 63 is hydrogen, OH, 0-Ci- 4 alkyl, 0-C(0)-Ci -4 alkyl, halogen or Cj- 6 alkyl; e is an integer from 1 to 3;
  • R 64 is:
  • R 68 is hydrogen or Ci-C 6 alkyl
  • R 69 is CO 2 R 70 , C(0)-R 78 , CONHNH 2 , OH, NH 2 , SH, or an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted heteroalkyl or an optionally substituted heterocycloalkyl group;
  • R 70 is an optionally substituted alkyl (e.g., amino Ci -6 alkyl), an optionally substituted heteroalkyl or an optionally substituted heterocycloalkyl group;
  • each of R 7 i and R 73 independently is hydrogen, halo, -N0 2 , -CN, -NHR 74 , Ci -6 alkyl, haloalkyl, alkoxy, and haloalkoxy;
  • R 72 is hydrogen, OR 43 , alkoxy, halogen, -NHR 74 , -0-C(0)-R4 7 , N0 2 , -CN, C 6-]0 aryl, C ]-6 alkyl, amino or dialkylamino;
  • R 74 is hydrogen, -CHO, -C(0)-C ]-4 alkyl, OH, amino group, alkyl amino or -
  • R 3 is H or -R ⁇ -R ⁇
  • R4 6 is -C(O)-; -C(0)-0-, -C(0)-NH-, or absent;
  • R 7 is as defined herein;
  • R 78 is X 3 -R 75 or NH-R ]9 ;
  • X 3 is O or S
  • R ]9 is hydrogen, OH, amino group, alkyl amino or -[C(R 2 oR 2 i)] a -R22;
  • R 7 5 is a hydrogen, an amino group, Ci -6 alkyl amino or -[C(R 2 oR 2 i)] a -R22;
  • each of R 20 and R 2] independently is hydrogen, Ci. 6 alkyl, C 6-] o aryl, hydroxylated C 6-] o aryl, polyhydroxylated C 6-] o aryl, 5 to 12-membered heterocycle, C 3-8 cycloalkyl, hydroxylated C 3-8 cycloalkyl, polyhydroxylated C 3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
  • R 22 is -OH, -NH 2 , -COOH, -R 82 -C(0)(CH 2 ) c -C(H)(R 23 )-N(H)(R 23 ), -R 82 -C(0)(CH 2 ) d -(0 CH 2 -CH 2 ) f -N(H)(R 23 ), or -R 82 -(C(0)-CH(X 2 )-NH) d -R 77 ;
  • each R 23 independently is hydrogen, Ci -6 alkyl, C 6- io aryl, C 3-8 cycloalkyl, -COOH, or -COO-Ci -6 alkyl;
  • X 2 is a side chain of a natural or unnatural amino acid
  • R 77 is a hydrogen or X 2 and NR 77 form a nitrogen containing cyclic compound
  • R 82 is -NH or oxygen; R47 is as defined herein;
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • d is an integer from 1 to 3;
  • f is an integer from 1 to 12;
  • R 69 is C(0)-X 3 -R 75 or C(0)-NH-Ri 9 , one or both of R71 and R 73 are -NHR74, and R 72 is OR 43; -NHR 74 or -0-C(0)-R 4 7, then at least one of Ri ⁇ R ⁇ , R 74 and R75 cannot be hydrogen.
  • R 57 is -CH 3 ;
  • R 59 is sec-butyl
  • R 6 o is hydrogen, methyl, ethyl, propyl, iso-propyl or iso-butyl;
  • R 6 i is iso-propyl
  • R 62 is hydrogen
  • R 63 is hydrogen, OH, -0-C 3 H 7 , 0-C(0)-CH 3 ;
  • R 68 is hydrogen or -CH 3 ;
  • R 69 is C0 2 H, CO 2 R 70 or C(0)-R 78 ;
  • R70 is Ci-6 alkyl amine
  • each of R71 and R ?3 independently is hydrogen
  • R 72 is hydrogen, -OR43, OH, F, -CH 3 or -OCH 3 ;
  • R 78 is OH, -OR 75 or - ⁇ 3 ⁇ 4 0 ;
  • e is the integer 2;
  • R 4 o is hydrogen, -OH, -NH 2 , or any of the following structures: (4)
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • R 5 is any one of the following structures:
  • a is an integer from 1 to 6;
  • R43 is hydrogen, -C(0)-(CH 2 ) a -NH 2 , or -C(0)-C(H)(CH 3 )-(CH 2 ) c -NH 2 ;
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • R 7 is any one of the following structures:
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • g is an integer from 2 to 6;
  • R 72 is -OH, then R 75 cannot be hydrogen; if R 69 is COOH then R 72 must be -OR 43 or-0-C(0)-R 47 .
  • tubulysin of Formula (XXII) is a compound of
  • R 76 is hydrogen , OH, OCH 3 , F, -OR ⁇ or -0-C(0)-R4 7 ;
  • R 78 , R 75 , R19, n and R4 3 are as defined herein;
  • R 76 is -OH, OCH 3 or F, then R 75 and R 19 cannot be hydrogen.
  • R47 is [00271] In another embodiment, R4-7 is
  • R47 is
  • the KSP inhibitor compound is a compound of Formula
  • R 30 is as defined herein.
  • R30 is:
  • a is an integer from 1 to 6;
  • c is an integer from 0 to 3;
  • g is an integer from 2 to 6.
  • the KSP inhibitor compound is a compound of Formula
  • Ri i is as defined herein.
  • therapeutic agents described herein can be modified in such a manner that the resulting compound still retains the specificity and/or activity of the original compound.
  • therapeutic agents of the present invention include analogues and derivatives of the compounds described herein.
  • Table A below provides more examples of the therapeutic agents and derivatives thereof suitable for conjugation to form the polymer-drug-protein conjugates or polymer-drug scaffolds of the invention. Spectral data of certain compounds are also provided (ND in the table means "not determined”). These examples may also be the active form of the drug when it is released from a conjugate in vitro or in vivo.
  • PBRMs Protein-Based Recognition Molecules
  • the protein-based recognition molecule directs the drug-polymer carrier conjugates to specific tissues, cells, or locations in a cell.
  • the protein-based recognition molecule can direct the modified polymer in culture or in a whole organism, or both.
  • the protein-based recognition molecule has a ligand that is present on the cell surface of the targeted cell(s) to which it binds with an effective specificity, affinity and avidity.
  • the protein-based recognition molecule targets the modified polymer to tissues other than the liver.
  • the protein-based recognition molecule targets the modified polymer to a specific tissue such as the liver, kidney, lung or pancreas.
  • the protein- based recognition molecule can target the modified polymer to a target cell such as a cancer cell, such as a receptor expressed on a cell such as a cancer cell, a matrix tissue, or a protein associated with cancer such as tumor antigen.
  • a target cell such as a cancer cell, such as a receptor expressed on a cell such as a cancer cell, a matrix tissue, or a protein associated with cancer such as tumor antigen.
  • cells comprising the tumor vasculature may be targeted.
  • Protein-based recognition molecules can direct the polymer to specific types of cells such as specific targeting to hepatocytes in the liver as opposed to Kupffer cells. In other cases, protein-based recognition molecules can direct the polymer to cells of the reticular endothelial or lymphatic system, or to professional phagocytic cells such as
  • the polymer itself might also be an effective delivery system, without the need for specific targeting).
  • the protein based recognition molecule can target the modified polymer to a location within the cell, such as the nucleus, the cytoplasm, or the endosome, for example.
  • the protein based recognition molecule can enhance cellular binding to receptors, or cytoplasmic transport to the nucleus and nuclear entry or release from endosomes or other intracellular vesicles.
  • the protein based recognition molecules include antibodies, proteins and peptides or peptide mimics.
  • Exemplary antibodies or antibodies derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments specific to the cell surface markers include, but are not limited to, 5T4, AOC3, ALK, AXL, C242, CA-125, CCL1 1 , CCR 5, CD2, CD3, CD4, CD5, CD15, CA15-3, CD18, CD19, CA19-9, CD20, CD22, CD23, CD25, CD28, CD30, CD31 , CD33, CD37, CD38, CD40, CD41, CD44, CD44 v6, CD51 , CD52, CD54, CD56, CD62E, CD62P, CD62L, CD70, CD74, CD79-B, CD80, CD125, CD138, CD141 , CD147, CD152, CD 154, CD326, CEA, clumping factor, CTLA-4, CXCR2, EGFR (HER1 , ErbB2, ErbB3, EpCAM, EPHA2, EPHB2, EPHB4,
  • FGFR1, FGFR2, FGFR3, FGFR4) FLT3, folate receptor, FAP, GD2, GD3, GPNMB, HGF, HER2, ICAM, IGF-1 receptor, VEGFR1, EphA2, TRPV1 , CFTR, gpNMB, CA9, Cripto, c-KIT, c-MET, ACE, APP, adrenergic receptor-beta2, Claudine 3, Mesothelin, MUC1, RON, ROR1, PD-L1, PD-L2, B7-H3, B7-B4, IL-2 receptor, IL-4 receptor, IL-13 receptor, integrins (including ⁇ 4 , ⁇ ⁇ ⁇ 3 , a ⁇ ⁇ 5 , ⁇ ⁇ ⁇ 6 , ⁇ 4 , ⁇ 4 ⁇ , ⁇ 4 ⁇ 7 ⁇ ⁇ 5 ⁇ , ⁇ 6 ⁇ 4 , ⁇ 3 integrin), IFN-a, IFN- ⁇ , IgE
  • the antibodies or antibody derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments specific to the cell surface markers include CA-125, C242, CD3, CD19, CD22, CD25, CD30, CD31, CD33, CD37, CD40, CD44, CD51 , CD54, CD56, CD62E, CD62P, CD62L, CD70, CD 138, CD141, CD326, CEA, CTLA-4, EGFR
  • HER1, ErbB2, ErbB3, FAP folate receptor, IGF-1 receptor, GD3, GPNMB, HGF, HER2, VEGF-A, VEGFR2, VEGFR1, EphA2, EpCAM, 5T4, TAG-72, tenascin C, TRPV1 , CFTR, gpNMB, CA9, Cripto, ACE, APP, PDGFR a, phosphatidylserine, prostatic carcinoma cells, adrenergic receptor-beta2, Claudine 3, mucin, MUC1 , Mesothelin, IL-2 receptor, IL-4 receptor, IL-13 receptor and integrins (including ⁇ ⁇ ⁇ 3 , ⁇ ⁇ 5 , ⁇ ⁇ 6 , ⁇ 4 , ⁇ 4 ⁇ , 5 ⁇ , ⁇ 6 ⁇ 4 integrins), tenascin C, TRAIL-R2 and vimentin.
  • integrins including ⁇ ⁇
  • Exemplary antibodies include 3F8, abagovomab, abciximab (REOPRO), adalimumab (HUMIRA), adecatumumab, afelimomab, afutuzumab, alacizumab, ALD518, alemtuzumab (CAMPATH), aitumomab, amatuximab, anatumomab, anrukinzumab, apolizumab, arcitumomab (CEA-SCAN), aselizumab, atlizumab (tocilizumab, Actemra, RoActemra), atorolimumab, bapineuzumab, basiliximab (Simulect), bavituximab, bectumomab
  • maslimomab matuzumab, mepolizumab (BOSATRIA), metelimumab, milatuzumab, minretumomab, mitumomab, morolimumab, motavizumab (NUMAX), muromonab-CD3 (ORTHOCLONE OKT3), nacolomab, naptumomab, natalizumab (TYSABRI), nebacumab, necitumumab, nerelimomab, nimotuzumab (THERACIM), nofetumomab, ocrelizumab, odulimomab, ofatumumab (ARZERRA), olaratumab, omalizumab (XOLAIR), ontecizumab, oportuzumab, oregovomab (OVAREX), otelixizumab, pagibaximab
  • ruplizumab (ANTOVA), satumomab pendetide, sevirumab, sibrotuzumab, sifalimumab, siltuximab, siplizumab, solanezumab, sonepcizumab, thankuzumab, stamulumab, sulesomab (LEUKOSCAN), tacatuzumab (AFP-CIDE), tetraxetan, tadocizumab, talizumab, tanezumab, taplitumomab paptox, tefibazumab (AUREXIS), telimomab, tenatumomab, teneliximab, teplizumab, TGN1412, ticilimumab (tremelimumab), tigatuzumab, TNX-650, tocilizumab (at
  • vapaliximab vapaliximab, vedolizumab, veltuzumab, vepalimomab, visilizumab (NUVION), volociximab (HUMASPECT), votumumab, zalutumumab (HuMEX-EGFr), zanolimumab (HuMAX-CD4), ziralimumab and zolimomab.
  • the antibodies are directed to cell surface markers for 5T4, CA-125, CEA, CD3, CD 19, CD20, CD22, CD30, CD33, CD40, CD44, CD51 , CTLA-4, EpCAM, HER2, EGFR (HER1), FAP, folate receptor, HGF, integrin ⁇ ⁇ ⁇ 3 , integrin ⁇ 5 ⁇ , IGF-1 receptor, GD3, GPNMB, mucin, MUCl , phosphatidylserine, prostatic carcinoma cells, PDGFR a, TAG-72, tenascin C, TRAIL-R2, VEGF-A and VEGFR2.
  • the antibodies are abagovomab, adecatumumab, alacizumab, altumomab, anatumomab, arcitumomab, bavituximab, bevacizumab (AVASTIN), bivatuzumab, blinatumomab, brentuximab,
  • cantuzumab catumaxomab, capromab , cetuximab, citatuzumab, clivatuzumab, conatumumab, dacetuzumab, edrecolomab, epratuzumab, ertumaxomab, etaracizumab, farletuzumab, figitumumab, gemtuzumab, glembatumumab, ibritumomab, igovomab, intetumumab, inotuzumab, labetuzumab, lexatumumab, lintuzumab, lucatumumab, matuzumab, mitumomab, naptumomab estafenatox, necitumumab, oportuzumab, oregovomab, panitumumab,
  • pemtumomab pertuzumab, pritumumab, rituximab (RITUXAN), rilotumumab, robatumumab, satumomab, sibrotuzumab, taplitumomab , tenatumomab, tenatumomab, ticilimumab
  • tremelimumab tigatuzumab, trastuzumab (HERCEPTIN), tositumomab, tremelimumab, tucotuzumab celmoleukin, volociximab and zalutumumab.
  • the antibodies directed to cell surface markers for HER2 are pertuzumab or trastuzumab and for EGFR (HER1) the antibody is cetuximab and for CD20 the antibody is rituximab and for VEGF-A is bevacizumab and for CD-22 the antibody is epratuzumab or veltuzumab and for CEA the antibody is labetuzumab.
  • Exemplary peptides or peptide mimics include integrin targeting peptides (RGD peptides), LHRH receptor targeting peptides, ErbB2 (HER2) receptor targeting peptides, prostate specific membrane bound antigen (PSMA) targeting peptides, lipoprotein receptor LRP1 targeting, ApoE protein derived peptides, ApoA protein peptides, somatostatin receptor targeting peptides, chlorotoxin derived peptides, and bombesin.
  • RGD peptides integrin targeting peptides
  • LHRH receptor targeting peptides LHRH receptor targeting peptides
  • HER2 (HER2) receptor targeting peptides ErbB2 (HER2) receptor targeting peptides
  • PSMA prostate specific membrane bound antigen
  • lipoprotein receptor LRP1 targeting
  • ApoE protein derived peptides ApoA protein peptides
  • somatostatin receptor targeting peptides chlorotoxin derived peptide
  • the peptides or peptide mimics are LHRH receptor targeting peptides and ErbB2 (HER2) receptor targeting peptides
  • Exemplary proteins comprise insulin, transferrin, fibrinogen-gamma fragment, thrombospondin, claudin, apolipoprotein E, Affibody molecules such as, for example, ABY-025, Ankyrin repeat proteins, ankyrin-like repeats proteins and synthetic peptides.
  • the protein drug polymer conjugates comprise broad spectrum cytotoxins in combination with cell surface markers for HER2 such as pertuzumab or trastuzumab; for EGFR such as cetuximab; for CEA such as labetuzumab; for CD20 such as rituximab; for VEGF-A such as bevacizumab; or for CD-22 such as epratuzumab or veltuzumab.
  • HER2 such as pertuzumab or trastuzumab
  • EGFR such as cetuximab
  • CEA such as labetuzumab
  • CD20 such as rituximab
  • VEGF-A such as bevacizumab
  • CD-22 such as epratuzumab or veltuzumab.
  • the protein-drug-polymer conjugates or protein-polymer conjugates used in the invention comprise combinations of two or more protein based recognition molecules, such as, for example, combination of bispecific antibodies directed to the EGF receptor (EGFR) on tumor cells and to CD3 and CD28 on T cells; combination of antibodies or antibody derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments and peptides or peptide mimetics; combination of antibodies or antibody derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments and proteins; combination of two bispecific antibodies such as CD3 x CD 19 plus CD28 x CD22 bispecific antibodies.
  • EGFR EGF receptor
  • the protein-drug-polymer conjugates or protein-polymer conjugates used in the invention comprise protein based recognition molecules are antibodies against antigens, such as, for example, B7-H4, B7-H3, CA125, CD33, CXCR2, EGFR, FGFR1 , FGFR2, FGFR3, FGFR4, HER2, PD-L1 and 5T4.
  • antigens such as, for example, B7-H4, B7-H3, CA125, CD33, CXCR2, EGFR, FGFR1 , FGFR2, FGFR3, FGFR4, HER2, PD-L1 and 5T4.
  • Table B below provides more examples of the PBRM described herein, which are suitable for conjugation to form the polymer-drug-protein conjugates or polymer-PBRM scaffolds of the invention.
  • the drug or PBRM is connected to the polymeric carrier via a linker L D or L p .
  • the linker is biocleavable/biodegradable under intracellular conditions, such that the cleavage of the linker releases the drug or PBRM from the polymer unit in the intracellular environment.
  • a linker is any chemical moiety that is capable of linking a drug or a PBRM to a polymer backbone through chemical bonds such that the drug or PBRM and the polymer are chemically coupled (e.g., covalently bonded) to each other.
  • the linker comprises a biodegradable linker moiety (e.g., a biodegradable bond such as an ester or amide bond).
  • the linker L D or L p is biodegradable under mild conditions, i.e., conditions within a cell under which the activity of the drug is not affected.
  • suitable biodegradable linker moiety include disulfide linkers, acid labile linkers, photolabile linkers, peptidase labile linkers, and esterase labile linkers.
  • the linker L D or L p is biocleavable under reducing conditions (e.g., a disulfide linker).
  • the drug or PBRM moiety is linked to the polymer through a disulfide bond.
  • the linker molecule comprises a reactive chemical group that can react with the drug.
  • Preferred reactive chemical groups for reaction with the drug or PBRM moiety are N-succinimidyl esters and N-sulfosuccinimidyl esters.
  • the linker molecule comprises a reactive chemical group, preferably a dithiopyridyl group that can react with the drug to form a disulfide bond.
  • the linker molecules include, for example, N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2- pyridyldithio)butanoate (SPDB), N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), N- succinimidyl-S-acetylthioacetate (SAT A) and N-succinimidyl-oxycarbonyl-alpha-methyl-alpha- (2-pyridyl-dithio)toluene or 2,5-dioxopyrrolidin-l-yl 4-(l-(pyridin-2-yldisulfanyl)ethyl)benzoate (SMPT).
  • SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
  • SPDB N-succinimidy
  • the biocleavable linker L D or L p is pH-sensitive, i.e., sensitive to hydrolysis at certain pH values.
  • the pH-sensitive linker is hydrolysable under acidic conditions.
  • an acid-labile linker that is hydrolysable in the lysosome or endosome e.g., a hydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetal, ketal, or the like
  • Such linkers are relatively stable under neutral pH conditions, such as those in the blood, but are unstable at below pH 5.5 or 5.0, the approximate pH of the lysosome.
  • the hydrolysable linker is a thioether linker (such as, e.g., a thioether attached to the therapeutic agent via an acylhydrazone bond.
  • the linker L D or L p is photo-labile and is useful at the body surface and in many body cavities that are accessible to light. Furthermore, L D or L p is biocleavable by infrared light which can penetrate tissue. Accordingly, L D or L p is useful for both applications on the body surface and in the tissue.
  • the linker L D or L p is biocleavable by a cleaving agent that is present in the intracellular environment (e.g., within a lysosome or endosome or caveolea).
  • the linker can be, for example, a peptidyl linker that is cleaved by an intracellular peptidase or protease enzyme, including, but not limited to, a lysosomal or endosomal protease.
  • the linker L D or L p is cleaved by esterases. Only certain esters can be cleaved by esterases present inside or outside cells. Esters are formed by the condensation of a carboxylic acid and an alcohol. Simple esters are esters produced with simple alcohols, such as aliphatic alcohols, and small cyclic and small aromatic alcohols.
  • the linker L D or L p is not biocleavable and the drug is released by antibody degradation. See, for example, U.S. Patent No. 7,498,298, which is incorporated by reference herein in its entirety and for all purposes.
  • the linker L D or L p is not substantially sensitive to the extracellular environment.
  • “not substantially sensitive to the extracellular environment,” in the context of a linker means that no more than about 20%, typically no more than about 15%, more typically no more than about 10%, and even more typically no more than about 5%, no more than about 3%, or no more than about 1% of the linkers, in a sample of Polymer Drug Conjugate, are cleaved when the Polymer Drug Conjugate presents in an extracellular environment (e.g., in plasma) for 24 hours.
  • Whether a linker is not substantially sensitive to the extracellular environment can be determined, for example, by incubating the Polymer Drug Conjugate with plasma for a predetermined time period (e.g., 2, 4, 8, 16, or 24 hours) and then quantitating the amount of free drug present in the plasma.
  • a predetermined time period e.g. 2, 4, 8, 16, or 24 hours
  • the linker L D has the structure:
  • the linker L p has the structure:
  • each of R L1 and R L2 independently is absent, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, aryl, or heteroaryl.
  • each of R L1 and R L2 independently is absent, alkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl.
  • R L1 is absent.
  • R L2 is absent.
  • each of X D and X P independently is -0-, -S-, -N(R')-, or absent, in which R 1 is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety, -
  • each occurrence of R 2 , R 3 , and R 4 independently is hydrogen or an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety, or each occurrence of -NR 2 - or -NR 2 NR 3 - is a heterocycloalkyl moiety.
  • each of M D1 , M D2 , M D3 , M D4 , M pl , M p2 , M p3 and M P4 is M D1 , M D2 , M D3 , M D4 , M pl , M p2 , M p3 and M P4 ,
  • non-biodegradable linker moiety selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl,
  • D 1 D2 D3 P 1 heterocycloalkyl, aryl, heteroaryl, and a combination thereof and each of M , M , M , M P2 , and M P3 optionally contains one or more -(C 0)- but does not contain any of the biodegradable linker moieties mentioned above.
  • each of M D1 , M D2 , M D3 , M w , M P1 , M P2 , M p3 and M P4 independently is Cue alkyl, C 1-6 alkyl-C(O)-C 0-6 alkyl, Ci- 6 alkyl-NH-C 0-6 alkyl, C, -6 alkyl-O-C 0-6 alkyl, C 1-6 alkyl-S-C 0-6 alkyl, C 1-6 alkyl-C(0)-Ci -6 alkyl-NH, C, -6 alkyl-C(0)-C, -6 alkyl-O, C 1-6 alkyl-C(O)- Ci -6 alkyl-S, C 3 -i 0 cycloalkyl-C(O)-C 0-6 alkyl, 3-19 membered heterocycloalkyl-C(0)-Co- 6 alkyl, aryl-C(O)-C 0-6 alkyl,
  • M D1 is not absent when X D is absent.
  • M P1 is not absent when X p is absent.
  • each of M D1 and M P1 independently is Ci -6 alkyl or C ]-6 heteroalkyl.
  • each of M D2 , M D3 , M D4 , M p2 , M P3 , and M P4 independently is absent,
  • M D2 and M D3 have one of the following structures:
  • q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3, and the other of M D2 or M D3 is either absent or a moiety different from the above, such as C 1-6 alkyl.
  • one of M P2 and M P3 has one of the following structures:
  • q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3, and the other of M n or M P3 is either absent or a moiety different from the above, such as Ci_ 6 alkyl.
  • p is 2.
  • q is 0 or 12.
  • t is 0 or 1.
  • each of -M D2 -Z D -, -Z D -M D3 -, -Z D -M D2 -, or -M D3 -Z D - independently has one of the following structures:
  • ring A or B independently is cycloalkyl or heterocycloalkyl; R is an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety; R u is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety; and ring D is heterocycloalkyl.
  • each of -M P2 -Z P -, -Z p -M p3 -, -Z P -M P2 -, and -M p3 -Z p - independently, has one of the following structures:
  • ring A is cycloalkyl or heterocycloalkyl and R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
  • ring A is 5-19 membered heterocycloalkyl, e.g.,
  • ring A is C 3-8 cycloalkyl.
  • ring D is piperazinyl or piperidinyl.
  • R w is C 1-6 alkyl.
  • R 1J is hydrogen or C )-6 alkyl.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric scaffold having one or more -LD-D, the PBRM being connected to the polymeric scaffold by Lp, wherein the polymeric scaffold comprises a linear, branched or cyclic polymer having four or more -OH groups. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric scaffold respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Description

HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES
RELATED APPLICATIONS
[0001] This application claims the benefit of and priority to U.S. Provisional Application
No. 61/736,483, filed December 12, 2012, the content of which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
[0002] Traditionally, pharmaceuticals have primarily consisted of small molecules that are dispensed orally (as solid pills and liquids) or as injectables. Over the past three decades, formulations (i.e., compositions that control the route and/or rate of drag delivery and allow delivery of the therapeutic agent at the site where it is needed) have become increasingly common and complex. Nevertheless, many questions and challenges regarding the development of new treatments as well as the mechanisms with which to administer them remain to be addressed. For example, many drugs exhibit limited or otherwise reduced potencies and therapeutic effects because they are either generally subject to partial degradation before they reach a desired target in the body, or accumulate in tissues other than the target, or both.
[0003] One objective in the field of drug delivery systems, therefore, is to deliver medications intact to specifically targeted areas of the body through a system that can stabilize the drug and control the in vivo transfer of the therapeutic agent utilizing either physiological or chemical mechanisms, or both.
[0004] Antibody-drug conjugates have been developed as target-specific therapeutic agents. Antibodies against various cancer cell-surface antigens have been conjugated with different cytotoxic agents that inhibit various essential cellular targets such as microtubules (maytansinoids, auristatins, taxanes: U.S. Patent Nos. 5,208,020; 5,416,064; 6,333,410;
6,441 ,163; 6,340,701 ; 6,372,738; 6,436,931 ; 6,596,757; and 7,276,497); DNA (calicheamicin, doxorubicin, CC-1065 analogs; U.S. Patent Nos. 5,475,092; 5,585,499; 5,846,545; 6,534,660; 6,756,397; and 6,630,579). Antibody conjugates with some of these cytotoxic drugs are actively being investigated in the clinic for cancer therapy (Ricart, A. D., and Tolcher, A. W., 2007, Nature Clinical Practice, 4, 245-255; Krop et al., 2010, J. Clin. Oncol, 28, 2698-2704).
However, existing antibody-drag conjugates have exhibited a few limitations. A major limitation is their inability to deliver a sufficient concentration of drug to the target site because of the limited number of targeted antigens and the relatively moderate cytotoxicity of cancer drugs like methotrexate, daunorubicin, maytansinoids, taxanes, and vincristine. One approach to achieving significant cytotoxicity is by linkage of a large number of drug molecules either directly or indirectly to the antibody. However such heavily modified antibodies often display impaired binding to the target antigen and fast in vivo clearance from the blood stream.
Therefore, there is a need to improve the ability to deliver a sufficient concentration of a drug to the target such that maximum cytotoxicity for the drug is achieved.
SUMMARY OF THE INVENTION
[0005] The present invention relates to a protein-hydroxyl polymer-drug conjugate that is biodegradable, biocompatible and exhibits high drug load as well as strong binding to target antigen. The present invention also relates to a polymeric scaffold useful to conjugate with a protein based recognition-molecule (PBRM) so as to obtain the protein-hydroxyl polymer-drug conjugate.
[0006] In one aspect, the invention features a polymeric scaffold useful to conjugate with a PBRM. The scaffold includes a linear, branched or cyclic polymer having one or more -OH
(0)u-C(=0)-LDi- -D
groups connected to the polymer, one or more ς connected to the
— (0)u-C(=0)-L^-LP2
polymer, and one or more ζ connected to the polymer, wherein:
the polymer is a hydroxyl polymer,
each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa;
LD1 is a carbonyl-containing moiety;
(0)u-C(=0)-LDi- _ (0)u-C(=0)-LD^-D
each occurrence of ς in ς
independently is a first linker that contains a biodegradable bond so that when the bond is broken, D is released in an active form for its intended therapeutic effect; in which each u
- - (0)u-C(=0)-LDi- -D D1 independently is an integer 0 or 1 , and the ς in ς between L and
D denotes direct or indirect attachment of D to LD1 ; and each occurrence of
Figure imgf000004_0001
is independently a second linker not yet connected to PBRM in which L is a moiety containing a functional group that is capable of forming a covalent bond with a functional roup of a PBRM, each u independently is an integer 0 or 1, and the ς in
Figure imgf000004_0002
denotes direct or indirect attachment of Lp2 to LD1, and each occurrence of the second linker is distinct from each occurrence of the first linker.
[0007] The polymeric scaffold can include one or more of the following features:
[0008] The hydroxyl polymer has a molecular weight ranging from 2 kDa to 300 kDa.
[0009] The polymeric carrier (e.g., hydroxyl polymer), is not a polyacetal or a polyketal.
The polymeric carrier is not poly(l-hydroxymethylethylene hydroxymethyl-formal, PHF).
[0010] The polymeric carrier is not a polysaccharide, carbohydrate, or oligosaccharide.
[0011] The polymeric carrier is not a naturally-occurring polymer selected from polysaccharide, carbohydrate, and oligosaccharide.
[0012] The polymeric carrier is selected from hydroxyalkyl starches, polyglycerols, PEG polymers, HPMA polymers, carboxymethyl dextrans (CM dextrans), polyvinyl alcohols, poly(acrylic acid), and dendrimers, copolymers and mixtures thereof.
[0013] The polymeric carrier has at least four -OH groups before modification.
[0014] When the one or more -OH groups are the hydroxyl groups of one or more
-COOH connected to the polymeric carrier, u is 0.
[0015] When the one or more -OH groups are not the hydroxyl groups of one or more
-COOH, u is 1.
[0016] LD1 is a carbonyl-containing moiety.
[0017] LD1 comprises— X-(CH )v-C(=0)— with X directly connected to the carbonyl group of -(0)u-C(=0), in which X is CH2, O, or NH, and v is an integer from 1 to 6.
[0018] Lp2 contains a biodegradable bond.
[0019] The functional group of Lp2 is selected from -SRP, -S-S-LG, maleimido, and halo, in which LG is a leaving group and Rp is H or a sulfur protecting group.
[0020] The polymer of the scaffold of the invention is a linear, branched or cyclic hydroxyl polymeric carrier having a molecular weight ranging from 2 kDa to 300 kDa. (i.e., MW of the unmodified hydroxyl polymer) and the hydroxyl polymer is not a polyacetal or polyketal. [0021] For conjugating a PBRM having a molecular weight of 40 kDa or greater (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa), the polymer of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 40 kDa (e.g., about 6-20 kDa or about 8- 15 kDa).
[0022] For conjugating a PBRM having a molecular weight of 200 kDa or less (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa), the hydroxyl polymer of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about ranging from about 20 kDa to about 300 kDa. (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30-100 kDa, or about 50-100 kDa).
[0023] The scaffold is of Formula (Ibb):
Pol mer
Figure imgf000005_0001
(Ibb),
wherein:
m is an integer from 1 to 2200
mi is an integer from 1 to 660,
m2 is an integer from 1 to 300,
m3 is an integer from 1 to 1 10, and
the sum of m, ml s m2 and m3 ranges from 4 to about 2200.
[0024] The scaffold of (Ibb) can include one or more of the following features:
[0025] When the hydroxyl polymeric carrier (i.e. hydroxyl polymer) in Formula (Ibb) has a molecular weight ranging from about 2 kDa to about 40 kDa, the sum of m, ml 5 m2, and m3 ranges from about 4 to about 300 (e.g., from about 45 to about 140; or from about 60 to about 1 10), m2 is an integer from 1 to about 40, m3 is an integer from 1 to about 18, and/or mi is an integer from 1 to about 140 (e.g., mi being about 1-90). For example, the sum of mi and m2 is an integer from 1 to 140.
[0026] When the hydroxyl polymeric carrier in Formula (Ibb) has a molecular weight ranging from 20 kDa to 300 kDa, the sum of m, mi, n¾, and m3 ranges from about 4 to about 2200 (e.g., from about 150 to about 1100; or from about 220 to about 740), m2 is an integer from 1 to about 300, m3 is an integer from 1 to about 110, and/or mi is an integer from 1 to about 660 (e.g., mi being about 10-250). For example, the sum of mi and m2 is an integer from 1 to 660.
[0027] For conjugating a PBRM having a molecular weight of 40 kDa or greater (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa), the polymer of the scaffold of the invention is a hydroxyl polymer having a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 40 kDa (e.g., from about 6 kDa to about 20 kDa; or from about 8 kDa to about 15 kDa) and the hydroxyl polymeric carrier is not a polyacetal or a polyketal.
[0028] For conjugating a PBRM having a molecular weight of 200 kDa or less (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa), the polymeric carrier of the scaffold of the invention is a hydroxyl polymer having a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about ranging from about 20 kDa to about 300 kDa (e.g., from about 20 kDa to about 150 kDa; or from about 30 kDa to about 100 kDa) and the hydroxyl polymeric carrier is not a polyacetal or a polyketal.
[0029] The scaffold of Formula (Ibb) further comprises a PBRM connected to the polymeric carrier via Lp.
[0030] One or more PBRMs are connected to one drug-carrying hydroxyl polymeric carrier.
[0031] The scaffold (e.g., a PBRM-polymer-drug-conjugate) of Formula (Ibb) is of
Formula (Ice):
Figure imgf000007_0001
(Ice),
wherein:
Figure imgf000007_0002
m between ΙΙΔ and PBRM denotes direct or indirect attachment of PBRM to Lp2,
each occurrence of PBRM independently has a molecular weight of less than 200 kDa (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa),
m is an integer from 1 to 2200,
\ is an integer from 1 to 660,
m2 is an integer from 1 to 300,
m3 is an integer from 1 to 110,
m4 is an integer from 1 to 60; and
the sum of m, mi, m2, m3 and m4 ranges from 4 to 2200.
[0032] When the hydroxyl polymeric carrier in Formula (Ice) has a molecular weight ranging from 20 kDa to 300 kDa, the sum of m, mi, m2, m3, and ni4 ranges from about 4 to about 2200 (e.g., from about 150 to about 1 100; or from about 220 to about 740), m2 is an integer from 1 to about 300, m3 is an integer from 1 to about 1 10, m4 is an integer from 1 to about 60, and/or \ is an integer from 1 to about 660 (e.g., mi being about 10-330 or about 15-100). For example, the sum of mi and m2 is an integer from 1 to 660, and the sum of m3 and m4 is an integer from 1 to 110. [0033] Alternatively or additionally, one or more drug-carrying polymeric carriers are connected to one PBRM. The scaffold (e.g., a PBRM-polymer-drug conjugate) comprises a PBRM with a molecular weight of greater than 40 kDa (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa) and one or more D-carrying polymeric carriers connected to the PBRM, in which each of the D-carrying polymeric carrier independently is of Formula (Idd):
Figure imgf000008_0001
wherein: terminal
Figure imgf000008_0002
in attached to L denotes direct or indirect attachment of L to PBRM such that the D-carrying polymeric carrier is connected to the PBRM,
m is an integer from 1 to 300,
mi is an integer from 1 to 140,
m2 is an integer from 1 to 40,
m3 is an integer from 0 to 18,
m4 is an integer from 1 to 10; and
the sum of m, mj, m2, m3, and m4 ranges from 4 to 300; provided that the total number of LP2 attached to the PBRM is 10 or less.
[0034] When the hydroxyl polymeric carrier in Formula (Idd) has a molecular weight ranging from 2 kDa to 40 kDa, the sum of m, mi, m2, m3, and m4 ranges from about 4 to about 300 (e.g., from about 45 to about 140; or from about 60 to about 1 10), m2 is an integer from 1 to about 40, m3 is an integer from 1 to about 18, m4 is an integer from 1 to about 10, and/or mj is an integer from 1 to about 140 (e.g., mi being about 10-330 or about 15-100). For example, the sum of mi and m2 is an integer from 1 to 140, and the sum of m3 and m4 is an integer from 1 to 18.
[0035] In Formula (Idd), the ratio of D to PBRM is between 5: 1 and 40:1 (e.g., 30: 1,
25: 1, 20: 1, 15: 1, 10:1, 9: 1 , 8:1 , 7: 1, 6;1, 5:1, 4:1, 3: 1, or 2: 1).
[0036] Each occurrence of D independently is selected from vinca alkaloids,
calicheamicins, SN38, non-natural camptothecins, pyrrolobenodiazepines, auristatins, tubulysins, duocarmycins, kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogs or prodrugs thereof.
[0037] Other features of scaffold of Formula (Ibb), (Ice) or (Idd) include those described herein where applicable.
[0038] In another aspect, the invention features a hydroxyl polymeric scaffold useful to conjugate with a PBRM. The scaffold comprises a polymeric carrier (e.g., a polymer), one or more -LD-D connected to the polymeric carrier, and one or more Lp connected to the polymeric carrier which is suitable for connecting a PBRM to the polymeric carrier but not yet connected to the PBRM, wherein:
each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa;
the polymeric carrier is a hydroxyl polymer containing one or more -OH and the polymer is not a polyacetal or a polyketal,
each occurrence of LD is independently a first linker having the structure:
RL1 -C(=0)-LD1-¾- ζ with R connected to an oxygen atom of the hydroxyl polymeric
D, RL1 -C(=0)-LD ,- D , . . carrier and L connected to D, and ^ in denotes direct or indirect attachment of D to LD!, and LD contains a biodegradable bond so that when the bond is broken,
D is released in an active form for its intended therapeutic effect;
LD! is a carbonyl-containing moiety;
each occurrence of Lp is independently a second linker not yet connected to PBRM having the structure:— RL2-C(=0)-LP! with RL2 connected to an oxygen atom of the polymeric carrier and LP1 suitable for connecting directly or indirectly to a PBRM, and each occurrence of the second linker is distinct from each occurrence of the first linker each of R and R independently is absent, alkyl, heteroalkyl, cycloalkyl, or heterocycloalkyl; and
each Lpl is independently a moiety containing a functional group that is capable of forming a covalent bond with a functional group of a PBRM but not yet connected to PBRM.
[0039] The hydroxyl polymeric scaffold can include one or more of the features of scaffold of Formula (Ibb), (Ice) or (Idd) described herein where applicable and one or more of the following features:
[0040] Each LD is independently -RL1-C(=0)-XD-MD1-YD-MD2-ZD-MD3-QD-MD4— with
MD4 directly connected to D, in which
each of RL1 independently is absent, alkyl, heteroalkyl, cycloalkyl, or heterocycloalkyl;
XD is -0-, -S-, -N R1)-, or absent, in which R1 is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety, -C(=0)R1B, -C(=0)OR1B, or -S02R1B, or -N R1)- is a heterocycloalkyl moiety, wherein R1B is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety;
each of YD, ZD, and QD, independently, is absent or a biodegradable linker moiety selected from the group consisting of— S-S— ,— C(=0)0— ,— C(=0)NR2— ,
— OC(=0)— ,— NR2C(=0)— ,— OC(=0)0— ,— OC(=0)NR2— ,— NR2C(=0)0— , — NR2C(=0)NR3— ,— C(OR2)0— ,— C(OR2)S— ,— C(OR2)NR3— ,— C(SR2)0— , — C(SR2)S— ,— C(SR2)NR3— ,— C(NR2R3)0— ,— C(NR2R3)S— ,— C(NR2R3)NR4— , — C(=0)S— ,— SC(=0)— ,— SC(=0)S— ,— OC(=0)S— ,— SC(=0)0— ,— C(=S)S— , — SC(=S)— ,— OC(=S)— ,— C(=S)0— ,— SC(=S)0— ,— OC(=S)S— ,— OC(=S)0— , —SC(=S)S— ,— C(=NR2)0— ,— C(=NR2)S— ,— C(=NR2)NR3— ,— OC(=NR2)— , — SC(=NR2)— ,— NR3C(=NR2)— ,— NR2S02— ,— NR2NR3— ,— C(=0)NR2NR3— , — NR2NR3C(=0)— ,— OC(=0)NR2NR3— ,— NR2NR3C(=0)0— ,— C(=S)NR2NR3— , — NR2NR3C(=S)— ,— C(=NR4)NR2NR3— ,— NR2NR3C(=NR4)— ,— 0(N=CR3)— , — (CR3=N)0— ,— C(=0)NR2-(N=CR3)— ,— (CR3=N)-NR2C(=0)— ,— S03— ,
— NR2S02NR3— ,— S02NR2— , and polyamide, wherein each occurrence of R2, R3, and R4 independently is hydrogen or an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety, or each occurrence of -NR2- or -NR2NR3- is a heterocycloalkyl moiety; and
each of MD1, MD2, MD3, and MD4 independently, is absent or a non-biodegradable linker moiety selected from the group consisting of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, a carbocyclic moiety, a heterocyclic moiety, and a combination thereof, and each of MD1, MD2, and MD3 optionally contains one or more -(C=0)- but does not contain any said biodegradable linker moiety;
provided that for each LD1 at least one of XD, YD, ZD, and QD is not absent.
Figure imgf000011_0001
[0041] Each when not connected to PBRJV1, independently comprises a terminal group Wp, in which each Wp independently is:
(1) (2) (3)
Figure imgf000011_0002
Figure imgf000011_0003
(7) (8) (9)
Figure imgf000011_0004
Figure imgf000011_0005
Figure imgf000011_0006
Figure imgf000012_0001
(23)
Figure imgf000012_0002
in which R1K is a leaving group (e.g., halide or RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety), R1A is a sulfur protecting group, and ring A is cycloalkyl or heterocycloalkyl, and R,J is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
[0042] Each R1A independently is
Figure imgf000012_0003
,
Figure imgf000012_0004
, or , in which r is 1 or 2 and each of Rsl , Rs2, and Rs3 is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
[0043] Each Lp is independently a linker having the structure:
RL1-C(=0)-LDJ- -LP2 P2
ζ in which L is a moiety containing a functional group that is capable of forming a covalent bond with a functional group of a PBRM, and ^ in
RL,-C(=0)-LD^-LP2 P2 D1
ς denotes direct or indirect attachment of L to L .
"LD1— - L P2
[0044] Each , when connected to PBRM, independently is -XP-MP1-
YP-MP2"-ZP-MP3-QP-MP4— , with XP directly connected to the carbonyl group of RL1-C(=0) and MP4 directly connected to PBRM, in which:
XP is -0-, -S-, -N(R')-, or absent, in which R1 is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety, -C(=0)R, B, -C(=0)OR1 B, or -S02R1 B, or -N(R')- is a heterocycloalkyl moiety, wherein R1 B is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety;
each of Yp, Zp, and Qp, independently, is absent or a biodegradable linker moiety selected from the group consisting of— S-S— ,— C(=0)0— ,— C(=0)NR2— ,
— OC(=0)— ,— NR2C(=0)— ,— OC(=0)0— ,— OC(=0)NR2— ,— R2C(=0)0— , — NR2C(=0)NR3— ,— C(OR2)0— ,— C(OR2)S— ,— C(OR2)NR3— ,— C(SR2)0— , — C(SR2)S— ,— C(SR2)NR3— ,— C(NR2R3)0— ,— C(NR2R3)S— ,— C(NR2R3)NR4— , — C(=0)S— ,— SC(=0)— ,— SC(=0)S— ,— OC(=0)S— ,— SC(=0)0— ,— C(=S)S— , — SC(=S)— ,— OC(=S)— ,— C(=S)0— ,— SC(=S)0— ,— OC(=S)S— ,— OC(=S)0— , — SC(=S)S— ,— C(=NR2)0— ,— C(=NR2)S— ,— C(=NR2)NR3— ,— OC(=NR2)— , — SC(=NR2)— ,— NR3C(=NR2)— ,— NR2S02— ,— NR2NR3— ,— C(=0)NR2NR3— , — NR2NR3C(=0)— ,— OC(=0)NR2NR3— ,— NR2NR3C(=0)0— ,— C(=S)NR2NR3— , — NR2NR3C(=S)— ,— C(=NR4)NR2NR3— ,— NR2NR3C(=NR4)— ,— 0(N=CR3)— , — (CR3=N)0— ,— C(=0)NR2-(N=CR3)— ,— (CR3=N)-NR2C(=0)— ,— S03— ,
— NR2S02NR3— ,— S02NR2— , and polyamide, wherein each occurrence of R2, R3, and R4 independently is hydrogen or an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety, or each occurrence of-NR2- or -NR2NR3- is a heterocycloalkyl moiety; and
each of MP1, MP2, MP3, and Mp4 independently, is absent or a non-biodegradable linker moiety selected from the group consisting of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, a carbocyclic moiety, a heterocyclic moiety, and a combination thereof, and each of MP1, MP2, and Mp3 optionally contains one or more -(C=0)- but does not contain any said biodegradable linker moiety; provided that for each
Figure imgf000013_0001
connected to PBRM, at least one of Xp, Yp, Zp, and Qp is not absent.
[0045] The functional group of L or LP2 is selected from -SRP, -S-S-LG, maleimido, and halo, in which LG is a leaving group and Rp is H or a sulfur protecting group.
[0046] LD1 comprises— X-(CH2)v-C(=0)— with X directly connected to the carbonyl group of RLI-C(=0), in which X is CH2, O, or NH, and v is an integer from 1 to 6.
[0047] LP1 or LP2 contains a biodegradable bond.
[0048] Each of RL! and RL2 is absent. [0049] The oxygen atom of the hydroxyl polymeric earner R and R is connected to the oxygen atom from the one or more -OH groups of the polymeric carrier.
[0050] Each of MD1 and MP1 independently is C]-6 alkyl or Ci-6 heteroalkyl.
[0051] Each of MD2, MD3, MD4, MP2, MP3, and Mp4, independently is absent, C]-6 alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, or a combination thereof.
LD1 £-LP2
[0052] In each ζ , at most one of MP2 and MP3 has one of the following
Figure imgf000014_0001
in which q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3. [0053] In yet another aspect, the invention encompasses a conjugate comprising a polymeric carrier, one or more -LD-D connected to the polymeric carrier, and a protein based recognition-molecule (PBRM) connected to the polymeric carrier via LP, wherein:
each occurrence of D is independently a therapeutic agent (e.g., a drug) having a molecular weight < 5 kDa;
the polymeric carrier is a hydroxyl polymeric carrier and the polymeric carrier is not a polyacetal or polyketal,
each occurrence of LD is independently a first linker having the structure:— RL1-C(=0)- XD-MD1-YD-MD2-ZD-MD3-QD-MD4— , with RL1 connected to an oxygen atom of the hydroxyl polymeric carrier and MD4 connected to D;
each occurrence of LP is independently a second linker having the structure:— RL2- C(=0)-XP-MP1-YP-MP2- ZP-MP3-QP-MP4— , with RL2 connected to an oxygen atom of the hydroxyl polymeric carrier and MP4 connected to the PBRM, and each occurrence of the second linker is distinct from each occurrence of the first linker;
each of RL1 and RL2 independently is absent, alkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl;
each of XD and Xp, independently is -0-, -S-, -N(R')-, or absent, in which R1 is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety, -C(=0)R1 B, -C(=0)OR1B, -S02R1B or -N(R')- is a heterocycloalkyl moiety, wherein R1B is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety;
each of YD, Yp, ZD, ZP, QD, and Qp, independently, is absent or a biodegradable linker moiety selected from the group consisting of— S-S— ,— C(=0)0— ,— C(=0)NR2— , — OC(=0)— ,— NR2C(=0)—— OC(=0)0— ,— OC(=0)NR2— ,— NR2C(=0)0— , — NR2C(=0)NR3— ,— C(OR2)0— ,— C(OR2)S— ,— C(OR2)NR3—— C(SR2)0— , — C(SR2)S—— C(SR2)NR3— ,— C( R2R3)0— ,— C( R2R3)S— ,— C( R2R3)NR4— , — C(=0)S— ,— SC(=0)— ,— SC(=0)S— ,— OC(=0)S— ,— SC(=0)0— ,— C(=S)S— — SC(=S)— ,— OC(=S)—— C(=S)0— ,— SC(=S)0— ,— OC(=S)S— ,— OC(=S)0— , — SC(=S)S— ,— C(=NR2)0— ,— C(=NR2)S— ,— C(=NR2)NR3— ,— OC(=NR2)— , — SC(=NR2)— ,— NR3C(=NR2)— ,— NR2S02— ,— NR2NR3— ,— C(=0)NR2NR3— , — NR2NR3C(=0)— ,— OC(=0)NR2NR3— ,— NR2NR3C(=0)0— , — C(=S)NR2NR3— — NR2NR3C(=S)— ,— C(=NR4)NR2NR3— ,— NR2NR3C(=NR4)— ,— 0(N=CR3)— , — (CR3=N)0— ,— C(=0)NR2-(N=CR3)— ,— (CR3=N)-NR2C(=0)— ,— S03— , — NR2S02NR3— ,— S02NR2— , and polyamide, wherein each occurrence of R2, R3, and R4 independently is hydrogen or an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety, or each occurrence of -NR2- or -NR2NR3- is a heterocycloalkyl moiety; and
each of MD1, MD2, MD3, MD4, MP1, MP2, MP3 and MP4, independently, is absent or a nonbiodegradable linker moiety selected from the group consisting of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, a carbocyclic moiety, a heterocyclic moiety, and a combination thereof, and each of MD1, MD2, MD3, MP1, Mp2, and MP3 optionally contains one or more -(C=0)- but does not contain any said biodegradable linker moiety;
provided that for each LD, at least one of XD, YD, ZD, and QD is not absent, and for each Lp, at least one of Xp, Yp, Zp, and Qp is not absent.
[0054] The conjugate can include one or more of the features of scaffold of Formula
(Ibb), (Ice) or (Idd) described herein where applicable and one or more of the following features:
[0055] The polymeric carrier can be a linear, branched or cyclic hydroxyl polymer, and the hydroxyl polymer is not a polyacetal or polyketal.
[0056] The oxygen atoms of the hydroxyl polymeric carrier that RL1 and RL2 are connected to are each an oxygen atom from the one or more -OH groups of the polymeric carrier.
[0057] For each LD, MD1 is not absent when XD is absent.
[0058] For each Lp, MP1 is not absent when Xp is absent.
[0059] The polymeric carrier can be further substituted with one or more— RL1-C(=0)-
XD-MD1-YD-MD2-WD, in which each WD independently is:
(1) (2) (3)
l-SH
(4) (5) (6)
Figure imgf000016_0001
Figure imgf000017_0001
(27) (28) (29)
Figure imgf000018_0001
(30) (31) (32) (33)
Figure imgf000018_0002
in which R1A is a sulfur protecting group, each of ring A and B, independently, is cycloalkyl or heterocycloaikyl, Rw is an aliphatic, heteroaliphatic, carbocyclic or heterocycloaikyl moiety; ring D is heterocycloaikyl; R1J is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or
heterocycloaikyl moiety; and R1K is a leaving group (e.g., halide or RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloaikyl moiety).
[0060] The polymeric carrier can be further substituted with one or more— R -C(=0)-
XP-MP1-YP-MP2'WP, in which each Wp independently is:
(1) (2) (3)
li-SH . -^-SR A . - -N3.
Figure imgf000018_0003
Figure imgf000019_0001
I .
in which R is a leaving group (e.g., halide or RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety), R1A is a sulfur protecting group, and ring A is cycloalkyl or heterocycloalkyl, and R1J is hydrogen, an aliphatic, heteroaliphatic,
carbocyclic, or heterocycloalkyl moiety. For exam le, R1A is
Figure imgf000019_0002
Figure imgf000019_0003
or , in which r is 1 or 2 and each of Rsl , Rs2, and Rs is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
[0061] Ring A can be C3-8 cycloalkyl or 5-19 membered heterocycloalkyl.
[0062] Ring A can be
Figure imgf000019_0004
[0063] Ring B can be C3-8 cycloalkyl or 3-12 membered heterocycloalkyl.
[0064] Ring D can be piperazinyl or piperidinyl.
[0065] Each of Rsl, Rs2, and Rs3 can be hydrogen or Ci-6 alkyl.
[0066] Each PBRM independently can be a peptide, a peptide mimetic, an antibody, or an antibody fragment.
[0067] Each of MD1 and MP1 independently can be C1-6 alkyl or C1-6 heteroalkyl.
[0068] Each of MD2, MD3, MD4, Mp2, MP3, and Mp4, independently can be absent, Ci-6 alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, or a combination thereof.
[0069] For each LD, at most two of MD2, MD3, and MD4 can be absent.
[0070] For each Lp, at most two of Mp2, MP3, and MP4 can be absent.
[0071] For each L , at most one of M and M can have one of the following
Figure imgf000020_0001
Figure imgf000021_0001
in which q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3.
p, at most one of Mp2 and Mp3 can have one of the following structures:
Figure imgf000021_0002
in which q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3.
Figure imgf000022_0001
21 21)
Figure imgf000023_0001
(22) (23) (24)
Figure imgf000023_0002
in which ring A or B independently is cycloalkyl or heterocycloalkyl; R is an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety; R1J is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety; and ring D is heterocycloalkyl.
[0074] For each Lp, each of-Mp2-Zp-, -ZP-MP3-, -ZP-MP2-, and -Mp3-Zp-, independently, can have one of the following structures:
(1)
Figure imgf000023_0003
(6)
Figure imgf000023_0004
(7) (8) (9)
Figure imgf000023_0005
(10) (1 1) (12)
Figure imgf000024_0001
in which ring A is cycloalkyl or heterocycloalkyl and R is hydrogen, an aliphatic,
heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
[0075] Each of XD and Xp, independently can be absent.
[0076] Each of XD and Xp, independently can be O or NH.
[0077] Each of XD and Xp, independently can be
Figure imgf000024_0002
[0078] Each of YD and Yp independently can be -S-S-, -OCO-, -COO-, -CONH-, -NHCO
[0079] Each of QD and Qp independently can be absent, -S-S-, -OCO-, -COO-, -CONH- -NHCO-, -OCONHNH- or -NHNHCOO-.
[0080] In particular, this invention features a conjugate of Formula (I):
Figure imgf000024_0003
(I), wherein each of n, ni, n2, n3, and r¼, is the molar fraction of the corresponding polymer unit ranging between 0 and 1 ; n + ni + n2 + n3 + 1¼ = 1 ; provided that none of n, n2, and i¼ is 0.
[0081] In the protein-polymer-drug conjugate of Formula (I), each D can be the same or different moiety and each PBRM can be the same or different moiety.
[0082] The ratio between n2 and i¼ can be greater than 1 :1 , and up to 200: 1 (e.g., up to
100: 1), e.g., between 2: 1 and 40:1 ; between 5:1 and 20: 1 ; between 10:1 and 50: 1 , between 25: 1 and 50: 1 , or between 30: 1 and 50: 1.
[0083] The ratio between n2 and i¼ can be about 50: 1 , 40: 1 , 30: 1 , 25 : 1 , 20: 1 , 10: 1 , 5: 1 or
2: 1.
[0084] For example the ratio between D and PBRM can be greater than 1 : 1, and up to
200: 1 (e.g., up to 100: 1), e.g., between 2:1 and 40:1 ; between 5:1 and 20: 1 ; between 10: 1 and 50: 1, between 25: 1 and 50: 1, or between 30: 1 and 50: 1. Examples of PBRM include but are not limited to, full length antibodies such as IgG and IgM, antibody fragments such as Fabs, scFv, scFvFc, camelids, Fab2, and the like, small proteins, and peptides.
[0085] In one embodiment the ratio between D and PBRM can be about 50: 1 , 40: 1 , 30: 1 ,
25:1 , 20:1 , 15: 1, 10: 1, 9:1 , 8:1, 7: 1, 6;1, 5:1, 4: 1, 3: 1 , or 2:1.
[0086] In another embodiment the ratio between D and PBRM can be about 25: 1 , 20:1,
15: 1, 10: 1, 5: 1 or 2: 1.
[0087] In another aspect, the invention provides compositions comprising the conjugates, methods for their preparation, and methods of use thereof in the treatment of various disorders, including, but not limited to cancer.
[0088] The invention also features a drug-polymer conjugate (e.g., therapeutic agent- polymer conjugate) that is similar to the protein-polymer-drug conjugate described above except that drug-polymer conjugate does not contain a PBRM. In this embodiment the polymer-drug conjugate may comprise a plurality of drug moieties in which each D can be the same or different. In this embodiment, r is 0 in the conjugate of Formula (I). The methods of producing the drug-polymer conjugates and methods of treating various disorders (e.g., cancer) are also contemplated and described herein.
[0089] The invention also features a protein-polymer conjugate (e.g., PBRM-polymer conjugate) that is similar to the protein-polymer-drug conjugate described above except that protein-polymer conjugate does not contain a drug. In this embodiment the protein-polymer conjugate may comprise a plurality of protein moieties in which each PBRM can be the same or different. In this embodiment, n2 is 0 in the conjugate of Formula (I). The methods of producing the drug-polymer conjugates or polymeric scaffolds and methods of treating various disorders (e.g., cancer) are also contemplated and described herein. The target cancer can be anal, astrocytoma, leukemia, lymphoma, head and neck, liver, testicular, cervical, sarcoma, hemangioma, esophageal, eye, laryngeal, mouth, mesothelioma, skin, myeloma, oral, rectal, throat, bladder, breast, uterus, ovary, prostate, lung, colon, pancreas, renal, or gastric cancer.
[0090] The invention further relates to a pharmaceutical composition comprising a polymeric scaffold or conjugate described herein and a pharmaceutically acceptable carrier.
[0091] In yet another aspect, the invention relates to a method of diagnosing a disorder in a subject suspected of having the disorder. The method comprises administering an effective amount of the conjugate described herein to the subject suspected of having the disorder or performing an assay to detect a target antigen/receptor in a sample from the subject so as to determine whether the subject expresses target antigen or receptor.
[0092] Also within the scope of the invention is a method of preparing a scaffold described above. The method comprises providing a hydroxyl polymer that is substituted with one or more -D and one or more— (0)u-C(=0)-LD1, and reacting the polymer with a compound containing an LP2 moiety to produce the scaffold comprising a polymer substituted both with one
— <0)u-C(=0)-iJ^-LP2
or more -D and with one or more ς . Alternativel the method comprises providing a polymer that is substituted with one or more
Figure imgf000026_0001
and one or more— (0)u-C(=0)-LD1, and reacting the polymer with D that contains a functional group that is capable of forming a covalent bond with— (0)u-C(=0)-LD1 to produce the scaffold com rising a polymer substituted both with one or more -D and with one or more
Figure imgf000026_0002
[0093] As used herein the terms "hydroxyl polymer," "polymer," "hydroxyl polymeric carrier," and "polymeric carrier" are used interchangeably when the polymer or polymeric carrier contains one or more -OH groups (i.e., hydroxyl of an alcohol or a carboxylic acid) connected to the polymer or polymeric carrier. As used herein the above terms do not include a polyacetal or polyketal. "Alcohol" refers to primary, secondary (sec), and tertiary (tert) alcohols. [0094] As used herein, the terms "polymeric scaffold" or simply "scaffold" and
"conjugate" are used interchangeably when the scaffold comprises one or more PBRM and one or more D molecules. The scaffold comprises a linear, branched or cyclic hydroxyl polymeric carrier and the hydroxyl polymeric carrier is not a polyacetal or polyketal.
[0095] As used herein, the expression "capable of or "suitable for" connecting to, conjugating with, or forming, in one embodiment, refers to an association (e.g., a bond such as a covalent bond) not yet present.
[0096] Unless otherwise specified, the appending groups of the polymeric carrier described herein, such as the appending groups containing D, PBRM, LD1, and LP2, etc., are randomly distributed along the polymer backbone.
[0097] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods and examples are illustrative only and are not intended to be limiting.
[0098] One of the advantages of the present invention is that the protein-polymer-drug conjugates or the polymeric scaffolds described herein greatly enhances the bioavailability of the drugs to be delivered and/or enhances the bioavailability of the protein attached to the polymeric carrier. Another advantage of the present invention is that the efficacy of the protein-polymer- drug conjugates described herein increases or at least remains substantially the same with increases in the drug load of the conjugates. Yet another advantage of the present invention is that the protein-polymer conjugates via thiol conjugation to the cysteine moiety of the protein exhibits substantially improved stability. Other features and advantages of the invention will be apparent from the following detailed description and claims. BRIEF DESCRIPTION OF FIGURES
[0099] Figure 1 is a group of tables listing "m" values per hydroxyl polymeric scaffold and polymer/PBRM ratios of embodiments of the invention. Table 1 relates to PBRM-drug polymer conjugates in which the PBRMs have a molecular weight of 40 kDa or greater (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa) and one or more hydroxyl polymer-Drug scaffolds are attached to one PBRM. Table 2 relates to PBRM- drug polymer conjugates in which the PBRMs have a molecular weight of 200 kDa or less (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa), and one or more PBRMs are attached to one hydroxyl polymer-Drug scaffold, wherein the polymer is a linear, branched or cyclic hydroxyl polymer.
DETAILED DESCRIPTION OF CERTAIN PREFERRED EMBODIMENTS OF THE INVENTION
[00100] The present invention provides novel protein-polymer-drug conjugates, polymeric scaffolds for making the conjugates, synthetic methods for making the conjugates or polymeric scaffolds, pharmaceutical compositions containing them and various uses of the conjugates.
[00101] The present invention also provides novel polymer-drug conjugates, synthetic methods for making the conjugates, pharmaceutical compositions containing them and various uses of the conjugates.
[00102] The present invention further provides novel drug derivatives, synthetic methods for making the derivatives, pharmaceutical compositions containing them and various uses of the drug derivatives.
Definition/Terminology
[00103] Certain compounds of the present invention and definitions of specific functional groups are also described in more detail herein. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, the entire contents of which are incorporated herein by reference. Furthermore, it will be appreciated by one of ordinary skill in the art that the synthetic methods, as described herein, utilize a variety of protecting groups.
[00104] The use of the articles "a", "an", and "the" in both the following description and claims are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising", "having", "including", and "containing" are to be construed as open terms (i.e., meaning "including but not limited to") unless otherwise noted. Additionally whenever "comprising" or another open-ended term is used in an embodiment, it is to be understood that the same embodiment can be more narrowly claimed using the intermediate term "consisting essentially of or the closed term "consisting of."
[00105] The term "about", "approximately", or "approximate", when used in connection with a numerical value, means that a collection or range of values is included. For example, "about X" includes a range of values that are ±20%, ±10%, ±5%, ±2%, ±1%, ±0.5%, ±0.2%, or ±0.1% of X, where X is a numerical value. In one embodiment, the term "about" refers to a range of values which are 5% more or less than the specified value. In another embodiment, the term "about" refers to a range of values which are 2% more or less than the specified value. In another embodiment, the term "about" refers to a range of values which are 1% more or less than the specified value.
[00106] Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. A range used herein, unless otherwise specified, includes the two limits of the range. For example, the expressions "x being an integer between 1 and 6" and "x being an integer of 1 to 6" both mean "x being 1 , 2, 3, 4, 5, or 6".
[00107] "Protecting group": as used herein, the term protecting group means that a particular functional moiety, e.g. , O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound. In preferred embodiments, a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group must be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the other functional groups; the protecting group forms an easily separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction. As detailed herein, oxygen, sulfur, nitrogen and carbon protecting groups may be utilized. For example, in certain embodiments, certain exemplary oxygen protecting groups may be utilized. These oxygen protecting groups include, but are not limited to methyl ethers, substituted methyl ethers (e.g., MOM (methoxymethyl ether), MTM (methylthiomethyl ether), BOM (benzyloxymethyl ether), and PMBM (p- methoxybenzyloxymethyl ether)), substituted ethyl ethers, substituted benzyl ethers, silyl ethers (e.g., TMS (trimethylsilyl ether), TES (triethylsilyl ether), TIPS (triisopropylsilyl ether), TBDMS (t-butyldimethylsilyl ether), tribenzyl silyl ether, and TBDPS (t-butyldiphenyl silyl ether), esters (e.g., formate, acetate, benzoate (Bz), trifluoroacetate, and dichloroacetate), carbonates, cyclic acetals and ketals. In certain other exemplary embodiments, nitrogen protecting groups are utilized. Nitrogen protecting groups, as well as protection and deprotection methods are known in the art. Nitrogen protecting groups include, but are not limited to, carbamates (including methyl, ethyl and substituted ethyl carbamates (e.g., Troc), amides, cyclic imide derivatives, N- Alkyl and N-Aryl amines, imine derivatives, and enamine derivatives. In yet other
embodiments, certain exemplary sulfur protecting groups may be utilized. The sulfur protecting groups include, but are not limited to those oxygen protecting group describe above as well as aliphatic carboxylic acid (e.g., acrylic acid), maleimide, vinyl sulfonyl, and optionally substituted maleic acid. Certain other exemplary protecting groups are detailed herein, however, it will be appreciated that the present invention is not intended to be limited to these protecting groups; rather, a variety of additional equivalent protecting groups can be readily identified using the above criteria and utilized in the present invention. Additionally, a variety of protecting groups are described in "Protective Groups in Organic Synthesis" Third Ed. Greene, T.W. and Wuts, P.G., Eds., John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.
[00108] "Leaving group" refers to a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage. Leaving groups can be anions or neutral molecules. Leaving groups include, but are not limited to halides such as CF, Br~, and Γ, sulfonate esters, such as ^ ra-toluenesulfonate ("tosylate", TsO~), and RC(0)0- in which R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety. [00109] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illustrate the invention and is not to be construed as a limitation on the scope of the claims unless explicitly otherwise claimed. No language in the specification is to be construed as indicating that any non-claimed element is essential to what is claimed.
[00110] "Antibody" refers to a full-length antibody or functional fragment of an antibody comprising an immunoglobulin. By a "functional fragment" it is meant a sufficient portion of the immunoglobulin or antibody is provided that the moiety effectively binds or complexes with the cell surface molecule for its target cell population.
[00111] An immunoglobulin may be purified, generated recombinantly, generated synthetically, or combinations thereof, using techniques known to those of skill in the art. While immunoglobulins within or derived from IgG antibodies are particularly well-suited for use in this invention, immunoglobulins from any of the classes or subclasses may be selected, e.g., IgG, IgA, IgM, IgD and IgE. Suitably, the immunoglobulin is_of the class IgG including but not limited to IgG subclasses (IgGl, 2, 3 and 4) or class IgM which is able to specifically bind to a specific epitope on an antigen. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoreactive portions of intact
immunoglobulins. Antibodies may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, camelized single domain antibodies, intracellular antibodies ("intrabodies"), recombinant antibodies, anti-idiotypic antibodies, domain antibodies, linear antibody, multispecific antibody, antibody fragments, such as, Fv, Fab, F(ab)2, F(ab)3, Fab', Fab'-SH, F(ab')2, single chain variable fragment antibodies (scFv), tandem/bis-scFv, Fc, pFc', scFvFc, (or scFv-Fc), disulfide Fv (dsfv), bispecific antibodies (bc-scFv) such as BiTE antibodies; camelid antibodies, resurfaced antibodies, humanized antibodies, fully human antibodies, single-domain antibody (sdAb, also known as NANOBODY®), chimeric antibodies, chimeric antibodies comprising at least one human constant region, dual-affinity antibodies such as, dual-affinity retargeting proteins (DART™), divalent (or bivalent) single-chain variable fragments (di-scFvs, bi-scFvs) including but not limited to minibodies, diabodies, triabodies or tribodies, tetrabodies, and the like, and multivalent antibodies. "Antibody fragment" refers to at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region. As used herein, the term "antibody" refers to both the full-length antibody and antibody fragments unless otherwise specified.
[00112] "Protein based recognition-molecule" or "PBRM" refers to a molecule that recognizes and binds to a cell surface marker or receptor such as, a transmembrane protein, surface immobilized protein, or proteoglycan. Examples of PBRMs include but are not limited to, antibodies (e.g., Trastuzumab, Cetuximab, Rituximab, Bevacizumab, Epratuzumab,
Veltuzumab, Labetuzumab, B7-H4, B7-H3, CA125, CD33, CXCR2, EGFR, FGFR1, FGFR2, FGFR3, FGFR4, HER2, PD-L1 and anti-5T4) or peptides (LHRH receptor targeting peptides, EC-1 peptide), lipocalins, such as, for example, anticalins, proteins such as, for example, interferons, lymphokines, growth factors, colony stimulating factors, and the like, peptides or peptide mimics, and the like. The protein based recognition molecule, in addition to targeting the modified polymer conjugate to a specific cell, tissue or location, may also have certain therapeutic effect such as antiproliferative (cytostatic and/or cytotoxic) activity against a target cell or pathway. The protein based recognition molecule comprises or may be engineered to comprise at least one chemically reactive group such as, -CO OH, primary amine, secondary amine -NHR, -SH, or a chemically reactive amino acid moiety or side chains such as, for example, tyrosine, histidine, cysteine, or lysine. In one embodiment, a PBRM may be a ligand (LG) or targeting moiety which specifically binds or complexes with a cell surface molecule, such as a cell surface receptor or antigen, for a given target cell population. Following specific binding or complexing of the ligand with its receptor, the cell is permissive for uptake of the ligand or ligand-drug-conjugate, which is then internalized into the cell. As used herein, a ligand that "specifically binds or complexes with" or "targets" a cell surface molecule preferentially associates with a cell surface molecule via intermolecular forces. For example, the ligand can preferentially associate with the cell surface molecule with a d of less than about 50 nM, less than about 5 nM, or less than 500 pM. Techniques for measuring binding affinity of a ligand to a cell surface molecule are well-known; for example, one suitable technique, is termed surface plasmon resonance (SPR). In one embodiment, the ligand is used for targeting and has no detectable therapeutic effect as separate from the drug which it delivers. In another embodiment, the ligand functions both as a targeting moiety and as a therapeutic or immunomodulatory agent (e.g., to enhance the activity of the active drug or prodrug). [00113] "Biocompatible" as used herein is intended to describe compounds that exert minimal destructive or host response effects while in contact with body fluids or living cells or tissues. Thus a biocompatible group, as used herein, refers to an aliphatic, cycloalkyl, heteroaliphatic, heterocycloalkyl, aryl, or heteroaryl moiety, which falls within the definition of the term biocompatible, as defined above and herein. The term "Biocompatibility" as used herein, is also taken to mean that the compounds exhibit minimal interactions with recognition proteins, e.g., naturally occurring antibodies, cell proteins, cells and other components of biological systems, unless such interactions are specifically desirable. Thus, substances and functional groups specifically intended to cause the above minimal interactions, e.g., drugs and prodrugs, are considered to be biocompatible. Preferably (with exception of compounds intended to be cytotoxic, such as, e.g., antineoplastic agents), compounds are "biocompatible" if their addition to normal cells in vitro, at concentrations similar to the intended systemic in vivo concentrations, results in less than or equal to 1% cell death during the time equivalent to the half-life of the compound in vivo {e.g. , the period of time required for 50% of the compound administered in vivo to be eliminated/cleared), and their administration in vivo induces minimal and medically acceptable inflammation, foreign body reaction, immunotoxicity, chemical toxicity and/or other such adverse effects. In the above sentence, the term "normal cells" refers to cells that are not intended to be destroyed or otherwise significantly affected by the compound being tested.
[00114] "Biodegradable": As used herein, "biodegradable" polymers are polymers that are susceptible to biological processing in vivo. As used herein, "biodegradable" compounds or moieties are those that, when taken up by cells, can be broken down by the lysosomal or other chemical machinery or by hydrolysis into components that the cells can either reuse or dispose of without significant toxic effect on the cells. The term "biocleavable" as used herein has the same meaning of "biodegradable". The degradation fragments preferably induce little or no organ or cell overload or pathological processes caused by such overload or other adverse effects in vivo. Examples of biodegradation processes include enzymatic and non-enzymatic hydrolysis, oxidation and reduction. Suitable conditions for non-enzymatic hydrolysis of the biodegradable protein-polymer-drug conjugates (or their components, e.g., the biodegradable polymeric carrier and the linkers between the carrier and the antibody or the drug molecule) described herein, for example, include exposure of the biodegradable conjugates to water at a temperature and a pH of lysosomal intracellular compartment. Biodegradation of some protein-polymer-drug conjugates (or their components, e.g., the biodegradable polymeric carrier and the linkers between the carrier and the antibody or the drug molecule), can also be enhanced extracellularly, e.g., in low pH regions of the animal body, e.g., an inflamed area, in the close vicinity of activated macrophages or other cells releasing degradation facilitating factors. In certain preferred embodiments, the effective size of the polymer carrier at pH~7.5 does not detectably change over 1 to 7 days, and remains within 50% of the original polymer size for at least several weeks. At pH~5, on the other hand, the polymer carrier preferably detectably degrades over 1 to 5 days, and is completely transformed into low molecular weight fragments within a two-week to several- month time frame. Polymer integrity in such tests can be measured, for example, by size exclusion HPLC. Although faster degradation may be in some cases preferable, in general it may be more desirable that the polymer degrades in cells with the rate that does not exceed the rate of metabolization or excretion of polymer fragments by the cells. In preferred embodiments, the polymers and polymer biodegradation byproducts are biocompatible.
[00115] "Bioavailability": The term "bioavailability" refers to the systemic availability (i.e., blood/plasma levels) of a given amount of drug or compound administered to a subject. Bioavailability is an absolute term that indicates measurement of both the time (rate) and total amount (extent) of drug or compound that reaches the general circulation from an administered dosage form.
[00116] "Hydrophilic": The term "hydrophilic" as it relates to substituents, e.g., on the polymer monomeric units does not essentially differ from the common meaning of this term in the art, and denotes chemical moieties which contain ionizable, polar, or polarizable atoms, or which otherwise may be solvated by water molecules. Thus a hydrophilic group, as used herein, refers to an aliphatic, cycloalkyl, heteroaliphatic, heterocycloalkyl, aryl or heteroaryl moiety, which falls within the definition of the term hydrophilic, as defined above. Examples of particular hydrophilic organic moieties which are suitable include, without limitation, aliphatic or heteroaliphatic groups comprising a chain of atoms in a range of between about one and twelve atoms, hydroxyl, hydroxyalkyl, amine, carboxyl, amide, carboxylic ester, thioester, aldehyde, nitryl, isonitryl, nitroso, hydroxylamine, mercaptoalkyl, heterocycle, carbamates, carboxylic acids and their salts, sulfonic acids and their salts, sulfonic acid esters, phosphoric acids and their salts, phosphate esters, polyglycol ethers, polyamines, polycarboxylates, polyesters and polythioesters. In certain embodiments, hydrophilic substituents comprise a carboxyl group (COOH), an aldehyde group (CHO), a ketone group (COCi-4 alkyl), a methylol (CH2OH) or a glycol (for example, CHOH-CH2OH or CH-(CH2OH)2), NH2, F, cyano, S03H, PO3H, and the like.
[00117] The term "hydrophilic" as it relates to the polymers of the invention generally does not differ from usage of this term in the art, and denotes polymers comprising hydrophilic functional groups as defined above. In a preferred embodiment, hydrophilic polymer is a water- soluble polymer. Hydrophilicity of the polymer can be directly measured through determination of hydration energy, or determined through investigation between two liquid phases, or by chromatography on solid phases with known hydrophobicity, such as, for example, C4 or CI 8.
[00118] "Polymeric Carrier": The term polymeric carrier, as used herein, refers to a hydroxyl polymer or a modified hydroxyl polymer, which is suitable for covalently attaching to or can be covalently attached to one or more drug molecules with a designated linker and/or one or more PBRMs with a designated linker. The unmodified hydroxyl polymer of the invention has four or more -OH groups connected to the polymer. The "-OH group" as used herein refers to either an alcohol hydroxyl group or a hydroxyl group from a carboxylic acid, unless otherwise specified.
[00119] "Hydroxyalkyl starch" refers to a starch derivative that has been substituted by one or more hydroxyalkyl groups. In some embodiments the hydroxyalkyl group comprises 2 to 4 carbon atoms, such as, for example, hydroxyethyl starch, hydroxypropyl starch and
hydroxybutyl starch. In another embodiment, the hydroxyalkyl starch is hydroxyethyl starch (HES).
[00120] "Polyglycerol" refers to a polymer obtained by condensation of glycerol or by anionic ring-opening polymerization of glycidol (l,2-epoxy-3-hydroxypropane). Polyglycerol polymers additionally can be modified by derivatization with other hydroxy containing compounds, such as, for example, polyethylene glycol (PEG) or carboxylic acids (such as, for example, propionic acid) to improve their polyglycerol solubility or biocompatibility.
[00121] "PEG polymer" refers to a linear or branched polyethyleneglycol (PEG) derivative (including but not limited to, multi-arm PEG) comprising terminal one or more hydroxy or carboxy groups. Branched PEGs are typically prepared by pegylation of hydroxy, carboxy or amino groups of multi-functional scaffolds selected from, but not limited to, pentaerithritol; sorbitol; amino-(trioxymethyl methane); di-, tri- and tetra-glycerol, and polyglycerol; poly(alpha-glutamic acid), poly(gamma-glutamic acid), poly(glutamic acid) dendrimers, and polylysine, polyethyleneimine.
[00122] "HPMA polymer" refers to polymers of N-(2-hydroxypropyl)methacylamide (HPMA) and/or HPMA copolymers with methacrylic acid and/or methacrylic acid ester or amide derivatives obtained by free radical polymerization thereof.
[00123] "Carboxymethyl dextrans" (CM dextran) refer to a dextran derivative that has up to 20% by weight of carboxymethyl groups. The dextrans are typically prepared by carboxymethylation of dextran hydroxyl groups with bromoacetic acid in basic conditions, and are available as CM dextran sodium salt.
[00124] "Polyvinyl alcohol" refers to the polymers prepared by exhaustive or partial hydrolysis of polyvinyl acetate. Polyvinyl alcohol additionally can be modified by derivatization with other hydroxy containing compounds such as, for example, polyethylene glycol (PEG) or carboxylic acids (such as, for example, propionic acid) to improve their polyglycerol solubility or biocompatibility.
[00125] "Poly(acrylic acid)" refers to homopolymers of acrylic acid, and/or polyacrylic acid obtained by partially crosslinked via a suitable crosslinking agent selected from but not limited to allyl ether, pentaerythritol allyl ether, sucrose allyl ether.
[00126] "Dendrimers" refers to neutral or acidic polyhydroxylated dendrimers comprising a surface layer of hydroxyl or carboxy functional groups resulting in polyglycerol dendrimers, poly(alpha-glutamic acid) and poly(gamma-polyglutamic acid) dendrimers, poly(2,2-bis(hydroxymethyl)propionic acid) dendrimers, poly(glycerol succinate) dendrimers, carboxylated and/or hydroxylated polylysine dendrimers, carboxylated and/or hydroxylated polyaminoamide (PAMAM) dendrimers, surface glycosylated dendrimers and combinations thereof.
[00127] "Physiological conditions": The phrase "physiological conditions", as used herein, relates to the range of chemical (e.g., pH, ionic strength) and biochemical (e.g., enzyme concentrations) conditions likely to be encountered in the extracellular fluids of living tissues. For most normal tissues, the physiological pH ranges from about 7.0 to 7.4. Circulating blood plasma and normal interstitial liquid represent typical examples of normal physiological conditions. [00128] "Polysaccharide", "carbohydrate" or "oligosaccharide": The terms
"polysaccharide", "carbohydrate", or "oligosaccharide" are known in the art and refer, generally, to substances having chemical formula (CH20)n, where generally n>2, and their derivatives. Carbohydrates are polyhydroxyaldehydes or polyhydroxyketones, or change to such substances on simple chemical transformations, such as hydrolysis, oxidation or reduction. Typically, carbohydrates are present in the form of cyclic acetals or ketals (such as, glucose or fructose). These cyclic units (monosaccharides) may be connected to each other to form molecules with few (oligosaccharides) or several (polysaccharides) monosaccharide units. Often, carbohydrates with well-defined number, types and positioning of monosaccharide units are called
oligosaccharides, whereas carbohydrates consisting of mixtures of molecules of variable numbers and/or positioning of monosaccharide units are called polysaccharides. The terms "polysaccharide", "carbohydrate", and "oligosaccharide", are used herein interchangeably. A polysaccharide may include natural sugars (e.g., glucose, fructose, galactose, mannose, arabinose, ribose, and xylose) and/or derivatives of naturally occurring sugars (e.g., - fluororibose, 2'-deoxyribose, and hexose).
[00129] "Drug": As used herein, the term "drug" refers to a compound which is biologically active and provides a desired physiological effect following administration to a subject in need thereof (e.g., an active pharmaceutical ingredient).
[00130] "Prodrug": As used herein the term "prodrug" refers to a precursor of an active drug, that is, a compound that can be transformed to an active drug. Typically such a prodrug is subject to processing in vivo, which converts the drug to a physiologically active form. In some instances, a prodrug may itself have a desired physiologic effect. A desired physiologic effect may be, e.g., therapeutic, cytotoxic, immunomodulatory, or the like.
[00131] "Cytotoxic": As used herein the term "cytotoxic" means toxic to cells or a selected cell population (e.g., cancer cells). The toxic effect may result in cell death and/or lysis. In certain instances, the toxic effect may be a sublethal destructive effect on the cell, e.g., slowing or arresting cell growth. In order to achieve a cytotoxic effect, the drug or prodrug may be selected from a group consisting of a DNA damaging agent, a microtubule disrupting agent, or a cytotoxic protein or polypeptide, amongst others.
[00132] "Cytostatic": As used herein the term "cytostatic" refers to a drug or other compound which inhibits or stops cell growth and/or multiplication. [00133] "Small molecule": As used herein, the term "small molecule" refers to molecules, whether naturally-occurring or artificially created (e.g. , via chemical synthesis) that have a relatively low molecular weight. Preferred small molecules are biologically active in that they produce a local or systemic effect in animals, preferably mammals, more preferably humans. In certain preferred embodiments, the small molecule is a drug and the small molecule is referred to as "drug molecule" or "drug" or "therapeutic agent". In certain embodiments, the drug molecule has MW less than or equal to about 5 kDa. In other embodiments, the drug molecule has MW less than or equal to about 1.5 kDa. In embodiments, the drug molecule is selected from vinca alkaloids, auristatins, tubulysins, duocarmycins, kinase inhibitors, MEK inhibitors, KSP inhibitors, calicheamicins, SN38, pyrrolobenodiazepines, and analogs thereof. Preferably, though not necessarily, the drug is one that has already been deemed safe and effective for use by an appropriate governmental agency or body, e.g., the FDA. For example, drugs for human use listed by the FDA under 21 C.F.R. §§ 330.5, 331 through 361 , and 440 through 460; drugs for veterinary use listed by the FDA under 21 C.F.R. §§ 500 through 589, incorporated herein by reference, are all considered suitable for use with the present hydrophilic polymers.
[00134] Classes of drug molecules that can be used in the practice of the present invention include, but are not limited to, anti-cancer substances, radionuclides, vitamins, anti-AIDS substances, antibiotics, immunosuppressants, anti- viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal anti-inflammatory agents, anti-angiogenic factors, anti -secretory factors, anticoagulants and/or antithrombotic agents, local anesthetics, ophthalmics,
prostaglandins, anti-depressants, anti-psychotic substances, anti-emetics, imaging agents . Many large molecules are also drugs and such large molecules may be used in the conjugates and other constructs described herein. Examples of suitable large molecules include, e.g., amino acid based molecules. Amino acid based molecules may encompass, e.g., peptides, polypeptides, enzymes, antibodies, immunoglobulins, or functional fragments thereof, among others.
[00135] A more complete, although not exhaustive, listing of classes and specific drugs suitable for use in the present invention may be found in "Pharmaceutical Substances: Syntheses, Patents, Applications" by Axel Kleemann and Jurgen Engel, Thieme Medical Publishing, 1999 and the "Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", Edited by Susan Budavari et al, CRC Press, 1996, both of which are incorporated herein by reference. In preferred embodiments, the drug used in this invention is a therapeutic agent that has
antiproliferative (cytostatic and/or cytotoxic) activity against a target cell or pathway. The drug may have a chemically reactive group such as, for example, -COOH, primary amine, secondary amine -NHR, -OH, -SH, -C(0)H, -C(0)R, -C(0)NHR2b, C(S)OH, -S(0)2OR2b, -P(0)2OR2b, - CN, -NC or -ONO, in which R is an aliphatic, heteroaliphatic, carbocyclic or heterocycloalkyl moiety and R2b is a hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety.
[00136] "Drug derivative" or "modified drug" or the like as used herein, refers to a compound that comprises the drug molecule intended to be delivered by the conjugate of the invention and a functional group capable of attaching the drug molecule to the polymeric carrier.
[00137] "Active form" as used herein refers to a form of a compound that exhibits intended pharmaceutical efficacy in vivo or in vitro. In particular, when a drug molecule intended to be delivered by the conjugate of the invention is released from the conjugate, the active form can be the drug itself or its derivatives, which exhibit the intended therapeutic properties. The release of the drug from the conjugate can be achieved by cleavage of a biodegradable bond of the linker which attaches the drug to the polymeric carrier. The active drug derivatives accordingly can comprise a portion of the linker.
[00138] "Diagnostic label": As used herein, the term diagnostic label refers to an atom, group of atoms, moiety or functional group, a nanocrystal, or other discrete element of a composition of matter, that can be detected in vivo or ex vivo using analytical methods known in the art. When associated with a conjugate of the present invention, such diagnostic labels permit the monitoring of the conjugate in vivo. Alternatively or additionally, constructs and
compositions that include diagnostic labels can be used to monitor biological functions or structures. Examples of diagnostic labels include, without limitation, labels that can be used in medical diagnostic procedures, such as, radioactive isotopes (radionuclides) for gamma scintigraphy and Positron Emission Tomography (PET), contrast agents for Magnetic Resonance Imaging (MRI) (for example paramagnetic atoms and superparamagnetic nanocrystals), contrast agents for computed tomography and other X-ray-based imaging methods, agents for ultrasound- based diagnostic methods (sonography), agents for neutron activation (e.g., boron, gadolinium), fluorophores for various optical procedures, and, in general moieties which can emit, reflect, absorb, scatter or otherwise affect electromagnetic fields or waves (e.g., gamma-rays, X-rays, radiowaves, microwaves, light), particles (e.g., alpha particles, electrons, positrons, neutrons, protons) or other forms of radiation, e.g., ultrasound.
[00139] "Aliphatic": In general, the term aliphatic, as used herein, includes both saturated and unsaturated, straight chain {i.e., unbranched) or branched aliphatic hydrocarbons, which are optionally substituted with one or more functional groups. As will be appreciated by one of ordinary skill in the art, "aliphatic" is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl moieties. Thus, as used herein, the term "alkyl" includes straight and branched alkyl groups. An analogous convention applies to other generic terms such as "alkenyl", "alkynyl" and the like. In certain embodiments, as used herein, "lower alkyl" is used to indicate those alkyl groups (substituted, unsubstituted, branched or unbranched) having about 1 -6 carbon atoms. "Substituted alkyl" refers to alkyl groups that are substituted with one or more functional groups. Substituents include, but are not limited to, any of the substituents mentioned below, i.e. , the substituents recited below resulting in the formation of a stable compound.
[00140] "Alkenyl": the term alkenyl denotes a monovalent group derived from a hydrocarbon moiety having at least one carbon-carbon double bond by the removal of a single hydrogen atom. "Substituted alkenyl" groups are substituted with one or more functional groups. Substituents include, but are not limited to, any of the substituents mentioned below, i.e., the substituents recited below resulting in the formation of a stable compound. Alkenyl groups include, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l -yl, and the like.
[00141] "Alkynyl": the term alkynyl as used herein refers to a monovalent group derived from a hydrocarbon having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. "Substituted alkenyl" groups are substituted with one or more functional groups. Substituents include, but are not limited to, any of the substituents mentioned below, i.e. , the substituents recited below resulting in the formation of a stable compound.
Representative alkynyl groups include ethynyl, 2-propynyl (propargyl), 1 -propynyl, and the like. [00142] In certain embodiments, the alkyl, alkenyl and alkynyl groups employed in the invention contain about 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-4 carbon atoms. Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n- pentyl, sec-pentyl, isopentyl, tert-pentyl, n-hexyl, sec-hexyl, moieties and the like, which again, may bear one or more substituents. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, and the like. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like.
[00143] "Alkylene" as used herein, the term alkylene by itself or part of another term refers to a saturated, branched or straight chain having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Alkylene radicals include, but are not limited to, methylene, 1 ,2, ethylene, 1 ,3-propyl, and the like. Suitable alkylenes include, but are not limited to methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, ocytylene, nonylene, decalene, and the like. The term "cycloalkylene" similarly refers to bivalent cycloalkyl. Cycloalkylene radicals include, but are not limited to, 1 ,1-cyclopentylene, 1,2-cyclopentylene, 1,1-cyclobutylene, 1,3- cyclobutylene, etc.
[00144] "Heteroaliphatic": as used herein, the term heteroaliphatic refers to aliphatic moieties in which one or more carbon atoms in the main chain have been substituted with a heteroatom. Thus, a heteroaliphatic group refers to an aliphatic chain which contains one or more oxygen, sulfur, nitrogen, phosphorus or silicon atoms, e.g. , in place of carbon atoms. Heteroaliphatic moieties may be branched or linear unbranched. In certain embodiments, heteroaliphatic moieties are substituted ("substituted heteroaliphatic") by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; heteroaliphatic; cycloalkyl; heterocycloalkyl; aryl; heteroaryl;
alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI ; Br; I; -N02; -CN; -CF3; -CH2CF3; -CHCi2; -CH2OH; - CH2CH2OH; -CH2NH2; -CH2S02CH3; - or -GRG1 wherein G is -0-, -S-, -NRG2-, -C(=0)-, -S(=0)-, - S02-, -C(=0)0-, -C(=0)NRG2-, -OC(=0)-, -NRG2C(=0)-, -OC(=0)0-, -OC(=0)NRG2-, - NRG2C(=0)0-, -NRG2C(=0)NRG2-, -C(=S)-, -C(=S)S-, -SC(=S)-, -SC(=S)S-, -C(=NRG2)-, - C(=NRG2)0-, -C(=NRG2)NRG3-, -OC(=NRG2)-, -NRG2C(=NRG3)-, -NRG2S02-, -NRG2S02NRG3-, or - So2N -, wherein each occurrence of , and independently includes, but is not limited to, hydrogen, halogen, or an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, each of which is optionally substituted.
Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
[00145] "Cycloalkyl": as used herein, the term cycloalkyl refers to a saturated or unsaturated nonaromatic hydrocarbon mono-or multi-ring system having 3 to 30 carbon atoms (e.g., C3-C10). Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloheptynyl, adamantyl, and the like.
[00146] "Heterocycloalkyl" as used herein refers to a saturated or unsaturated
nonaromatic 3-8 membered monocyclic, 8-12 membered bicyclic, or 1 1-19 membered tricyclic ring system having one or more heteroatoms (such as O, N, S, or Se), unless specified otherwise. In certain embodiments, the term "heterocycloalkyl" refers to a non-aromatic 5-, 6-, 7- or 8- membered ring or a polycyclic group, including, but not limited to a bi- or tri-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5 -membered ring has 0 to 2 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quaternized, and (iv) any of the above heterocycloalkyl; rings may be fused to an aryl or heteroaryl ring. Examples of heterocycloalkyl groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, tetrahydrothienyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1,2,3, 6-tetrahy drop yridinyl, tetrahydro-2H-pyranyl, 3,6- dihydro-2H-pyranyl, morpholinyl, and the like. [00147] "Aryl": as used herein, refers to groups with aromaticity, including "conjugated," or multicyclic systems with at least one aromatic ring and do not contain any heteroatom in the ring structure. Examples include phenyl, benzyl, 1 ,2,3,4-tetrahydronaphthalenyl, etc.
[00148] "Heteroaryl": as used herein, refers to aryl groups, as defined above, except having from one to four heteroatoms in the ring structure, and may also be referred to as "aryl heterocycles" or "heteroaromatics." As used herein, the term "heteroaryl" is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 1 1- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g. \ , 2, 3, 4, 5, or 6 heteroatoms,
independently selected from the group consisting of nitrogen, oxygen and sulfur. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or other substituents, as defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N—»0 and S(0)p, where p = 1 or 2). It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl include pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, tetrazolyl, pyridazinyl, quinazolinyl, dihydroquinazolyl, and tetrahydroquinazolyl and the like.
[00149] Furthermore, the terms "aryl" and "heteroaryl" include multicyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
[00150] In the case of multicyclic aromatic rings, only one of the rings needs to be aromatic (e.g. , 2,3-dihydroindole), although all of the rings may be aromatic (e.g., quinoline). The second ring can also be fused or bridged.
[00151] "Carbocycle" or "carbocyclic moiety" as used herein, is intended to include any stable monocyclic, bicyclic or tricyclic ring having the specified number of carbons, any of which may be saturated, unsaturated, or aromatic. Carbocycle includes cycloalkyl and aryl. For example, a C3-Q carbocycle is intended to include a monocyclic, bicyclic or tricyclic ring having 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13 or 14 carbon atoms. Examples of carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, fluorenyl, phenyl, naphthyl, indanyl, adamantyl and tetrahydronaphthyl.
Bridged rings are also included in the definition of carbocycle, including, for example,
[3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane and [2.2.2]bicyclooctane. A bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms. In one embodiment, bridge rings are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge. Fused (e.g., naphthyl, tetrahydronaphthyl) and spiro rings are also included.
[00152] "Heterocycle" or "heterocyclic moiety" as used herein, includes any ring structure (saturated, unsaturated, or aromatic) which contains at least one ring heteroatom (e.g. , N, O or S). Heterocycle includes heterocycloalkyl and heteroaryl. Examples of heterocycles include, but are not limited to, morpholine, pyrrolidine, tetrahydrothiophene, piperidine, piperazine and tetrahydrofuran.
[00153] Examples of heterocyclic groups include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-l,5,2-dithiazinyl, dihydrofuro[2,3-6]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4- oxadiazolyl, 1,2,5-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,4-oxadiazol5(4H)-one, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-l,2,5-thiadiazinyl, 1 ,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1 ,2,5-thiadiazolyl, 1 ,3,4- thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1 ,2,3-triazolyl, 1 ,2,4-triazolyl, 1 ,2,5-triazolyl, 1 ,3,4-triazolyl and xanthenyl. Multiple-ring heterocycle can include fused, bridged or spiro rings.
[00154] The cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring (or the carbocyclic or heterocyclic group) can be substituted at one or more ring positions (e.g., the ring-forming carbon or heteroatom such as N) with such substituents as described above, for example, aliphatic; heteroaliphatic; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; alkylaryl;
alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio;
heteroalkylthio; heteroarylthio; F; CI ; Br; I; -N02; -CN; -CF3; -CH2CF3; -CHC12; -CH2OH; - CH2CH2OH; -CH2NH2; -CH2S02CH3; - or -GRG1 wherein G is -0-, -S-, -NRG2-, -C(=0)-, - S(=0)-, -S02-, -C(=0)0-, -C(=0)NRG2-, -OC(=0)-, -NRG2C(=0)-, -OC(=0)0-, -OC(=0)NRG2-, -NRG2C(=0)0-, -NRG2C(=0)NRG2-, -C(=S)-, -C(=S)S-, -SC(=S)-, -SC(=S)S-, -C(=NRG2)-, - C(=NRG2)0-, -C(=NRG2)NRG3-, -OC(=NRG2)-, -NRG2C(=NRG3)-, -NRG2S02-, -NRG2S02NRG3-, or -S02NR -, wherein each occurrence of R , R and R independently includes, but is not limited to, hydrogen, halogen, or an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, each of which is optionally substituted. Aryl and heteroaryl groups can also be fused or bridged with cycloalkyl or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedioxyphenyl).
[00155] "Alkoxy" (or "alkyloxy"): as used herein, the term alkoxy (or alkyloxy) refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom ("alkoxy")- In certain embodiments, the alkyl group contains about 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains about 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains about 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains about 1 -6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains about 1-4 aliphatic carbon atoms. Examples of alkoxy groups, include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert- butoxy, neopentoxy and n-hexoxy.
[00156] "Aryloxy": as used herein, the term aryloxy refers to an aryl group, as defined herein, attached to the parent molecular moiety through an oxygen atom. Examples of aryloxy groups include but are not limited to phenoxy and napthyloxy.
[00157] "Heteroaryloxy": as used herein, the term heteroaryloxy refers to a heteroaryl group, as defined herein, attached to the parent molecular moiety through an oxygen atom. Examples of heteroaryloxy groups include but are not limited to, quinolyloxy and
isoquinolizinyloxy.
[00158] "Amine": the term amine refers to a group having the structure -N(R)2 wherein each occurrence of R is independently hydrogen, or an aliphatic or heteroaliphatic moiety, or the R groups, taken together, may form a heterocyclic moiety. In certain instances, an amine group can be charged (protonized) or quarternized, e.g., -HN+(R)2 or -N+(R)3.
[00159] "Alkylamino": as used herein, the term alkylamino refers to a group having the structure -NHR' wherein R' is alkyl, as defined herein. The term "aminoalkyl" refers to a group having the structure NH2R'-, wherein R' is alkyl, as defined herein. In certain embodiments, the alkyl group contains about 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains about 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain about 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains about 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains about 1-4 aliphatic carbon atoms. Examples of alkylamino include, but are not limited to, methylamino, ethylamino, iso-propylamino and the like.
[00160] "Alkylthio" (or "thioalkyl") means an alkyl group as defined herein with the indicated number of carbon atoms attached through a sulfur atom. C1-6 alkylthio, is intended to include C], C2, C3, C4, C5, and C6 alkylthio groups. Ci-8 alkylthio, is intended to include Cl s C2, C3, C4, C5, C6, C7, and C8 alkylthio groups. The thioalkyl groups can be substituted with groups such as alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, amino (including alkylamino, dialkylamino, arylamino, diarylamino and
alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonate, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl alkylaryl, or an aryl or heteroaryl moieties.
[00161] "Thiocarbonyl" or "thiocarboxy" includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom. [00162] "Thioether" includes moieties which contain a sulfur atom bonded to two carbon atoms or heteroatoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls and alkthioalkynyls. The term "alkthioalkyls" include moieties with an alkyl, alkenyl or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group. Similarly, the term "alkthioalkenyls" refers to moieties wherein an alkyl, alkenyl or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkenyl group; and alkthioalkynyls" refers to moieties wherein an alkyl, alkenyl or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.
[00163] "Arylthio" (or "thioaryl") means an aryl group as defined herein with the indicated number of carbon atoms attached through a sulfur atom.
[00164] "Carboxylic acid" as used herein refers to a compound comprising a group of formula -C02H.
[00165] "Dicarboxylic acid" refers to a compound comprising two groups of formula - C02H.
[00166] "Halo, halide and halogen": The terms halo, halide and halogen as used herein refer to an atom selected from fluorine, chlorine, bromine, and iodine.
[00167] "Methylol": The term methylol as used herein refers to an alcohol group of the structure -CH2OH.
[00168] "Hydroxyalkyl": As used herein, the term hydroxyalkyl refers to an alkyl group, as defined above, bearing at least one OH group.
[00169] "Mercaptoalkyl": The term mercaptoalkyl as used therein refers to an alkyl group, as defined above, bearing at least one SH group.
[00170] "Acyl" includes moieties that contain the acyl radical (-C(O)-) or a carbonyl group. "Substituted acyl" includes acyl groups where one or more of the hydrogen atoms are replaced by, for example, alkyl groups, alkynyl groups, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including
alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfmyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aryl or heteroaryl moiety.
[00171] "Hydrocarbon": The term hydrocarbon, as used herein, refers to any chemical group comprising hydrogen and carbon. The hydrocarbon may be substituted or unsubstituted. The hydrocarbon may be unsaturated, saturated, branched, unbranched, cyclic, polycyclic, or heterocyclic. Illustrative hydrocarbons include, for example, methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, allyl, vinyl, n-butyl, tert-butyl, ethynyl, cyclohexyl, methoxy, diethylamino, heterocycloalkyl, aryl, heteroaryl, thioalkyl, and the like. As would be known to one skilled in this art, all valencies must be satisfied in making any substitutions.
[00172] "Alkylaryl" as used herein refers to an aryl group substituted with one or more alkyl groups {e.g., methylphenyl).
[00173] "Alkylarylamino" as used herein refers to -N RG4RG5, wherein RG4 is alkyl, as defined herein, and RG5 is an aryl, as defined herein, or at least one of RG4 and RG5 is an alkylaryl as defined herein.
[00174] "Substituted": The terms substituted, whether preceded by the term "optionally" or not, and substituent, as used herein, refers to the replacement of a hydrogen radical in a given structure with the radical of a specified substituent. When more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. Examples of substituents include, but are not limited to aliphatic; heteroaliphatic; cycloalkyl; heterocycloalkyl; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy;
heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI ; Br; I; - N02; -CN; -CF3; -CH2CF3; -CHC12; -CH2OH; -CH2CH2OH; -CH2NH2; -CH2S02CH3; - or - GRG1 wherein G is -0-, -S-, -NRG2-, -C(=0)-, -S(=0)-, -S02-, -C(=0)0-, -C(=0)NRG2-, -
OC(=0)-, -NR° (=0)-, -OC(=0)0-, -OC(=0)NR -NR0iC(=0)0-, -NR0iC(=0)NR - C(=S)-, -C(=S)S-, -SC(=S)-, -SC(=S)S-, -C(=NRG2)-, -C(=NRG2)0-, -C(=NRG2)NRG3-, , OC(=NRG2)-, -NR02C(=NR03)-, -NR02S02-, -NR02S02NR or -S02NRU2-, wherein each occurrence of R , R and R independently includes, but is not limited to, hydrogen, halogen, or an aliphatic, heteroaliphatic, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, eac of which is optionally substituted. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
[00175] The following are more general terms used throughout the present application:
[00176] "Animal": The term animal, as used herein, refers to humans as well as non- human animals, at any stage of development, including, for example, mammals, birds, reptiles, amphibians, fish, worms and single cells. Cell cultures and live tissue samples are considered to be pluralities of animals. Preferably, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig). An animal may be a transgenic animal or a human clone. The term "subject" encompasses animals.
[00177] "Efficient amount": In general, as it refers to an active agent or drug delivery device, the term "efficient amount" refers to the amount necessary to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the efficient amount of an agent or device may vary depending on such factors as the desired biological endpoint, the agent to be delivered, the composition of the encapsulating matrix, the target tissue, etc. For example, the efficient amount of microparticles containing an antigen to be delivered to immunize an individual is the amount that results in an immune response sufficient to prevent infection with an organism having the administered antigen.
[00178] "Natural amino acid" as used herein refers to any one of the common, naturally occurring L-amino acids found in naturally occurring proteins: glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), isoleucine (He), lysine (Lys), arginine (Arg), histidine (His), proline (Pro), serine (Ser), threonine (Thr), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Tip), aspartic acid (Asp), glutamic acid (Glu), asparagine (Asn), glutamine (Gin), cysteine (Cys) and methionine (Met).
[00179] "Unnatural amino acid" as used herein refers to any amino acid which is not a natural amino acid. This includes, for example, amino acids that comprise α-, β-, ω-, D-, L- amino acyl residues. More generally, the unnatural amino acid comprises a residue of the general formula
Figure imgf000050_0001
wherein the side chain R is other than the amino acid side chains occurring in nature. Exemplary unnatural amino acids, include, but are not limited to, sarcosine (N-methylglycine) , citrulline (cit), homocitrulline, β-ureidoalanine, thiocitrulline,
hydroxyproline, allothreonine, pipecolic acid (homoproline), a-aminoisobutyric acid, tert- butylglycine, tert-butylalanine, allo-isoleucine, norleucine, a-methylleucine, cyclohexylglycine, β-cyclohexylalanine, β-cyclopentylalanine, a-methylproline, phenylglycine, a- methylphenylalanine and homophenylalanine.
[00180] "Amino acyl": More generally, the term amino acyl, as used herein, encompasses natural amino acid and unnatural amino acids.
[00181] "Polyamide": refers to homo- or hetero- polymers of natural amino acid and unnatural amino acids. Illustrative homo-polymers include, but are not limited to, poly-lysine, poly-arginine, poly-y-glutaric acid, and the like. Illustrative hetero- polymers include, but are not limited to, polymers comprising peptides fragments selected from peptidases, lysozymes, metalloproteinases, and the like.
[00182] "PHF" refers to poly(l -hydroxymethylethylene hydroxymethyl-formal).
[00183] As used herein, the terms "polymer unit", "monomeric unit", "monomer", "monomer unit", "unit" all refer to a repeatable structural unit in a polymer.
[00184] As used herein, "molecular weight" or "MW" of a polymer or polymeric carrier/scaffold or polymer conjugates refers to the weight average molecular weight unless otherwise specified.
[00185] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.
[00186] The present invention is intended to include all isomers of the compound, which refers to and includes, optical isomers, and tautomeric isomers, where optical isomers include enantiomers and diastereomers, chiral isomers and non-chiral isomers, and the optical isomers include isolated optical isomers as well as mixtures of optical isomers including racemic and non-racemic mixtures; where an isomer may be in isolated form or in a mixture with one or more other isomers.
Polymeric Carriers
[00187] In certain exemplary embodiments, the conjugates of the invention find use in biomedical applications, such as drug delivery and tissue engineering, and the polymeric carriers of the conjugates are biocompatible and biodegradable. In certain embodiments, the polymeric carrier is a soluble hydroxyl polymer, in the form of, e.g., a nanoparticle, gel, liposome, micelle, suture, or an implant, etc. In certain embodiments, the carrier is a fully synthetic, semi-synthetic or naturally-occurring polymer. In certain other embodiments, the carrier is hydrophilic.
[00188] In certain exemplary embodiments, the carriers used in the present invention are biodegradable biocompatible polymers having at least four -OH groups connected to the polymer wherein the hydroxyl polymer of the invention is not a polyacetal or a polyketal. In some embodiments, the four or more -OH groups are the hydroxyl groups of four or more - COOH groups connected to the polymer. In other embodiments, the four or more -OH groups are the alcohol hydroxyl groups (i.e., not those of-COOH groups) connected to the polymer. In yet other embodiments, the four or more -OH groups are a combination of alcohol hydroxyl groups and hydroxyl groups of-COOH. The properties (e.g. , solubility, bioadhesivity and hydrophilicity) of biodegradable biocompatible polymer conjugates can be modified by subsequent substitution of additional hydrophilic or hydrophobic groups.
[00189] The conjugates of this invention are hydrophilic, hydrolysable and comprise drug molecules (e.g. , vinca alkaloids or derivatives, non-natural camptothecin compounds or derivatives, auristatins, tubulysins, duocarmycins, PI3 kinases, MEK inhibitors, KSP inhibitors, calicheamicins, SN38, non-natural camptothecins, pyrrolobenodiazepines and analogs or prodrugs thereof) and antibodies (e.g., Trastuzumab, Cetuximab, Rituximab, Bevacizumab, Epratuzumab, Veltuzumab, Labetuzumab, B7-H4, B7-H3, CA125, CD33, CXCR2, EGFR, FGFR1 , FGFR2, FGFR3, FGFR4, HER2, PD-L1 and anti-5T4) or peptides (LHRH receptor targeting peptides, EC-1 peptide) covalently attached to the polymer carrier via linkages that contain one or more biodegradable bonds. Thus, in certain exemplary embodiments, carriers suitable for practicing the present invention are polyals having at least one acetal/ketal oxygen atom in each monomer unit positioned within the main chain. [00190] In certain embodiments, biodegradable biocompatible hydroxyl polymer carriers, used for preparation of polymer conjugates of the invention, are any -OH group-containing polymer known in the art except polyacetals and polyketals, such as, for example, hydroxyalkyl starches, polyglycerols, PEG polymers, HPMA polymers, carboxymethyl dextrans (CM dextran), polyvinyl alcohols, poly(acrylic acid), dendrimers and products of their oxidation,
fictionalization, modification, cross-linking, and conjugation.
[00191] In certain embodiments, the polymeric carrier is a hydrophilic biodegradable polymer selected from the group consisting of hydroxyalkyl starches, polyglycerols, PEG polymers, HPMA polymers, carboxymethyl dextrans (CM dextran), polyvinyl alcohols, poly(acrylic acid), dendrimers, and derivatives thereof.
[00192] For example, the unmodified hydroxyl polymers having -OH groups connected to the polymer backbone are of Formula (III):
Polymer
(k
(HI).
[00193] The molar fraction, n, of unmodified polymer units is the molar fraction available to promote biocompatibility, solubility and increase half-life, based on the total number of polymer units in the modified polymer. The molar fraction n may be the minimal fraction of unmodified monomer polymer units needed to provide biocompatibility, solubility, stability, or a particular half-life, or can be some larger fraction. The most desirable degree of cytotoxicity is substantially none, i.e., the modified polymer is substantially inert to the subject. However, as is understood by those of ordinary skill in the art, some degree of cytotoxicity can be tolerated depending on the severity of disease or symptom being treated, the efficacy of the treatment, the type and degree of immune response, and like considerations.
[00194] In one embodiment, biodegradable biocompatible hydroxyl polymers suitable for practicing the present invention have a molecular weight of between about 0.5 and about 300 kDa. In a preferred embodiment of the present invention, the biodegradable biocompatible hydroxyl polymers have a molecular weight of between about 1 and about 300 kDa (e.g., between about 1 and about 200 kDa, between about 2 and about 300 kDa, between about 2 and about 200 kDa, between about 5 and about 100 kDa, between about 10 and about 70 kDa, between about 20 and about 50 kDa, between about 20 and about 300 kDa, between about 40 and about 150 kDa, between about 50 and about 100 kDa, between about 2 and about 40 kDa, between about 6 and about 20 kDa, or between about 8 and about 15 kDa).
[00195] In one embodiment, the biodegradable biocompatible hydroxyl polymers suitable for practicing the present invention are modified before conjugating with a drug or a PBRM. For example, the polyals may contain subunits of linkers LD or Lp, such as— ^X-(CH2)v-C(=0)— with X being CH2, O, or NH, and v being an integer from 1 to 6
Therapeutic Agents
[00196] In certain embodiments, the therapeutic agent is a small molecule having a molecular weight preferably < about 5 kDa, more preferably < about 4 kDa, more preferably < about 3 kDa, most preferably < about 1.5 kDa or < about 1 kDa.
[00197] In certain embodiments, the therapeutic agent has an IC5o of about less than 1 nM.
[00198] In another embodiment, the therapeutic agent has an IC5o of about greater than 1 nM, for example, the therapeutic agent has an IC5o of about 1 to 50 nM.
[00199] Some therapeutic agents having an IC5o of greater than about 1 nM (e.g., "less potent drugs") are unsuitable for conjugation with a PBRM using art-recognized conjugation techniques. Without wishing to be bound by theory, such therapeutic agents have a potency that is insufficient for use in targeted PBRM-drug conjugates using conventional techniques as sufficient copies of the drug (i.e., more than 8) cannot be conjugated using art-recognized techniques without resulting in diminished pharmacokinetic and physiochemical properties of the conjugate. However sufficiently high loadings of these less potent drugs can be achieved using the conjugation strategies described herein thereby resulting in high loadings of the therapeutic agent while maintaining the desirable pharmacokinetic and physiochemical properties. Thus, the invention also relates to a PBRM-drug conjugate which includes a PBRM, hydroxyl polymer and at least eight therapeutic agent moieties, wherein the therapeutic agent has an IC5o of greater than about 1 nM.
[00200] In certain embodiments, about 0.1 to about 25 % monomers comprise a therapeutic agent, more preferably about 0.5 to about 20%, more preferably about 1 to about 15%, and even more preferably about 2 to about 10%. [00201] The small molecule therapeutic agents used in this invention (e.g.,
antiproliferative (cytotoxic and cytostatic) agents capable of being linked to a polymer carrier) include cytotoxic compounds (e.g., broad spectrum), angiogenesis inhibitors, cell cycle progression inhibitors, PBK/m-TOR/AKT pathway inhibitors, MAPK signaling pathway inhibitors, kinase inhibitors, protein chaperones inhibitors, HDAC inhibitors, PARP inhibitors, Wnt/Hedgehog signaling pathway inhibitors and RNA polymerase inhibitors.
[00202] Broad spectrum cytotoxins include, but are not limited to, DNA-binding or alkylating drugs, microtubule stabilizing and destabilizing agents, platinum compounds, and topoisomerase I inhibitors.
[00203] Exemplary DNA-binding or alkylating drugs include, CC-1065 and its analogs, anthracyclines (doxorubicin, epirubicin, idarubicin, daunorubicin) and its analogs, alkylating agents, such as calicheamicins, dactinomycines, mitromycines, pyrrolobenzodiazepines, and the like.
[00204] Exemplary CC-1065 analogs include duocarmycin SA, duocarmycin A, duocarmycin CI , duocarmycin C2, duocarmycin Bl, duocarmycin B2, duocarmycin D, DU-86, KW-2189, adozelesin, bizelesin, carzelesin, seco-adozelesin, related analogs and prodrug forms, examples of which are described in U.S. Patent Nos. 5,475,092; 5,595,499; 5,846,545;
6,534,660; 6,586,618; 6,756,397 and 7,049,316. Doxorubicin and its analogs include those described in U.S. Patent No. 6,630,579. Calicheamicins include those described in U.S. Patent Nos. 5,714,586 and 5,739,1 16. Duocarmycins include those described in U.S. Patent
Nos.5,070,092; 5,101 ,038; 5,187,186; 6,548,530; 6,660,742; and 7,553,816 B2; and Li et al., Tet Letts. , 50:2932 - 2935 (2009). Pyrrolobenzodiazepines (PBD) include those described in Denny, Exp. Opin. Ther. Patents., 10(4):459-474 (2000).
[00205] Exemplary microtubule stabilizing and destabilizing agents include taxane compounds, such as paclitaxel, docetaxel, tesetaxel and carbazitaxel; maytansinoids, auristatins and analogs thereof, tubulysin A and B derivatives, vinca alkaloid derivatives, epothilones and cryptophycins.
[00206] Exemplary maytansinoids or maytansinoid analogs include maytansinol and maytansinol analogs, maytansine or DM-1 and DM-4 are those described in U.S. Patent Nos. 5,208,020; 5,416,064; 6,333.410; 6,441 ,163; 6,716,821 ; RE39,151 and 7,276,497. In certain embodiments, the cytotoxic agent is a maytansinoid, another group of anti-tubulin agents (ImmunoGen, Inc.; see also Chari et al., 1992, Cancer Res. 52: 127-131), maytansinoids or maytansinoid analogs. Examples of suitable maytansinoids include maytansinol and
maytansinol analogs. Suitable maytansinoids are disclosed in U.S. Patent Nos. 4,424,219;
4,256,746; 4,294,757; 4,307,016; 4,313,946; 4,315,929; 4,331 ,598; 4,361,650; 4,362,663;
4,364,866; 4,450,254; 4,322,348; 4,371,533; 6,333,410; 5,475,092; 5,585,499; and 5,846,545.
[00207] Exemplary auristatins include auristatin E (also known as a derivative of dolastatin-10), auristatin EB (AEB), auristatin EFP (AEFP), mono methyl auristatin E (MMAE), monomethyl auristatin F (MMAF), auristatin F, auristatin F phenylenediamine (AFP), auristatin F HPA and dolastatin. Suitable auristatins are also described in U.S. Publication Nos.
2003/0083263, 201 1/0020343, and 2011/0070248; PCT Application Publication Nos. WO 09/1 17531, WO 2005/08171 1 , WO 04/010957; WO 02/088172 and WO01/24763, and U.S. Patent Nos. 7,498,298; 6,884,869; 6,323,315; 6,239,104; 6,124,431 ; 6,034,065; 5,780,588;
5,767,237; 5,665,860; 5,663,149; 5,635,483; 5,599,902; 5,554,725; 5,530,097; 5,521,284;
5,504,191 ; 5,410,024; 5,138,036; 5,076,973; 4,986,988; 4,978,744; 4,879,278; 4,816,444; and 4,486,414, the disclosures of which are incorporated herein by reference in their entirety.
[00208] Exemplary tubulysin compounds include compounds described in U.S. Patent Nos. 7,816,377; 7,776,814; 7,754,885; U.S. Publication Nos. 2011/0021568; 2010/004784; 2010/0048490; 2010/00240701 ; 2008/0176958; and PCT Application Nos. WO 98/13375; WO 2004/005269; WO 2008/138561; WO 2009/002993; WO 2009/055562; WO 2009/012958; WO 2009/026177; WO 2009/134279; WO 2010/033733; WO 2010/034724; WO 201 1/017249; WO 201 1/057805; the disclosures of which are incorporated by reference herein in their entirety.
[00209] Exemplary vinca alkaloids include vincristine, vinblastine, vindesine, and navelbine (vinorelbine). Suitable Vinca alkaloids that can be used in the present invention are also disclosed in U.S. Publication Nos. 2002/0103136 and 2010/0305149, and in U.S. Patent No. 7,303,749 Bl , the disclosures of which are incorporated herein by reference in their entirety.
[00210] Exemplary epothilone compounds include epothilone A, B, C, D, E and F, and derivatives thereof. Suitable epothilone compounds and derivatives thereof are described, for example, in U.S. Patent Nos. 6,956,036; 6,989,450; 6,121 ,029; 6,117,659; 6,096,757; 6,043,372; 5,969,145; and 5,886,026; and WO 97/19086; WO 98/08849; WO 98/22461 ; WO 98/25929; WO 98/38192; WO 99/01 124; WO 99/02514; WO 99/03848; WO 99/07692; WO 99/27890; and WO 99/28324; the disclosures of which are incorporated herein by reference in their entirety. [00211] Exemplary cryptophycin compounds are described in U.S. Patent Nos. 6,680,31 1 and 6,747,021.
[00212] Exemplary platinum compounds include cisplatin (PLATINOL®), carboplatin
(PARAPLATIN®), oxaliplatin (ELOXATINE®), iproplatin, ormaplatin, and tetraplatin.
[00213] Exemplary topoisomerase I inhibitors include camptothecin, camptothecin, derivatives, camptothecin analogs and non- natural camptothecins, such as, for example, CPT-1 1 (irinotecan), SN-38, topotecan, 9-aminocamptothecin, rubitecan, gimatecan, karenitecin, silatecan, lurtotecan, exatecan, diflomotecan, belotecan, lurtotecan and S39625. Other camptothecin compounds that can be used in the present invention include those described in, for example, J. Med. Chem., 29:2358-2363 (1986); J. Med. Chem., 23:554 (1980); J. Med. Chem., 30: 1774 (1987).
[00214] Angiogenesis inhibitors include, but are not limited, MetAP2 inhibitors, VEGF inhibitors, PIGF inhibitors, VGFR inhibitors, PDGFR inhibitors, MetAP2 inhibitors. Exemplary VGFR and PDGFR inhibitors include sorafenib (Nexavar), sunitinib (Sutent) and vatalanib. Exemplary MetAP2 inhibitors include fumagillol analogs, meaning any compound that includes the fumagillin core structure, including fumagillamine, that inhibits the ability of MetAP-2 to remove NH2-terminal methionines from proteins as described in Rodeschini et al., J. Org.
Chem. , 69, 357-373, 2004 and Liu, et al., Science 282, 1324-1327, 1998. Non limiting examples of "fumagillol analogs" are disclosed in J. Org. Chem., 69, 357, 2004; J Org. Chem., 70, 6870, 2005; European Patent Application 0 354 787; J. Med. Chem., 49, 5645, 2006; Bioorg. Med. Chem., 1 1, 5051, 2003; Bioorg. Med. Chem., 14, 91, 2004; Tet. Lett. 40, 4797, 1999;
W099/61432; U.S. Patent Nos. 6,603,812; 5,789,405; 5,767,293; 6,566,541 ; and 6,207,704.
[00215] Exemplary cell cycle progression inhibitors include CDK inhibitors such as, for example, BMS-387032 and PD0332991 ; Rho-kinase inhibitors such as, for example
GSK429286; checkpoint kinase inhibitors such as, for example, AZD7762; aurora kinase inhibitors such as, for example, AZD1 152, MLN8054 and MLN8237; PLK inhibitors such as, for example, BI 2536, BI6727 (Volasertib), GSK461364, ON-01910 (Estybon); and KSP inhibitors such as, for example, SB 743921 , SB 715992 (ispinesib), MK-0731 , AZD8477, AZ3146 and ARRY-520. [00216] Exemplary PI3K/m-TOR/AKT signaling pathway inhibitors include phosphoinositide 3-kinase (PI3K) inhibitors, GSK-3 inhibitors, ATM inhibitors, DNA-PK inhibitors and PDK-1 inhibitors.
[00217] Exemplary PI3 kinases are disclosed in U.S. Patent No. 6,608,053, and include BEZ235, BGT226, BKM120, CAL101, CAL263, demethoxyviridin, GDC-0941 , GSK615, IC87114, LY294002, Palomid 529, perifosine, PF-04691502, PX-866, SAR245408,
SAR245409, SF1 126, Wortmannin, XL147 and XL765.
[00218] Exemplary AKT inhibitors include, but are not limited to AT7867.
[00219] Exemplary MAPK signaling pathway inhibitors include MEK, Ras, JNK, B-Raf and p38 MAPK inhibitors.
[00220] Exemplary MEK inhibitors are disclosed in U.S. Patent No. 7,517,994 and include GDC-0973, GSK1 120212, MSC1936369B, AS703026, R05126766 and R04987655, PD0325901, AZD6244, AZD 8330 and GDC-0973.
[00221] Exemplary B-raf inhibitors include CDC-0879, PLX-4032, and SB590885.
[00222] Exemplary B p38 MAPK inhibitors include BIRB 796, LY2228820 and SB 202190.
[00223] Receptor tyrosine kinases (RTK) are cell surface receptors which are often associated with signaling pathways stimulating uncontrolled proliferation of cancer cells and neoangiogenesis. Many RTKs, which over express or have mutations leading to constitutive activation of the receptor, have been identified, including, but not limited to, VEGFR, EGFR, FGFR, PDGFR, EphR and RET receptor family receptors. Exemplary specific RTK targets include ErbB2, FLT-3, c-Kit, and c-Met.
[00224] Exemplary inhibitors of ErbB2 receptor (EGFR family) include but not limited to AEE788 (NVP-AEE 788), BIBW2992, (Afatinib), Lapatinib, Erlotinib (Tarceva), and Gefitinib (Iressa).
[00225] Exemplary RTK inhibitors targeting more than one signaling pathway
(multitargeted kinase inhibitors) include AP24534 (Ponatinib) that targets FGFR, FLT-3, VEGFR-PDGFR and Bcr-Abl receptors; ABT-869 (Linifanib) that targets FLT-3 and VEGFR- PDGFR receptors; AZD2171 that targets VEGFR-PDGFR, Flt-1 and VEGF receptors; CHR-258 (Dovitinib) that targets VEGFR-PDGFR, FGFR, Flt-3, and c-Kit receptors; Sunitinib (Sutent) that targets VEGFR, PDGFR, KIT, FLT-3 and CSF-IR; Sorafenib (Nexavar) and Vatalanib that target VEGFR, PDGFR as well as intracellular serine/threonine kinases in the Raf/Mek/Erk pathway.
[00226] Exemplary protein chaperon inhibitors include HSP90 inhibitors. Exemplary
HSP90 inhibitors include 17AAG derivatives, BIIB021, BIIB028, SNX-5422, NVP-AUY-922 and KW-2478.
[00227] Exemplary HDAC inhibitors include Belinostat (PXD101), CUDC-101,
Droxinostat, ITF2357 (Givinostat, Gavinostat), JNJ-26481585, LAQ824 (NVP-LAQ824, Dacinostat), LBH-589 (Panobinostat), MCI 568, MGCD0103 (Mocetinostat), MS-275
(Entinostat), PCI-24781, Pyroxamide (NSC 696085), SB939, Trichostatin A and Vorinostat (SAHA).
[00228] Exemplary PARP inhibitors include iniparib (BSI 201 ), olaparib (AZD-2281 ),
ABT-888 (Veliparib), AG014699, CEP 9722, MK 4827, KU-0059436 (AZD2281), LT-673, 3- aminobenzamide, A-966492, and AZD2461.
[00229] Exemplary Wnt/Hedgehog signaling pathway inhibitors include vismodegib (RG3616/GDC-0449), cyclopamine (1 1-deoxojervine) (Hedgehog pathway inhibitors) and XAV-939 (Wnt pathway inhibitor)
[00230] Exemplary RNA polymerase inhibitors include amatoxins. Exemplary amatoxins include a- amanitins, β- amanitins, γ- amanitins, ε-amanitins, amanullin, amanullic acid, amaninamide, amanin, and proamanullin.
[00231] In one embodiment the drug of the invention is a non-natural camptothecin compound, vinca alkaloid, kinase inhibitor (e.g., PI3 kinase inhibitor (GDC-0941 and PI-103)), MEK inhibitor, KSP inhibitor, RNA polymerase inhibitor, PARP inhibitor, docetaxel, paclitaxel, doxorubicin, duocarmycin, tubulysin, auristatin, dolastatin, calicheamicins, SN38,
pyrrolobenodiazepines, or a platinum compound, and analogs thereof. In specific embodiments, the drug is a derivative of SN-38, vindesine, vinblastine, PI-103, AZD 8330, auristatin E, auristatin F, a duocarmycin compound, tubulysin compound, or ARRY-520.
[00232] In another embodiment, the drug used in the invention is a combination of two or more drugs, such as, for example, PI3 kinases and MEK inhibitors; broad spectrum cytotoxic compounds and platinum compounds; PARP inhibitors and platinum compounds; broad spectrum cytotoxic compounds and PARP inhibitors. [00233] In yet another embodiment, the drug used in the invention is auristatin F- hydroxypropylamide-L-alanine.
[00234] In one embodiment, the Vinca alkaloid is a compound of Formula (V):
Figure imgf000059_0001
wherein:
Ri4 is hydrogen, -C(0)-Ci-3 alkyl or -C(0)-chloro substituted C1-3 alkyl;
Ri5 is hydrogen, -CH3 or -CHO;
when Ri7 and R] 8 are taken independently, Rig is hydrogen, and either R]6 or Ri7 is ethyl and the other is hydroxyl;
when Ri 7 and Rig are taken together with the carbon to which they are attached to form an oxiran ring, Ri6 is ethyl;
Ri9 is hydrogen, OH, amino group, alkyl amino or -[C(R2oR2i)]a-R22;
each of R20 and R2] independently is hydrogen, Ci-6 alkyl, C6-i0 aryl, hydroxylated C6-i0 aryl, polyhydroxylated C6-i0 aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
R22 is -OH, -NH2, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d-(0 CH2-CH2)f -N(H)(R23) or -Rg2-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, Ci_6 alkyl, C6-i0 aryl, C3-8 cycloalkyl, -COOH, or -COO-C,-6 alkyl;
X2 is a side chain of a natural or unnatural amino acid; R77 is hydrogen or X2 and NR77 form a nitrogen containing heterocyclic moiety;
R82 is -NH or oxygen;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00235] Further examples of Vinca alkaloids are described in, e.g., US 2010/0305149 and US 2002/0103136.
[00236] In one embodiment the Vinca alkaloid of Formula (V) is a compound of Formula
(VI):
Figure imgf000060_0001
wherein:
R40 is hydrogen, -OH, -NH2, or any of the following structures:
Figure imgf000060_0002
Figure imgf000060_0003
Figure imgf000061_0001
Figure imgf000061_0002
wherein:
a is an integer from 1 to 6; and
c is an integer from 0 to 3.
[00237] In one embodiment, in Formula (VI), R 0 is
Figure imgf000061_0003
[00238]
Figure imgf000061_0004
[00239] In another embodiment, R40 is
Figure imgf000062_0001
[00240] In another embodiment, the compound of Formula (VI) is a compound of Formula (Via) or (VIb):
Figure imgf000062_0002
or
Figure imgf000062_0003
[00241] In another embodiment, the non-natural camptothecin is a compound of Formula
(VII):
Figure imgf000062_0004
wherein:
R24 is -H, -CI, -F, -OH or alkyl; or R24 and R25, may be taken together to form an optionally substituted five- or six-membered ring;
R25 is -H, -F, -OH, -CH3, -CH=N-0-t-Butyl, -CH2CH2Si(CH3)3, -Si((CH3)2)-t-butyl, -O- C(0)-R29;
R29 is -NH2, -R28-Cj-6 alkyl-R22, 5 to 12-membered heterocycloalkyl, R28-C5-j2 heterocycloalkyl-Ci-6 alkyl-R22 or -R28-C[-6 alkyl-C6-i2 aryl-Ci-6 alkyl-R22; or R29 is R47 as defined herein;
R26 is -H, -CH2-N(CH3)2, NH2, or N02;
R27 is ethyl, N-methyl piperidine, cycloalkyl, -CH2CH2NHCH(CH3)2, or
-N-4-methylcyclohexylamine;
R79 is -H or -C(0)-R28-[C(R2oR2i)]a-R22;
each of R2o and R2i independently is hydrogen, Ci_6 alkyl, C -i0 aryl, hydroxylated C6-io aryl, polyhydroxylated C6-io aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
R22 is -OH, -NH2, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d-(0 CH2-CH2)f -N(H)(R23), or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, Ci-6 alkyl, C6-io aryl, C3-8 cycloalkyl, -COOH, or -COO-C1-6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
or R26 and R27 when taken together with the two carbon atoms to which they attach and the third carbon atom connecting the two carbon atoms form an optionally substituted six-membered ring;
R28 is absent, NH or oxygen;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3; f is an integer from 1 to 12;
u is an integer 0 or 1 ;
w is an integer 0 or 1 ; and
with the proviso that the compound of Formula (VII) must contain at least one of R29 and
R79.
[00242] In one embodiment the non-natural camptothecin compound of Formula (VII) is a compound of Formula (VIII) or Formula (XXV):
Figure imgf000064_0001
wherein R30 is -NH2, -R28-Ci-6 alkyl-R22, 5 to 12-membered heterocycloalkyl, R28-C5-i2 heterocycloalkyl-Ci-6 alkyl-R22 or -R28-Ci-6 alkyl-C6-i2 aryl-C1 -6 alkyl-R22;
R28 is absent, NH or oxygen;
R22 is -OH, -NH2, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d-(0 CH2-CH2)f -N(H)(R23) or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, C]-6 alkyl, C6-io aryl, C3-8 cycloalkyl, -COOH, or -COO-C1.6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound; R82 is -NH or oxygen;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00243] In some embodiments R30 is any one of the following structures:
-NH-(CH2VNH; -NH-(CH2) OH
(1) (2)
Figure imgf000065_0001
-(CH2)a-NH2 -C(H)(CH3)— (CH2)CNH2
(7) (8)
and
Figure imgf000065_0002
wherein:
a is an integer from 1 to 6;
c is an integer from 0 to 3; and
g is an integer from 2 to 6.
[00244] In another embodiment the PI3 kinase is a compound of Formula (IX):
Figure imgf000065_0003
wherein R47 is an amino group, -R9-[C(R2oR2i)]a-Rio, -R9-C5-12 heterocycloalkyl-Ci-6 alkyl-Ri0, 5 to 12-membered heterocycloalkyl, or -R9-C6-io aryl ;
each of R2o and R2i independently is hydrogen, Ci-6 alkyl, C6-i0 aryl, hydroxylated C6-io aryl, polyhydroxylated C6-i0 aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
Rio is -OH, -NHR83, -N-(R83)Rn, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82- C(0)(CH2)d-(0 CH2-CH -N(H)(R23), -R82-(C(0)-CH(X2)-NH)d-R77 or -R82-C(0)-
[C(R20R2i)]a-R82-R83 Or
Figure imgf000066_0001
;
each R23 independently is hydrogen, Ci-6 alkyl, C6-io aryl, C3-8 cycloalkyl, -COOH, or -COO-C1-6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
R9 is absent, N-(R83) or oxygen;
R83 is hydrogen or CH3;
R11 is :
Figure imgf000066_0002
each Ri2 independently is hydrogen, chloride, -CH3 or -OCH3;
Ri3 is hydrogen or -C(0)-(CH2)d-(0-CH2-CH2)rNH2;
R82 is -NH or oxygen
X4 is the side chain of lysine, arginine, citrulline, alanine or glycine;
X5 is the side chain of phenylalanine, valine, leucine, isoleucine or tryptophan; each of X6 and X7 is independently the side chain of glycine, alanine, serine, valine or proline;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3;
f is an integer from 1 to 12; and
each u independently is an integer 0 or 1 ;
or Rn is -Yu-Wq-Rss,
wherein:
Y is any one of the following structures:
Figure imgf000067_0001
in each of which the terminal NR 3 group of Y is proximal to R ;
R 3 is hydrogen or CH3;
each W is an amino acid unit;
each Ri2' independently is halogen , -Ci- alkyl, -0-Ci- alkyl, nitro or cyano;
R is hydrogen or -C(0)-(CH2)f^(NH-C(0))aa-Ej-(CH2)bb-R85
Figure imgf000067_0002
E is -CH2- or -CH2CH20-;
u is an integer 0 or 1 ;
q is an integer from 0 to 12;
aa is an integer 0 or 1 ;
bb is an integer 0 or 2;
ff is an integer from 0 to 10;
h is an integer from 0 to 4; j is an integer from 0 to 12; and
when E is -C¾-, bb is 0 and j is an integer from 0 to 10; and when E is -CH2CH2 2 and j is an integer from 1 to 12;
Figure imgf000068_0001
R83 is hydrogen or CH3;
R84 is C 1-6 alkyl or C6-io aryl;
each R12' independently is halogen , -C]-8 alkyl, -0-C]-8 alkyl, nitro or cyano;
h is an integer from 0 to 4; and
u is an integer 0 or 1.
[00245] In some embodiments, Rj 1 is:
Figure imgf000068_0002
each R12' independently is chloride, -CH3 or -OCH3;
R88 is hydrogen or -C(0)-(CH2)fr(CH2-CH20)rCH2-CH2-NH2;
R82 is -NH or oxygen
X4 is the side chain of lysine, arginine, citrulline, alanine or glycine;
X5 is the side chain of phenylalanine, valine, leucine, isoleucine or tryptophan;
each of X6 and X7 is independently the side chain of glycine, alanine, serine, valine or proline;
ff is an integer from 1 to 3; j is an integer from 1 to 12
h is an integer from 0 to 4; and
each u independently is an integer 0 or 1.
[00246] In some embodiments,
u X4 O X6 O . . „. ,. , .
is crtrulhne-valine; lysn phenylalanine; citrulline-phenylalanine; citralline-leucine; citralline-valine-glycine-glyc glycine-phenylalanine-glycine-glycine; valine; proline; leucine or isoleucine.
[00247] In another embodiment, Rn is any one of the following structures:
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
[00248] some embodiments ¾7 is any one of the following structures
-NH-(CH2)g^NH2 -NH'(CH2)„^OH
(1) (2)
Figure imgf000071_0002
-(CH2)a'NH2 -C(H)(CH3)— (CH2)CNH2
(?) (8)
Figure imgf000071_0003
CH, O
I !
-N— (CH2) NH2 (CH2)g-0-C -(CH2)
(1 1) (12)
Figure imgf000071_0004
Figure imgf000072_0001
71 19)
Figure imgf000073_0001
a is an integer from 1 to 6;
c is an integer from 0 to 3; and
g is an integer from 2 to 6.
In another embodiment the auristatin is a com ound of Formula (X):
Figure imgf000073_0002
(X), wherein:
each of R31 and R32 independently is hydrogen or CI -8 alkyl and at most one of R31 and R32 is hydrogen;
R33 is hydrogen, Cpg alkyl, C3-8 carbocycle, C6-io aryl, Cp8 alkyl-C6-i0 aryl, X'-(C3-g carbocycle), C3-g heterocycle or X!-(C3-g heterocycle);
R34 is hydrogen, Cpg alkyl, C3-g carbocycle, C6-io aryl, X'-C6-10 aryl, X'-(C3-g carbocycle), C3-g heterocycle or X'-(C3-g heterocycle);
R35 is hydrogen or methyl;
or R34 and R35> together with the carbon atom to which they attach form a carbocyclic ring having the formula -(CRssR^t,- wherein each of R55 and R41 independently is hydrogen or Cpg alkyl and b is an integer from 3 to 7;
R36 is hydrogen or Cpg alkyl;
R37 is hydrogen, Cpg alkyl, C3-g carbocycle, C6-i0 aryl, -X'-Ce-io aryl, -X!-(C3-g carbocycle), C3-8 heterocycle or -X' -(C3-8 heterocycle);
each R38 independently is hydrogen, OH, Cpg alkyl, C3-g carbocycle or 0-(Cpg alkyl);
R53 is:
Figure imgf000074_0001
R39 is H, Ci-g alkyl, C6-10 aryl,
Figure imgf000074_0002
aryl, C3-g carbocycle, C3-g heterocycle, -X]-C3-g heterocycle, -Ci-8 alkylene-NH2, or (CH2)2SCH3
each X1 independently is Ci-10 alkylene or C3.i0 cycloalkyl ene;
R 4 is hydrogen or Cpg alkyl;
R45 is X3-R42 or NH-Ri9;
X3 is O or S;
R]9 is hydrogen, OH, amino group, alkyl amino or -[C(R20R2i)]a-R-22;
R42 is an amino group, Ci_6 alkyl amino or -[C(R2oR2i)]a-R22;
each of R2o and R2i independently is hydrogen, Ci-6 alkyl, C -io aryl, hydroxylated C6-io aryl, polyhydroxylated C6_io aryl, 5 to 12-membered heterocycle, C3-g cycloalkyl, hydroxylated C3-g cycloalkyl, polyhydroxylated C3_g cycloalkyl or a side chain of a natural or unnatural amino acid; R22 is -OH, -NHR23, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d- (O CH2-CH2)f -N(H)(R23) or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, C1-6 alkyl, C6-io aryl, C3-8 cycloalkyl, -COOH, or -COO-Ci-6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
R54 is -C(R56)2-C(R56)2-C6-io aryl, -C(R56)2-C(R56)2-C3-8 heterocycle or -C(R56)2- C(R56)2-C3-8 carbocycle;
R56 is independently selected from H, OH, C1-8 alkyl, C3-8 carbocycle, -0-Ci-8 alkyl, -O- C(0)-R29 and -0-R23-0-Ci.6 alkyl-NH2;
R29 is an amino group, 5 to 12-membered heterocycloalkyl, -R28-Ci-6 alkyl-R22, R28-C5-i2 heterocycloalkyl-C1-6 alkyl-R22, -[C(R20R2i)]a-R22, or -R28-Ci-6 alkyl-C6-12 aryl-C!.6 alkyl-R22; or R29 is R47 as defined herein;
R28 is absent, NH or oxygen;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00250 In some embodiments, in the auristatin compound of Formula (X):
Figure imgf000075_0001
R44 is hydrogen.
[00251] In another embodiment the auristatin is a compound of Formula (Xa):
Figure imgf000076_0001
(Xa)
wherein:
R33 through R38, and R^ are as defined herein,
one of R3i and R32 is hydrogen or C1-8 alkyl and the other is:
Figure imgf000076_0002
wherein:
R83 is hydrogen or CH3;
R84 is Ci-6 alkyl or C6-io aryl;
each R12' independently is halogen , -Ci-8 alkyl, -0-Ci-8 alkyl, nitro or cyano; h is an integer from 0 to 4; and
u is an integer 0 or 1 ;
Figure imgf000076_0003
heterocycle, -C] -8 alkylene-NH2, or (CH2)2SCH3,
each X1 independently is CMO alkylene or C3-io cycloalkylene;
R45 is Χ3^2 or NH-Ri9;
X3 is O or S;
Ri9 is hydrogen, OH, amino group, alkyl amino or -~[C(R2oR2i)]a-R22;
R42 is H, an amino group, Ci-6 alkyl amino or -[C(R2oR2i)]a-R22; each of R2o and R21 independently is hydrogen, Ci-6 alkyl, C6-10 aryl, hydroxylated C6.i0 aryl, polyhydroxylated C6-10 aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3_g cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
R22 is -OH, -NHR23, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d- (O CH2-CH2)f -N(H)(R23) or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, C1-6 alkyl, C6-10 aryl, C3.8 cycloalkyl, -COOH, or -COO-Ci-6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
R54 is -C(R56)2-C(R56)2-C6-1o aryl, -C(R56)2-C(R56)2-C3-8 heterocycle or -C(R56)2- C(R56)2-C3-8 carbocycle;
R56 is independently selected from H, OH, Ci-8 alkyl, C3-8 carbocycle, -O-Cj-g alkyl, -O- C(0)-R29 and -0-R23-0-Ci-6 alkyl-NH2;
R29 is an amino group, 5 to 12-membered heterocycloalkyl, -R28-Ci-6 alkyl-R22, R28-C5-i2 heterocycloalkyl-Ci-6 alkyl-R22, -[C(R20R2i)]a-R22, or -R28-Ci-6 alkyl-C6-i2 aryl-Ci-6 alkyl-R22; or R29 is R 7 as defined herein;
R28 is absent, NH or oxygen;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00252] In one embodiment, the auristatin compound of Formula (Xa) is a compound of Formula (XIa) or Formula (Xlb):
Figure imgf000078_0001
Figure imgf000078_0002
Figure imgf000078_0003
R83 is hydrogen or CH3.
[00253] In one embodiment the auristatin of Formula (X) is a compound of Formula (XI), Formula (XII) or Formula (XIII):
wherein the compound of Formula (XI) is:
Figure imgf000078_0004
wherein R42 is -CH3 or any one of the following structures:
Figure imgf000079_0001
wherein:
a is an integer from 1 to 6; and c is an integer from 0 to 3; wherein the compound of Formula (XII) is:
Figure imgf000080_0001
Figure imgf000080_0002
Figure imgf000080_0003
Figure imgf000081_0001
Figure imgf000081_0002
wherein:
a is an integer from 1 to 6; and
c is an integer from 0 to 3;
rein the compound of Formula (XIII) is:
Figure imgf000081_0003
(XIII),
wherein R29 is an amino group, 5 to 12-membered heterocycloalkyl, -R28-Ci-6 alkyl-R22, R28-C5-i 2 heterocycloalkyl-Ci-6 alkyl-R22, -R28-[C(R20R2i)]a-R22, or -R28-Ci-6 alkyl-C6-i2 ar l-Ci. 6 alkyl-R22; or R29 is R47 as defined herein;
each of R20 and R21 independently is hydrogen, C1-6 alkyl, C6-io aryl, hydroxylated C6-i o aryl, polyhydroxylated C6-io aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
R22 is -OH, -NHR23, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d- (O CH2-CH2)f -N(H)(R23) or -R82-(C(0)-CH(X2)-NH)d-R77 ; each R23 independently is hydrogen, Ci-6 alkyl, C6-io aryl, C3-8 cycloalkyl, -COOH, -Ci-6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
R28 is absent, NH or oxygen;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00254] In one embodiment, in Formula (XII), R40 is
Figure imgf000082_0001
Figure imgf000082_0002
[00255] In another embodiment, the compound of Formula (XII) is a compound of
Formula (Xllb) or (XIIc):
Figure imgf000082_0003
[00256] In one embodiment in the compound of Formula (XIII), R29 is -NH2, 5 membered heterocycloalkyl, -R28-C]-6 alkyl-R22, R28-C5-i2 heterocycloalkyl-Ci-6 alkyl-R22 or -R28-Ci-6 alkyl-C6-]2 aryl-C]-6 alkyl-R22;; or R29 is R41 as defined herein;
R28 is absent, NH or oxygen;
R22 is -OH, -NHR23, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d- (O CH2-CH2)f -N(H)(R23) or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, C]-6 alkyl, C6-i0 aryl, C3-8 cycloalkyl, -COOH, or -COO-C.6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00257] In yet another embodiment, R29 is any one of the following structures:
;-NH-(CH2) NH2 !-NH-(CH2) OH
Figure imgf000083_0001
Figure imgf000084_0001
83 19)
Figure imgf000085_0001
wherein:
a is an integer from 1 to 6;
c is an integer from 0 to 3; and
g is an integer from 2 to 6.
[00258] In one emb f Formula (XIV):
Figure imgf000085_0002
wherein R43 is H or -R 6-R 7; each of R20 and R2i independently is hydrogen, C1-6 alkyl, C6-i0 aryl, hydroxylated C6-i0 aryl, polyhydroxylated C6-i0 aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
R22 is -OH, -NH2, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d-(0 CH2-CH2)f -N(H)(R23) or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, Ci-6 alkyl, C6_io aryl, C3-8 cycloalkyl, -COOH, or -COO-Ci-6 alkyl;
X 2 i *s a si *de chain of a natural or unnatural amino acid;
R77 is a hydrogen or X and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
R46 is -C(O)-; -C(0)-0-, -C(0)-NH-, or absent;
R47 is as defined herein;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00259] Further examples of the MEK inhibitor are disclosed in e.g., US 7,517,994 B2.
[00260] In some embodiments R^ is -C(0)-(CH2)a-NH2, or -C(0)-C(H)(CH3)-(CH2)c- NH2; in which a is an integer from 1 to 6; and c is an integer from 0 to 3.
[00261] In another embodiment, the duocarmycin compound is a compound of Formula
(XV):
Figure imgf000086_0001
wherein: R47 is as defined herein;
R48 is hydrogen, -COOC,-6 alkyl, -COOH, -NH2 or -CH3;
R49 is CI, Br or -OH;
R5o is hydrogen, -OCH3,
Figure imgf000087_0001
each of R51 and R52 independently is hydrogen or -OCH3; and
ring AA is either a phenyl or pyrrolyl ring.
[00262] Further examples of duocarmycin compounds are disclosed in e.g., US 7,553,816.
[00263] In one embodiment the duocarmycin compound of Formula (XV) is a compound of Formula (XVI),
Figure imgf000087_0002
(XVIII)
Figure imgf000088_0001
wherein:
R49 is CI, Br or -OH; and
R -7 is as defined herein.
[00264] In another embodiment, the duocarmycin compound is a duocarmycin SA compound of Formula (XX), see, e.g., US 5101038; or (XXI):
Figure imgf000088_0002
Figure imgf000089_0001
wherein:
R42 is Ci-6 alkyl amino or -[C(R20R2i)]a-R22;
each of R20 and R2i independently is hydrogen, C1-6 alkyl, C6-io aryl, hydroxylated C6-1o aryl, polyhydroxylated C6-io aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
R22 is -OH, -NH2, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d-(0 CH2-CH2)f -N(H)(R23), or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, Ci-6 alkyl, C6-1o aryl, C3-8 cycloalkyl, -COOH, or -COO-C,.6 alkyl;
2 ·
X is a side chain of a natural or unnatural ammo acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3; and
f is an integer from 1 to 12.
[00265] In some embodiments, ^ is any one of the following structures:
Figure imgf000090_0001
Figure imgf000090_0002
wherein:
a is an integer from 1 to 6; and c is an integer from 0 to 3. [00266] In another embodiment, the duocarmycin compound is Duocarmycin A,
Duocarmycin Bl, Duocarmycin B2, Duocarmycin CI, Duocarmycin C2, Duocarmycin 1065, Adozelesin, Bizelesin or Carzelesin
[00267 In another embodiment the tubulysin is a compound of Formula (XXII):
Figure imgf000091_0001
(ΧΧΠ),
wherein:
R57 is Ci-4 alkyl or -C(0)R58;
R-58 is Cj-6 alkyl, CF3 or C6-1o aryl;
R59 is Ci -6 alkyl;
R60 is hydrogen, Cr6 alkyl, C2-7 alkenyl, -CH2-phenyl, CH2OR65 or CH2OCOR66; R65 is hydrogen, Ci-6 alkyl, C2-7 alkenyl, C6-io aryl or C(0)R67 ;
R67 is Ci-6 alkyl, C2-6 alkenyl, C6-io aryl or heteroaryl;
R66 is Ci-6 alkyl, -C6H5 or -CH2-phenyl;
R6i is C 1 -6 alkyl;
R62 is hydrogen, OH, 0-C,-4 alkyl or 0-C(0)-C,-4 alkyl;
R63 is hydrogen, OH, 0-Ci-4 alkyl, 0-C(0)-Ci-4 alkyl, halogen or Cj-6 alkyl; e is an integer from 1 to 3;
R64 is:
Figure imgf000091_0002
wherein: R68 is hydrogen or Ci-C6 alkyl;
R69 is CO2R70, C(0)-R78, CONHNH2, OH, NH2, SH, or an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted heteroalkyl or an optionally substituted heterocycloalkyl group;
R70 is an optionally substituted alkyl (e.g., amino Ci-6 alkyl), an optionally substituted heteroalkyl or an optionally substituted heterocycloalkyl group;
each of R7i and R73 independently is hydrogen, halo, -N02, -CN, -NHR74, Ci-6 alkyl, haloalkyl, alkoxy, and haloalkoxy;
R72 is hydrogen, OR43, alkoxy, halogen, -NHR74, -0-C(0)-R47, N02, -CN, C6-]0 aryl, C]-6 alkyl, amino or dialkylamino;
R74 is hydrogen, -CHO, -C(0)-C]-4 alkyl, OH, amino group, alkyl amino or -
[C(R20R2i)]a-R22;
R 3 is H or -R^-R^;
R46 is -C(O)-; -C(0)-0-, -C(0)-NH-, or absent;
R 7 is as defined herein;
R78 is X3-R75 or NH-R]9;
X3 is O or S;
R]9 is hydrogen, OH, amino group, alkyl amino or -[C(R2oR2i)]a-R22;
R75 is a hydrogen, an amino group, Ci-6 alkyl amino or -[C(R2oR2i)]a-R22;
each of R20 and R2] independently is hydrogen, Ci.6 alkyl, C6-]o aryl, hydroxylated C6-]o aryl, polyhydroxylated C6-]o aryl, 5 to 12-membered heterocycle, C3-8 cycloalkyl, hydroxylated C3-8 cycloalkyl, polyhydroxylated C3-8 cycloalkyl or a side chain of a natural or unnatural amino acid;
R22 is -OH, -NH2, -COOH, -R82-C(0)(CH2)c-C(H)(R23)-N(H)(R23), -R82-C(0)(CH2)d-(0 CH2-CH2)f -N(H)(R23), or -R82-(C(0)-CH(X2)-NH)d-R77 ;
each R23 independently is hydrogen, Ci-6 alkyl, C6-io aryl, C3-8 cycloalkyl, -COOH, or -COO-Ci-6 alkyl;
X2 is a side chain of a natural or unnatural amino acid;
R77 is a hydrogen or X2 and NR77 form a nitrogen containing cyclic compound;
R82 is -NH or oxygen; R47 is as defined herein;
a is an integer from 1 to 6;
c is an integer from 0 to 3;
d is an integer from 1 to 3;
f is an integer from 1 to 12; and
with the proviso that when R69 is C(0)-X3-R75 or C(0)-NH-Ri9, one or both of R71 and R73 are -NHR74, and R72 is OR43; -NHR74 or -0-C(0)-R47, then at least one of Ri^ R^, R74 and R75 cannot be hydrogen.
[00268] In some embodiments in the compound of Formula (XXII):
R57 is -CH3;
R59 is sec-butyl;
R6o is hydrogen, methyl, ethyl, propyl, iso-propyl or iso-butyl;
R6i is iso-propyl,
R62 is hydrogen;
R63 is hydrogen, OH, -0-C3H7, 0-C(0)-CH3;
R68 is hydrogen or -CH3;
R69 is C02H, CO2R70 or C(0)-R78;
R70 is Ci-6 alkyl amine;
each of R71 and R?3 independently is hydrogen;
R72 is hydrogen, -OR43, OH, F, -CH3 or -OCH3;
R78 is OH, -OR75 or -ΝΗ¾0;
e is the integer 2;
R4o is hydrogen, -OH, -NH2, or any of the following structures:
Figure imgf000093_0001
Figure imgf000093_0002
(4)
Figure imgf000094_0001
wherein:
a is an integer from 1 to 6;
c is an integer from 0 to 3;
R 5 is any one of the following structures:
Figure imgf000094_0002
Figure imgf000095_0001
- -(CH2)a' H2 -C(H)(CH3)— (CH2)CNH2
(17) * ; and (18) ?
wherein:
a is an integer from 1 to 6; and
c is an integer from 0 to 3; R43 is hydrogen, -C(0)-(CH2)a-NH2, or -C(0)-C(H)(CH3)-(CH2)c-NH2;
wherein:
a is an integer from 1 to 6;
c is an integer from 0 to 3; and
R 7 is any one of the following structures:
-NH-(CH2) NH2 -NH'(CH2) OH
(1) (2)
Figure imgf000096_0001
-(CH2)a'NH2 ;-C(H)(CH3)— (CH2)CNH2
(?) (8)
Figure imgf000096_0002
CH, O
I I
N— (CH2) NH2 -N— (CH2)g-0-C-(CH2)g-NH2
(1 1) (12)
Figure imgf000096_0003
(15)
Figure imgf000096_0004
(16)
Figure imgf000097_0001
Figure imgf000098_0001
(21)
Figure imgf000098_0002
wherein:
a is an integer from 1 to 6;
c is an integer from 0 to 3; and
g is an integer from 2 to 6;
with the proviso that if R72 is -OH, then R75 cannot be hydrogen; if R69 is COOH then R72 must be -OR43 or-0-C(0)-R47.
[00269] In some embodiments, the tubulysin of Formula (XXII) is a compound of
Formula (
Figure imgf000098_0003
Figure imgf000099_0001
wherein:
R76 is hydrogen , OH, OCH3, F, -OR^ or -0-C(0)-R47;
wherein R78, R75, R19, n and R43 are as defined herein; and
with the proviso that if R76 is -OH, OCH3 or F, then R75 and R19 cannot be hydrogen.
[00270] In one embodiment, R47 is
Figure imgf000099_0002
[00271] In another embodiment, R4-7 is
Figure imgf000100_0001
272] In yet another embodiment, R47 is
Figure imgf000100_0002
[00273] In another embodiment, the KSP inhibitor compound is a compound of Formula
(XXVI):
Figure imgf000100_0003
wherein R30 is as defined herein.
[00274] In some embodiments R30 is:
-NH-(CH2)^NH2 -NH-(CH2)g^OH
(1) (2)
Figure imgf000101_0001
-(CH2)a-NH2 -C(H)(CH3)— (CH2)CNH2
or (8)
Figure imgf000101_0002
wherein:
a is an integer from 1 to 6;
c is an integer from 0 to 3; and
g is an integer from 2 to 6.
[00275] In another embodiment the KSP inhibitor compound is a compound of Formula
(XXVII), (XXVIII) or (XXIX):
Figure imgf000101_0003
(XXVII) (XXVIII) (XXIX) wherein:
Ri i is as defined herein.
[00276] One skilled in the art of therapeutic agents will readily understand that each of the therapeutic agents described herein can be modified in such a manner that the resulting compound still retains the specificity and/or activity of the original compound. The skilled artisan will also understand that many of these compounds can be used in place of the therapeutic agents described herein. Thus, the therapeutic agents of the present invention include analogues and derivatives of the compounds described herein.
[00277] Table A below provides more examples of the therapeutic agents and derivatives thereof suitable for conjugation to form the polymer-drug-protein conjugates or polymer-drug scaffolds of the invention. Spectral data of certain compounds are also provided (ND in the table means "not determined"). These examples may also be the active form of the drug when it is released from a conjugate in vitro or in vivo.
Table A
Figure imgf000102_0002
Figure imgf000102_0001
Figure imgf000102_0003
Figure imgf000103_0002
Figure imgf000103_0001
Figure imgf000103_0003
Figure imgf000104_0001
103
Figure imgf000105_0001
m/z 553.1
538.1 564.1
566.1
568.1
ND
ND
667.2
622.2
632.02
986.2
Figure imgf000107_0001
106
Figure imgf000108_0001
Figure imgf000109_0001
108
Figure imgf000110_0001
109
Figure imgf000111_0001
(XXVII) (XXVIII) (XXIX)
Figure imgf000111_0002
Figure imgf000112_0001
Protein-Based Recognition Molecules (PBRMs)
[00278] The protein-based recognition molecule directs the drug-polymer carrier conjugates to specific tissues, cells, or locations in a cell. The protein-based recognition molecule can direct the modified polymer in culture or in a whole organism, or both. In each case, the protein-based recognition molecule has a ligand that is present on the cell surface of the targeted cell(s) to which it binds with an effective specificity, affinity and avidity. In some embodiments, the protein-based recognition molecule targets the modified polymer to tissues other than the liver. In other embodiments the protein-based recognition molecule targets the modified polymer to a specific tissue such as the liver, kidney, lung or pancreas. The protein- based recognition molecule can target the modified polymer to a target cell such as a cancer cell, such as a receptor expressed on a cell such as a cancer cell, a matrix tissue, or a protein associated with cancer such as tumor antigen. Alternatively, cells comprising the tumor vasculature may be targeted. Protein-based recognition molecules can direct the polymer to specific types of cells such as specific targeting to hepatocytes in the liver as opposed to Kupffer cells. In other cases, protein-based recognition molecules can direct the polymer to cells of the reticular endothelial or lymphatic system, or to professional phagocytic cells such as
macrophages or eosinophils. (In such cases the polymer itself might also be an effective delivery system, without the need for specific targeting).
[00279] In still other embodiments, the protein based recognition molecule can target the modified polymer to a location within the cell, such as the nucleus, the cytoplasm, or the endosome, for example. In specific embodiments, the protein based recognition molecule can enhance cellular binding to receptors, or cytoplasmic transport to the nucleus and nuclear entry or release from endosomes or other intracellular vesicles.
[00280] In specific embodiments the protein based recognition molecules include antibodies, proteins and peptides or peptide mimics.
[00281] Exemplary antibodies or antibodies derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments specific to the cell surface markers, include, but are not limited to, 5T4, AOC3, ALK, AXL, C242, CA-125, CCL1 1 , CCR 5, CD2, CD3, CD4, CD5, CD15, CA15-3, CD18, CD19, CA19-9, CD20, CD22, CD23, CD25, CD28, CD30, CD31 , CD33, CD37, CD38, CD40, CD41, CD44, CD44 v6, CD51 , CD52, CD54, CD56, CD62E, CD62P, CD62L, CD70, CD74, CD79-B, CD80, CD125, CD138, CD141 , CD147, CD152, CD 154, CD326, CEA, clumping factor, CTLA-4, CXCR2, EGFR (HER1 , ErbB2, ErbB3, EpCAM, EPHA2, EPHB2, EPHB4, FGFR (i.e. FGFR1, FGFR2, FGFR3, FGFR4), FLT3, folate receptor, FAP, GD2, GD3, GPNMB, HGF, HER2, ICAM, IGF-1 receptor, VEGFR1, EphA2, TRPV1 , CFTR, gpNMB, CA9, Cripto, c-KIT, c-MET, ACE, APP, adrenergic receptor-beta2, Claudine 3, Mesothelin, MUC1, RON, ROR1, PD-L1, PD-L2, B7-H3, B7-B4, IL-2 receptor, IL-4 receptor, IL-13 receptor, integrins (including α4, ανβ3, a νβ5, ανβ6, αιβ4, α4βι, α4β7ι α5βι, α6β4, αι^β3 integrin), IFN-a, IFN-γ, IgE, IgE , IGF-1 receptor, IL-1, IL-12, IL-23, IL-13, IL-22, IL-4, IL-5, IL-6, interferon receptor, ITGB2 (CD 18), LFA-1 (CD 11 a), L-selectin (CD62L), mucin, MUC1, myostatin, NCA-90, NGF, PDGFRa, phosphatidylserine, prostatic carcinoma cell, Pseudomonas aeruginosa, rabies, RANKL, respiratory syncytial virus, Rhesus factor, SLAMF7, sphingosine- 1 -phosphate, TAG-72, T-cell receptor, tenascin C, TGF-1, TGF^2, TGF-β, TNF-a, TRAIL-Rl, TRAIL-R2, tumor antigen CTAA16.88, VEGF-A, VEGFR2, vimentin, and the like.
[00282] In one embodiment the antibodies or antibody derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments specific to the cell surface markers include CA-125, C242, CD3, CD19, CD22, CD25, CD30, CD31, CD33, CD37, CD40, CD44, CD51 , CD54, CD56, CD62E, CD62P, CD62L, CD70, CD 138, CD141, CD326, CEA, CTLA-4, EGFR
(HER1), ErbB2, ErbB3, FAP, folate receptor, IGF-1 receptor, GD3, GPNMB, HGF, HER2, VEGF-A, VEGFR2, VEGFR1, EphA2, EpCAM, 5T4, TAG-72, tenascin C, TRPV1 , CFTR, gpNMB, CA9, Cripto, ACE, APP, PDGFR a, phosphatidylserine, prostatic carcinoma cells, adrenergic receptor-beta2, Claudine 3, mucin, MUC1 , Mesothelin, IL-2 receptor, IL-4 receptor, IL-13 receptor and integrins (including ανβ3, νβ5, νβ6, ιβ4, α4βι, 5βι, α6β4 integrins), tenascin C, TRAIL-R2 and vimentin.
[00283] Exemplary antibodies include 3F8, abagovomab, abciximab (REOPRO), adalimumab (HUMIRA), adecatumumab, afelimomab, afutuzumab, alacizumab, ALD518, alemtuzumab (CAMPATH), aitumomab, amatuximab, anatumomab, anrukinzumab, apolizumab, arcitumomab (CEA-SCAN), aselizumab, atlizumab (tocilizumab, Actemra, RoActemra), atorolimumab, bapineuzumab, basiliximab (Simulect), bavituximab, bectumomab
(LYMPHOSCAN), belimumab (BENLYSTA), benralizumab, bertilimumab, besilesomab (SCINITIMUN), bevacizumab (AVASTIN), biciromab (FIBRISCINT), bivatuzumab, blinatumomab, brentuximab , briakinumab, canakinumab (ILARIS), cantuzumab, capromab, catumaxomab (REMOVAB), CC49, cedelizumab, certolizumab, cetuximab (ERBITUX), citatuzumab , cixutumumab, clenoliximab, clivatuzumab, conatumumab, CR6261, dacetuzumab, daclizumab (ZENAPAX), daratumumab, denosumab (PROLIA), detumomab, dorlimomab , dorlixizumab, ecromeximab, eculizumab (SOLIRIS), edobacomab, edrecolomab (PANOREX), efalizumab (RAPTIVA), efungumab (MYCOGRAB), elotuzumab, elsilimomab, enlimomab, epitumomab , epratuzumab, erlizumab, ertumaxomab (REXOMUN), etaracizumab (ABEGRIN), exbivirumab, fanolesomab (NEUTROSPEC), faralimomab, farletuzumab, felvizumab, fezakinumab, figitumumab, fontolizumab (HuZAF), foravirumab, fresolimumab, galiximab, gantenerumab, gavilimomab, gemtuzumab girentuximab, glembatumumab, golimumab
(SIMPONI), gomiliximab, ibalizumab, ibritumomab, igovomab (INDIMACIS-125), imciromab (MYOSCINT), infliximab (REMICADE), intetumumab, inolimomab, inotuzumab, ipilimumab, iratumumab, keliximab, labetuzumab (CEA-CIDE), lebrikizumab, lemalesomab, lerdelimumab, lexatumumab, libivirumab, lintuzumab, lucatumumab, lumiliximab, mapatumumab,
maslimomab, matuzumab, mepolizumab (BOSATRIA), metelimumab, milatuzumab, minretumomab, mitumomab, morolimumab, motavizumab (NUMAX), muromonab-CD3 (ORTHOCLONE OKT3), nacolomab, naptumomab, natalizumab (TYSABRI), nebacumab, necitumumab, nerelimomab, nimotuzumab (THERACIM), nofetumomab, ocrelizumab, odulimomab, ofatumumab (ARZERRA), olaratumab, omalizumab (XOLAIR), ontecizumab, oportuzumab, oregovomab (OVAREX), otelixizumab, pagibaximab, palivizumab (SYNAGIS), panitumumab (VECTIBIX), panobacumab, pascolizumab, pemtumomab (THERAGYN), pertuzumab (OMNITARG), pexelizumab, pintumomab, priliximab, pritumumab, PRO 140, rafivirumab, ramucirumab, ranibizumab (LUCENTIS), raxibacumab, regavirumab, reslizumab, rilotumumab, rituximab (RITUXAN), robatumumab, rontalizumab, rovelizumab
(LEUKARREST), ruplizumab (ANTOVA), satumomab pendetide, sevirumab, sibrotuzumab, sifalimumab, siltuximab, siplizumab, solanezumab, sonepcizumab, sontuzumab, stamulumab, sulesomab (LEUKOSCAN), tacatuzumab (AFP-CIDE), tetraxetan, tadocizumab, talizumab, tanezumab, taplitumomab paptox, tefibazumab (AUREXIS), telimomab, tenatumomab, teneliximab, teplizumab, TGN1412, ticilimumab (tremelimumab), tigatuzumab, TNX-650, tocilizumab (atlizumab, ACTEMRA), toralizumab, tositumomab (BEXXAR), trastuzumab (HERCEPTIN), tremelimumab, tucotuzumab, tuvirumab, urtoxazumab, ustekinumab
(STELERA), vapaliximab, vedolizumab, veltuzumab, vepalimomab, visilizumab (NUVION), volociximab (HUMASPECT), votumumab, zalutumumab (HuMEX-EGFr), zanolimumab (HuMAX-CD4), ziralimumab and zolimomab.
[00284] In some embodiments the antibodies are directed to cell surface markers for 5T4, CA-125, CEA, CD3, CD 19, CD20, CD22, CD30, CD33, CD40, CD44, CD51 , CTLA-4, EpCAM, HER2, EGFR (HER1), FAP, folate receptor, HGF, integrin ανβ3, integrin α5βι, IGF-1 receptor, GD3, GPNMB, mucin, MUCl , phosphatidylserine, prostatic carcinoma cells, PDGFR a, TAG-72, tenascin C, TRAIL-R2, VEGF-A and VEGFR2. In this embodiment the antibodies are abagovomab, adecatumumab, alacizumab, altumomab, anatumomab, arcitumomab, bavituximab, bevacizumab (AVASTIN), bivatuzumab, blinatumomab, brentuximab,
cantuzumab, catumaxomab, capromab , cetuximab, citatuzumab, clivatuzumab, conatumumab, dacetuzumab, edrecolomab, epratuzumab, ertumaxomab, etaracizumab, farletuzumab, figitumumab, gemtuzumab, glembatumumab, ibritumomab, igovomab, intetumumab, inotuzumab, labetuzumab, lexatumumab, lintuzumab, lucatumumab, matuzumab, mitumomab, naptumomab estafenatox, necitumumab, oportuzumab, oregovomab, panitumumab,
pemtumomab, pertuzumab, pritumumab, rituximab (RITUXAN), rilotumumab, robatumumab, satumomab, sibrotuzumab, taplitumomab , tenatumomab, tenatumomab, ticilimumab
(tremelimumab), tigatuzumab, trastuzumab (HERCEPTIN), tositumomab, tremelimumab, tucotuzumab celmoleukin, volociximab and zalutumumab.
[00285] In specific embodiments the antibodies directed to cell surface markers for HER2 are pertuzumab or trastuzumab and for EGFR (HER1) the antibody is cetuximab and for CD20 the antibody is rituximab and for VEGF-A is bevacizumab and for CD-22 the antibody is epratuzumab or veltuzumab and for CEA the antibody is labetuzumab.
[00286] Exemplary peptides or peptide mimics include integrin targeting peptides (RGD peptides), LHRH receptor targeting peptides, ErbB2 (HER2) receptor targeting peptides, prostate specific membrane bound antigen (PSMA) targeting peptides, lipoprotein receptor LRP1 targeting, ApoE protein derived peptides, ApoA protein peptides, somatostatin receptor targeting peptides, chlorotoxin derived peptides, and bombesin.
[00287] In specific embodiments the peptides or peptide mimics are LHRH receptor targeting peptides and ErbB2 (HER2) receptor targeting peptides [00288] Exemplary proteins comprise insulin, transferrin, fibrinogen-gamma fragment, thrombospondin, claudin, apolipoprotein E, Affibody molecules such as, for example, ABY-025, Ankyrin repeat proteins, ankyrin-like repeats proteins and synthetic peptides.
[00289] In some embodiments of the invention the protein drug polymer conjugates comprise broad spectrum cytotoxins in combination with cell surface markers for HER2 such as pertuzumab or trastuzumab; for EGFR such as cetuximab; for CEA such as labetuzumab; for CD20 such as rituximab; for VEGF-A such as bevacizumab; or for CD-22 such as epratuzumab or veltuzumab.
[00290] In other embodiments of the invention the protein-drug-polymer conjugates or protein-polymer conjugates used in the invention comprise combinations of two or more protein based recognition molecules, such as, for example, combination of bispecific antibodies directed to the EGF receptor (EGFR) on tumor cells and to CD3 and CD28 on T cells; combination of antibodies or antibody derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments and peptides or peptide mimetics; combination of antibodies or antibody derived from Fab, Fab2, scFv or camel antibody heavy-chain fragments and proteins; combination of two bispecific antibodies such as CD3 x CD 19 plus CD28 x CD22 bispecific antibodies.
[00291] In other embodiments of the invention the protein-drug-polymer conjugates or protein-polymer conjugates used in the invention comprise protein based recognition molecules are antibodies against antigens, such as, for example, B7-H4, B7-H3, CA125, CD33, CXCR2, EGFR, FGFR1 , FGFR2, FGFR3, FGFR4, HER2, PD-L1 and 5T4.
[00292] Table B below provides more examples of the PBRM described herein, which are suitable for conjugation to form the polymer-drug-protein conjugates or polymer-PBRM scaffolds of the invention.
Table B
Figure imgf000117_0001
Figure imgf000118_0001
117
Figure imgf000119_0001
Linkers (LD and Lp)
[00293] As described above, the drug or PBRM is connected to the polymeric carrier via a linker LD or Lp. In some embodiments, the linker is biocleavable/biodegradable under intracellular conditions, such that the cleavage of the linker releases the drug or PBRM from the polymer unit in the intracellular environment.
[00294] A linker is any chemical moiety that is capable of linking a drug or a PBRM to a polymer backbone through chemical bonds such that the drug or PBRM and the polymer are chemically coupled (e.g., covalently bonded) to each other. In some embodiments, the linker comprises a biodegradable linker moiety (e.g., a biodegradable bond such as an ester or amide bond).
[00295] In other embodiments, the linker LD or Lp is biodegradable under mild conditions, i.e., conditions within a cell under which the activity of the drug is not affected. Examples of suitable biodegradable linker moiety include disulfide linkers, acid labile linkers, photolabile linkers, peptidase labile linkers, and esterase labile linkers.
[00296] In some embodiments, the linker LD or Lp is biocleavable under reducing conditions (e.g., a disulfide linker). In this embodiment the drug or PBRM moiety is linked to the polymer through a disulfide bond. The linker molecule comprises a reactive chemical group that can react with the drug. Preferred reactive chemical groups for reaction with the drug or PBRM moiety are N-succinimidyl esters and N-sulfosuccinimidyl esters. Additionally the linker molecule comprises a reactive chemical group, preferably a dithiopyridyl group that can react with the drug to form a disulfide bond. In some embodiments the linker molecules include, for example, N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2- pyridyldithio)butanoate (SPDB), N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), N- succinimidyl-S-acetylthioacetate (SAT A) and N-succinimidyl-oxycarbonyl-alpha-methyl-alpha- (2-pyridyl-dithio)toluene or 2,5-dioxopyrrolidin-l-yl 4-(l-(pyridin-2-yldisulfanyl)ethyl)benzoate (SMPT).
[00297] In other embodiments, the biocleavable linker LD or Lp is pH-sensitive, i.e., sensitive to hydrolysis at certain pH values. Typically, the pH-sensitive linker is hydrolysable under acidic conditions. For example, an acid-labile linker that is hydrolysable in the lysosome or endosome (e.g., a hydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetal, ketal, or the like) can be used. Such linkers are relatively stable under neutral pH conditions, such as those in the blood, but are unstable at below pH 5.5 or 5.0, the approximate pH of the lysosome. In certain embodiments, the hydrolysable linker is a thioether linker (such as, e.g., a thioether attached to the therapeutic agent via an acylhydrazone bond.
[00298] In other embodiments the linker LD or Lp is photo-labile and is useful at the body surface and in many body cavities that are accessible to light. Furthermore, LD or Lp is biocleavable by infrared light which can penetrate tissue. Accordingly, LD or Lp is useful for both applications on the body surface and in the tissue.
[00299] In some embodiments, the linker LD or Lp is biocleavable by a cleaving agent that is present in the intracellular environment (e.g., within a lysosome or endosome or caveolea).
The linker can be, for example, a peptidyl linker that is cleaved by an intracellular peptidase or protease enzyme, including, but not limited to, a lysosomal or endosomal protease.
[00300] In some embodiments the linker LD or Lp is cleaved by esterases. Only certain esters can be cleaved by esterases present inside or outside cells. Esters are formed by the condensation of a carboxylic acid and an alcohol. Simple esters are esters produced with simple alcohols, such as aliphatic alcohols, and small cyclic and small aromatic alcohols.
[00301] In yet other embodiments, the linker LD or Lp is not biocleavable and the drug is released by antibody degradation. See, for example, U.S. Patent No. 7,498,298, which is incorporated by reference herein in its entirety and for all purposes.
[00302] Typically, the linker LD or Lp is not substantially sensitive to the extracellular environment. As used herein, "not substantially sensitive to the extracellular environment," in the context of a linker, means that no more than about 20%, typically no more than about 15%, more typically no more than about 10%, and even more typically no more than about 5%, no more than about 3%, or no more than about 1% of the linkers, in a sample of Polymer Drug Conjugate, are cleaved when the Polymer Drug Conjugate presents in an extracellular environment (e.g., in plasma) for 24 hours. Whether a linker is not substantially sensitive to the extracellular environment can be determined, for example, by incubating the Polymer Drug Conjugate with plasma for a predetermined time period (e.g., 2, 4, 8, 16, or 24 hours) and then quantitating the amount of free drug present in the plasma.
[00303] In embodiments, the linker LD has the structure:
— RL1-C(=0)-XD-MD1-YD-MD2-ZD-MD3-QD-MD4— , with RL1 connected to an oxygen atom of the polymeric carrier and MD4 connected to the drug molecule to be delivered.
[00304] In embodiments, the linker Lp has the structure:
— RL2-C(=0)-XP-MP1-YP-MP2- ZP-MP3-QP-MP4— , with RL2 connected to an oxygen atom of the polymeric carrier and MP4 connected to the PBRM.
[00305] For example, each of RL1 and RL2 independently is absent, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, aryl, or heteroaryl.
[00306] For example, each of RL1 and RL2 independently is absent, alkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl.
[00307] For example, RL1 is absent.
[00308] For example, RL2 is absent.
[00309] For example, each of XD and XP, independently is -0-, -S-, -N(R')-, or absent, in which R1 is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety, -
C(=0)R1B, -C(=0)OR1B, -S02R1B or -N(R')- is a heterocycloalkyl moiety, wherein R1B is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
[00310] For example, each of YD, Yp, ZD, ZP, QD, and Qp, independently, is absent or a biodegradable linker moiety selected from the group consisting of— S-S— ,— C(=0)0— ,
— C(=0)NR2— ,— OC(=0)— ,— NR2C(=0)— ,— OC(=0)C— ,— OC(=0)NR2— ,
— NR2C(=0)0— ,— NR2C(=0)NR3— ,— C(OR2)0— ,— C(OR2)S— ,— C(OR2)NR3— ,
— C(SR2)0— ,— C(SR2)S— ,— C(SR2)NR3— ,— C(NR2R3)0— ,— C(NR2R3)S— ,
— C(NR2R3)NR4— ,— C(=0)S— ,— SC(=0)— ,— SC(=0)S— ,— OC(=0)S— ,— SC(=0)0-,
— C(=S)S— ,— SC(=S)— ,— OC(=S)— ,— C(=S)0— ,— SC(=S)0— ,— OC(=S)S— , — OC(=S)0— ,— SC(=S)S— ,— C(=NR2)0— ,— C(=NR2)S— ,— C(=NR2)NR3— ,
__OC(=NR2)— ,— SC(=NR2)— ,— NR3C(=NR2)— ,— NR2S02— ,— NR2NR3— ,
— C(=0)NR2NR3— ,— NR2NR3C(=0)— ,— OC(=0)NR2NR3—— NR2NR3C(=0)0— ,
— C(=S)NR2NR3— ,— NR2NR3C(=S)— ,— C(=NR4)NR2NR3—,— NR2NR3C(=NR4)— ,
— 0(N=CR3)— ,— (CR3=N)0— ,— C(=0)NR2-(N=CR3)— ,— (CR3=N)-NR2C(=0)— ,
— S03— ,— NR2S02NR3— ,— S02NR2— , and polyamide, wherein each occurrence of R2, R3, and R4 independently is hydrogen or an aliphatic, heteroaliphatic, carbocyclic, or heterocyclic moiety, or each occurrence of -NR2- or -NR2NR3- is a heterocycloalkyl moiety.
[00311] For example, each of MD1 , MD2, MD3, MD4, Mpl , Mp2, Mp3 and MP4,
independently, is absent or a non-biodegradable linker moiety selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl,
D 1 D2 D3 P 1 heterocycloalkyl, aryl, heteroaryl, and a combination thereof and each of M , M , M , M , MP2, and MP3 optionally contains one or more -(C=0)- but does not contain any of the biodegradable linker moieties mentioned above.
[00312] For example, each of MD1 , MD2, MD3, Mw, MP1 , MP2, Mp3 and MP4, independently is Cue alkyl, C1-6 alkyl-C(O)-C0-6 alkyl, Ci-6 alkyl-NH-C0-6 alkyl, C,-6 alkyl-O-C0-6 alkyl, C1-6 alkyl-S-C0-6 alkyl, C1-6 alkyl-C(0)-Ci-6 alkyl-NH, C,-6 alkyl-C(0)-C,-6 alkyl-O, C1-6 alkyl-C(O)- Ci-6 alkyl-S, C3-i0 cycloalkyl-C(O)-C0-6 alkyl, 3-19 membered heterocycloalkyl-C(0)-Co-6 alkyl, aryl-C(O)-C0-6 alkyl, (CU2CU20)i-n, and the like.
[00313] For example, for each LD, MD1 is not absent when XD is absent.
[00314] For example, for each Lp, MP1 is not absent when Xp is absent.
[00315] For example, for each LD, at least one of XD, YD, ZD, and QD is not absent.
[00316] For example, for each Lp, at least one of Xp, Yp, Zp, and Qp is not absent.
[00317] For example, each of MD1 and MP1 independently is Ci-6 alkyl or C]-6 heteroalkyl.
[00318] For example, each of MD2, MD3, MD4, Mp2, MP3, and MP4, independently is absent,
Ci-<5 alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, or a combination thereof.
[00319] For example, for each LD, at most two of MD2, MD3, and MD4 are absent.
[00320] For example, for each Lp, at most two of MP2, MP3, and MP4 are absent.
[00321] For example, for each L , one of MD2 and MD3 has one of the following structures:
Figure imgf000123_0001
in which q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3, and the other of MD2 or MD3 is either absent or a moiety different from the above, such as C1-6 alkyl.
[00322] For example, for each Lp, one of MP2 and MP3 has one of the following structures:
Figure imgf000124_0001
in which q is an integer from 0 to 12 and each of p and t independently is an integer from 0 to 3, and the other of Mn or MP3 is either absent or a moiety different from the above, such as Ci_6 alkyl.
[00323] For example, p is 2.
[00324] For example, q is 0 or 12.
[00325] For example, t is 0 or 1.
[00326] For example, each of -MD2-ZD-, -ZD-MD3-, -ZD-MD2-, or -MD3-ZD-, independently has one of the following structures:
Figure imgf000125_0001
(16) (17) (18)
Figure imgf000125_0002
Figure imgf000126_0001
Figure imgf000126_0002
in which ring A or B independently is cycloalkyl or heterocycloalkyl; R is an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety; Ru is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety; and ring D is heterocycloalkyl.
[00327] For example, each of -MP2-ZP-, -Zp-Mp3-, -ZP-MP2-, and -Mp3-Zp- independently, has one of the following structures:
Figure imgf000126_0003
Figure imgf000127_0001
in which ring A is cycloalkyl or heterocycloalkyl and R is hydrogen, an aliphatic, heteroaliphatic, carbocyclic, or heterocycloalkyl moiety.
[00328] For example, ring A is 5-19 membered heterocycloalkyl, e.g.,
Figure imgf000127_0002
[00329] For example, ring A is C3-8 cycloalkyl.
[00330] For example, ring D is piperazinyl or piperidinyl.
[00331] For example, Rw is C1-6 alkyl.
[00332] For example, R1J is hydrogen or C)-6 alkyl.
[00333] For example, Z is
For example, Zp is
Figure imgf000127_0003
For example, XD is absent, O or NH.
For example, Xp is absent, O or NH.
For example, each of XD and Xp, independently
Figure imgf000127_0004
[00338] For example, each of YD and Yp independently is -S-S-, -OCO-, -COO-, -CONH- or -NHCO-.
[00339] For example, each of QD and Qp independently is absent,-S-S-, -OCO-, -COO-, - CONH-, -NHCO-, -OCONHNH-, or -NHNHCOO-.
[00340] For example, -LD-D can have one of the following structures below, in which the wavy bond indicates that D (i.e., Drug) is either connected to the functional linker directly or via another moiety:
Figure imgf000128_0001
Figure imgf000129_0001

Figure imgf000130_0001
 R82 is -NH or oxygen.
[00341] For example, polymeric carrier-Lp-PBRM can have one of the following structures below:
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000134_0002
[00342] Additional examples of linker LD and Lp suitable for use in the present invention are described in US 2012/0321583 and US 2013/0101546, each of which is hereby incorporated by reference in its entirety.
[00343] While biocleavable linkers preferably are used in the invention, a non- biocleavable linker also can be used to generate the above-described conjugate. A non- biocleavable linker is any chemical moiety that is capable of linking a drug or PBRM, to a polymer in a stable, covalent manner. Thus, non-biocleavable linkers are substantially resistant to acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and/or disulfide bond cleavage, at conditions under which the drug or polymer remains active.
[00344] In one embodiment, a substantial amount of the drug moiety is not cleaved from the conjugate until the protein-polymer-drug conjugate enters a cell with a cell-surface receptor specific for the PBRM of the protein-polymer-drug conjugate, and the drug moiety is cleaved from the protein-polymer-drug conjugate when the protein-polymer-drug conjugate does enter the cell.
[00345] In another embodiment, the bioavailability of the protein-polymer-drug conjugate or an intracellular metabolite of the protein-polymer-drug conjugate in a subject is improved when compared to a drug compound or conjugate comprising the drug moiety of the protein- polymer-drug conjugate, or when compared to an analog of the compound not having the drug moiety. [00346] In another embodiment, the drug moiety is intracellularly cleaved in a subject from the protein-polymer-drug conjugate, or an intracellular metabolite of the protein-polymer- drug conjugate.
Conjugates or Polymeric Scaffolds
[00347] Conjugates of the invention comprise one or more occurrences of D, where D is a therapeutic agent, e.g., a drug, wherein the one or more occurrences of D may be the same or different.
[00348] In certain other embodiments, one or more occurrences of PBRM is attached to the polymeric carrier, wherein the one or more occurrences of PBRM may be the same or different. In certain other embodiments, one or more polymer carriers that contains one or more occurrences of D are connected to a PBRM (e.g., an antibody).
[00349] As discussed more generally above, in certain embodiments, each polymeric carrier independently, has about 0.1 to about 25 % monomers comprising a D, more preferably about 0.5 to about 20%, more preferably about 1 to about 15%, and even more preferably about 2 to about 10%.
[00350] In certain embodiments, the conjugate of this invention is of Formula (I):
Figure imgf000135_0001
(I), wherein:
each of n, ni, n2, n3, and Ώ4, is the molar fraction of the corresponding polymer unit ranging between 0 and 1 ; n + n! + n2 + n3 + 114 = 1 ; provided that none of n, n2, and 114 is 0.
[00351] For example, the ratio between n2 and ¾ is greater than 1 : 1 and <200: 1.
[00352] For example, the ratio between n2 and n is between 10:1 and 50:1.
[00353] For example, the ratio between n2 and n is between 30:1 and 50:1.
[00354] For example, the ratio between n2 and r is about 50:1 , 25: 1, 10:1, 5:1 or 2:1.
[00355] In certain embodiments, the conjugates are formed in several steps. These steps include (1) modifying a polymer so that it contains a functional group that can react with a functional group of the drug or its derivative; (2) reacting the modified polymer with the drug or its derivative so that the drug is linked to the polymer; (3) modifying the polymer-drug conjugate so that the polymer contains a functional group that can react with a functional group of the PBRM or its derivative; and (4) reacting the modified polymer-drug conjugate with the PBRM or its derivative to form the conjugate of this invention. Step (3) may be omitted if the modified polymer produced by step (1) contains a functional group that can react with a functional group of the PBRM or its derivative.
[00356] In another embodiment the conjugates are formed in several steps: (1) modifying a polymer so that it contains a functional group that can react with a functional group of a first drug or its derivative; (2) reacting the modified polymer with the first drug or its derivative so that the first drug is linked to the polymer; (3) modifying the polymer-drug conjugate so that it contains a different functional group that can react with a functional group of a second drug or its derivative (4) reacting the modified polymer-drug conjugate with the second drug or its derivative so that the second drug is linked to the polymer-drug conjugate; (5) modifying the polymer-drug conjugate containing 2 different drugs so that the polymer contains a functional group that can react with a functional group of the PBRM or its derivative; and (6) reacting the modified polymer-drug conjugate of step (5) with the PBRM or its derivative to form the conjugate of this invention. Steps (5) and (6) may be repeated if 2 different PBRM or its derivatives are to be conjugated to form a polymer-drug conjugate comprising two different drugs and two different PBRMs.
[00357] In yet another embodiment, the conjugates are formed in several steps. These steps include (1) modifying a polymer so that it contains a functional group that can react with a functional group of the drug or its derivative; (2) further modifying the polymer so that it also contains a functional group that can react with a functional group of the PBRM or its derivative;
(3) reacting the modified polymer with the drug or its derivative so that the drug is linked to the polymer; and (4) reacting the modified polymer-drug conjugate with the PBRM or its derivative to form the conjugate of this invention. The sequence of steps (1) and (2) or that of steps (3) and
(4) can be reversed. Further either step (1) or (2) may be omitted if the modified polymer contains a functional group that can react with both a functional group of the drug or its derivatives and a functional group of the PBRM or its derivative.
[00358] In another embodiment the conjugates are formed in several steps: (1) modifying a polymer so that it contains a functional group that can react with a functional group of a first drug or its derivative; (2) further modifying a polymer so that it contains a functional group that can react with a functional group of the PBRM or its derivative; (3) reacting the modified polymer with the first drug or its derivative so that the first drug is linked to the polymer; (4) modifying the polymer-drug conjugate so that it contains a different functional group that can react with a functional group of a second drug or its derivative (5) reacting the modified polymer-drug conjugate with the second drug or its derivative so that the second drug is linked to the polymer-drug conjugate; (6) reacting the modified polymer-drug conjugate containing 2 different drugs so that the polymer with the PBRM or its derivative to form the conjugate of this invention. Step (6) may be repeated if 2 different PBRM or its derivatives are to be conjugated to form a polymer-drug conjugate comprising two different drugs and two different PBRMs. Step (4) may be carried out after step (1) so that the modified polymer contains two different functional groups that can react with two different drugs or their derivatives. In this
embodiment, the modified polymer containing two different functional group that can react with two different drugs or their derivatives can be further modified so that it contains a functional group that can react with a functional group of the PBRM or its derivative; prior to the reaction of the modified polymer with either the two different drugs (step (3) and step (5) or PBRM (step (6).
[00359] The biodegradable biocompatible conjugates of the invention can be prepared to meet desired requirements of biodegradability and hydrophilicity. For example, under physiological conditions, a balance between biodegradability and stability can be reached. For instance, it is known that molecules with molecular weights beyond a certain threshold (generally, above 40-100 kDa, depending on the physical shape of the molecule) are not excreted through kidneys, as small molecules are, and can be cleared from the body only through uptake by cells and degradation in intracellular compartments, most notably lysosomes. This observation exemplifies how functionally stable yet biodegradable materials may be designed by modulating their stability under general physiological conditions (pH=7.5±0.5) and at lysosomal pH (pH near 5). For example, hydrolysis of acetal and ketal groups is known to be catalyzed by acids, therefore polyals will be in general less stable in acidic lysosomal environment than, for example, in blood plasma. One can design a test to compare polymer degradation profile at, for example, pH=5 and pH=7.5 at 37 °C in aqueous media, and thus to determine the expected balance of polymer stability in normal physiological environment and in the "digestive" lysosomal compartment after uptake by cells. Polymer integrity in such tests can be measured, for example, by size exclusion HPLC. One skilled on the art can select other suitable methods for studying various fragments of the degraded conjugates of this invention.
[00360] In many cases, it will be preferable that at pH=7.5 the effective size of the polymer will not detectably change over 1 to 7 days, and remain within 50% from the original for at least several weeks. At pH=5, on the other hand, the polymer should preferably detectably degrade over 1 to 5 days, and be completely transformed into low molecular weight fragments within a two- week to several-month time frame. Although faster degradation may be in some cases preferable, in general it may be more desirable that the polymer degrades in cells with the rate that does not exceed the rate of metabolization or excretion of polymer fragments by the cells. Accordingly, in certain embodiments, the conjugates of the present invention are expected to be biodegradable, in particular upon uptake by cells, and relatively "inert" in relation to biological systems. The products of carrier degradation are preferably uncharged and do not significantly shift the pH of the environment. It is proposed that the abundance of alcohol groups may provide low rate of polymer recognition by cell receptors, particularly of phagocytes. The polymer backbones of the present invention generally contain few, if any, antigenic determinants (characteristic, for example, for some polysaccharides and polypeptides) and generally do not comprise rigid structures capable of engaging in "key-and-lock" type interactions in vivo unless the latter are desirable. Thus, the soluble, crosslinked and solid conjugates of this invention are predicted to have low toxicity and bioadhesivity, which makes them suitable for several biomedical applications. [00361] In certain embodiments of the present invention, the biodegradable biocompatible conjugates can form linear or branched structures. For example, the biodegradable
biocompatible polyal conjugates of the present invention can be chiral (optically active).
Optionally, the biodegradable biocompatible polyal conjugates of the present invention can be scalemic.
[00362] In certain embodiments, the conjugates of the invention are water-soluble. In certain embodiments, the conjugates of the invention are water-insoluble. In certain
embodiments, the inventive conjugate is in a solid form. In certain embodiments, the conjugates of the invention are colloids. In certain embodiments, the conjugates of the invention are in particle form. In certain embodiments, the conjugates of the invention are in gel form.
[00363] This invention also features a polymeric scaffold useful for conjugating with a PBRM to form a hydroxyl polymer-drug-PBRM conjugate described herein. The scaffold includes a linear, branched or cyclic polymer having one or more -OH groups connected to the (0)u-C(=0)-LDi- -D
polymeric carrier one or more ς connected to the polymer, and one or more
Figure imgf000139_0001
connected to the polymer,
wherein:
the polymer is a hydroxyl polymer having a molecular weight ranging from 2 kDa to 300 kDa and the polymer is not a polyacetal or a polyketal,
each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa;
LDI is a carbonyl-containing moiety;
(0)u-C(=0)-LD^- each occurrence of ς is a first linker that contains a
biodegradable bond so that when the bond is broken, D is released from the polymeric carrier in an active form for its intended therapeutic effect; in which each u independently is an integer 0
- - (0)u-C(=0)-LD-L -D D.
or 1 , and the ς in ς between L and D denotes direct or indirect attachment of D to LD1 ; and — (0)u-C(=0)-L^-LP2
each occurrence of ζ is a second linker not yet connected to
* P2
PBRM m which L is a moiety containing a functional group that is capable of forming a covalent bond with a functional group of a PBRM, each u independently is an integer 0 or 1 , and
Figure imgf000140_0001
denotes direct or indirect attachment of LP2 to LD1.
— (0)u-C(=0)-L^-LP2
[00364] For example, L is a linker having the structure: ς in
* P2
which L is a moiety containing a functional group that is capable of forming a covalent bond with a functional roup of a PBRM and not yet connected to PBRM, and ^ in
Figure imgf000140_0002
denotes direct or indirect attachment of L to L .
[00365] For example, the functional group of LP2 is selected from -SRP, -S-S-LG, maleimido, and halo, in which LG is a leaving group and Rp is H or a sulfur protecting group.
[00366] For example, LD1 comprises— X-(CH2)V-C(=0)— with X directly connected to the carbonyl group of -(0)u-C(=0), in which X is CH2, O, or NH, and v is an integer from 1 to 6.
[00367] For example, L contains a biodegradable bond.
[00368] For example, the polymer of the scaffold of the invention is a linear, branched or cyclic hydroxyl polymer having a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 300 kDa. The selection of a polymeric carrier with a specific MW range may depend on the size of the PBRM to be conjugated with.
[00369] For example, for conjugating a PBRM having a molecular weight of 40 kDa or greater (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 40-200 kDa, 40-180 kDa, 40- 140 kDa, 60-200 kDa, 60-180 kDa, 60-140 kDa, 80-200 kDa, 80-180 kDa, 80- 140 kDa, 100-200 kDa, 100-180 kDa, or 100-140 kDa),the hydroxyl polymer of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 40 kDa (e.g., about 6-20 kDa or about 8-15 kDa).
[00370] For example, for conjugating a PBRM having a molecular weight of 40 kDa to 200 kDa, the hydroxyl polymeric carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 40 kDa (e.g., about 6-20 kDa or about 8-15 kDa). For example, for conjugating a PBRM having a molecular weight of 60 kDa to 120 kDa, the hydroxyl polymer carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 8 kDa to about 40 kDa (e.g., about 8-30 kDa, about 8-20 kDa or about 8-15 kDa). For example the hydroxyl polymeric carrier has a molecular weight of about 10 kDa, 20 kDa, 30 kDa or 40 kDa.
[00371] PBRMs in this molecular weight range, include but are not limited to, for example, camelids, Fab2, scFvSc and the like.
[00372] For example, for conjugating a PBRM having a molecular weight of 140 kDa to 180 kDa, the hydroxyl polymer carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 2 kDa to about 40 kDa (e.g., about 6-20 kDa or about 8-15 kDa). For example the hydroxyl polymeric carrier has a molecular weight of about 8 kDa, 10 kDa or 15 kDa.
[00373] PBRMs in this molecular weight range, include but are not limited to, for example, full length antibodies, such as, IgG, IgM.
[00374] For example, for conjugating a PBRM having a molecular weight of 200 kDa or less (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa), the hydroxyl polymeric carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 20 kDa to about 300 kDa (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30- 100 kDa, or about 50-100 kDa).
[00375] For example, for conjugating a PBRM having a molecular weight of 4 kDa to 80 kDa (e.g., 4-20 kDa, 20-30 kDa, or 30-70 kDa), the hydroxyl polymer carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 20 kDa to about 300 kDa (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30-100 kDa, or about 50-100 kDa).
[00376] For example, for conjugating a PBRM having a molecular weight of 80 kDa or less (e.g., 70 kDa or less, 60 kDa or less, 50 kDa or less or 40 kDa or less), the hydroxyl polymer carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 20 kDa to about 300 kDa (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30-100 kDa, or about 50-100 kDa). For example the hydroxyl polymer carrier has a molecular weight of about 50 kDa, 70 kDa or 100 kDa.
[00377] PBRMs in this molecular weight range, include but are not limited to, for example, antibody fragments such as, for example Fabs.
[00378] For example, for conjugating a PBRM having a molecular weight of 30 kDa or less (e.g., about 20 kDa or less), the hydroxyl polymeric carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 20 kDa to about 300 kDa (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30- 100 kDa, or about 50-100 kDa). For example the hydroxyl polymeric carrier has a molecular weight of about 30 kDa, 40 kDa, 50 kDa, 70 kDa, 100 kDa, 120 kDa or 150 kDa.
[00379] PBRMs in this molecular weight range, include but are not limited to, for example, antibody fragments, such as, scFv.
[00380] For example, for conjugating a PBRM having a molecular weight of 20 kDa or less (e.g., 10 kDa or less), the hydroxyl polymer carrier of the scaffold of the invention has a molecular weight (i.e., MW of the unmodified hydroxyl polymer) ranging from about 20 kDa to about 300 kDa (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30-100 kDa, or about 50-100 kDa). For example the hydroxyl polymer carrier has a molecular weight of about 30 kDa, 40kDa, 50 kDa, 70 kDa, 100 kDa, 120 kDa or 150 kDa.
[00381] PBRMs in this molecular weight range, include but are not limited to, for example, small proteins and peptides.
[00382] For example, the scaffold is of Formula (Ibb):
POLYMER
Figure imgf000142_0001
(Ibb), wherein:
m is an integer from 1 to 2200,
mi is an integer from 1 to 660,
m2 is an integer from 1 to 300,
m3 is an integer from 1 to 110, and
the sum of m, m1} m2 and m3 ranges from 4 to about 2200.
[00383] For example, when the hydroxyl polymeric carrier in Formula (Ibb) has a molecular weight ranging from about 2 kDa to about 40 kDa, the sum of m, mi, m2, and m3 ranges from about 4 to about 300, m2 is an integer from 1 to about 40, m3 is an integer from 1 to about 18, and/or mi is an integer from 1 to about 140 (e.g., mi being about 1-90).
[00384] For example, when the hydroxyl polymeric carrier in Formula (Ibb) has a molecular weight ranging from 20 kDa to 300 kDa, the sum of m, ml5 m2, and m3 ranges from about 4 to about 2200, m2 is an integer from 1 to about 300, m3 is an integer from 1 to about 1 10, and/or mi is an integer from 1 to about 660 (e.g., mi being about 10-250).
[00385] For example, the scaffold further comprises a PBRM connected to the polymeric carrier via Lp.
[00386] For example, when the hydroxyl polymeric carrier has a molecular weight ranging from 20 kDa to 300 kDa, (e.g., about 20-150 kDa, about 30-150 kDa, about 50-150 kDa, about 30-100 kDa, or about 50-100 kDa), the number of drugs per hydroxyl polymeric carrier (e.g., m2) is an integer from about 1 to about 300, (e.g., about 1 to about 150 or about 1 to about 100). This scaffold can be used, for example, for conjugating a PBRM having a molecular weight of 200 kDa or less (e.g., 120 kDa or less, 80 kDa or less, 60 kDa or less, 40 kDa or less, 20 kDa or less or 10 kDa or less, or about 4-80 kDa). In this embodiment the ratio of PBRM per hydroxyl polymeric carrier is between about 1 : 1 and about 60: 1, for example, between about 1 : 1 and about 30: 1 ; between about 1 : 1 and about 20: 1 , between about 1 : 1 and about 10: 1 , between about 1 : 1 and about 9: 1, between about 1 :1 and about 8:1, between about 1 : 1 and about 7: 1, between about 1 : 1 and about 6:1 , between about 1 : 1 and about 5: 1 , between about 1 : 1 and about 4: 1 , between about 1 : 1 and about 3 : 1 , or between about 1 : 1 and about 2: 1. See, for example, Formula (lb).
[00387] For example, the scaffold further comprises a PBRM connected to the polymeric carrier via Lp. For example, one or more PBRMs are connected to one drug-carrying polymeric carrier. [00388] For example, the scaffold (e.g., a PBRM-polymer-drug conjugate) is of Formula
(Ice):
Figure imgf000144_0001
(Ice),
wherein:
Figure imgf000144_0002
in LP2 and PBRM denotes direct or indirect attachment of PBRM to LP2,
each occurrence of PBRM independently has a molecular weight of less than 200 kDa; m is an integer from 1 to 2200,
mi is an integer from 1 to 660,
m2 is an integer from 1 to 300,
m3 is an integer from 0 to 110,
m4 is an integer from 1 to 60; and
the sum of m, ml s m2, m3 and m4 ranges from 4 to 2200.
[00389] For example, in Formula (Ice), mi is an integer from about 10 to about 660 (e.g., about 10-250).
[00390] For example, when the hydroxyl polymeric carrier in Formula (Ice) has a molecular weight ranging from 20 kDa to 300 kDa, the sum of m, mi, m2, m3, and m4 ranges from about 4 to about 2200, m2 is an integer from 3 to about 150, m3 is an integer from 1 to about 75 (e.g., from 1 to about 55), m4 is an integer from 1 to about 300, and/or mi is an integer from 1 to about 660 (e.g., mi being about 10-330 or about 15-100). The PBRM in Formula (Ice), can have, for example, a molecular weight of about 4 kDa to about 70 kDa. [00391] For example, when the hydroxyl polymeric carrier in Formula (Ice) has a molecular weight ranging from 50 kDa to 150 kDa, the number of drugs per hydroxyl polymeric carrier (e.g., m2) is an integer from 1 to about 300). The PBRM in Formula (Ice), can have, for example, a molecular weight of about 4 kDa to about 20 kDa. In this embodiment the ratio of PBRM per hydroxyl polymeric carrier is between about 1 :1 to 10:1 , between about 1 : 1 and about 9: 1 , between about 1 : 1 and about 8:1, between about 1 : 1 and about 7:1 , between about 1 : 1 and about 6: 1, between about 1 : 1 and about 5:1 , between about 1 : 1 and about 4 : 1 , between about 1 : 1 and about 3 : 1 , or between about 1 : 1 and about 2:1.
[00392] PBRMs in this molecular weight range, include but are not limited to, for example, small proteins and peptides.
[00393] For example, when the hydroxyl polymeric carrier in Formula (Ice) has a molecular weight ranging from about 30 kDa to about 100 kDa, the sum of m, mi , m2, m3, and m4 ranges from about 225 to about 740, m2 is an integer from 5 to about 100, m3 is an integer from 1 to about 40, m4 is an integer from 1 to about 20, and/or mi is an integer from 1 to about 220 (e.g., mi being about 15-80).
[00394] For example, when the hydroxyl polymeric carrier has a molecular weight ranging from 30 kDa to 150 kDa, (e.g.,50-100 kDa) , thenumber of drugs per hydroxyl polymeric carrier (e.g., m2) is an integer from about 3 to about 150 (e.g., about 3 to about 100). This scaffold can be used, for example, for conjugating a PBRM having a molecular weight of about 30 kDa to about 70 kDa In this embodiment the ratio of PBRM per hydroxyl polymeric carrier is between about 1 : 1 and about 30: 1 , between about 1 : 1 and about 10:1 , between about 1 : 1 and about 9:1 , between about 1 : 1 and about 8: 1 , between about 1 : 1 and about 7: 1 , between about 1 : 1 and about 6: 1, between about 1 : 1 and about 5:1 , between about 1 : 1 and about 4:1 , between about 1 : 1 and about 3 : 1 , or between about 1 : 1 and about 2:1.
[00395] PBRMs in this molecular weight range, include but are not limited to, for example, antibody fragments such as, for example Fab.
[00396] Alternatively or additionally, one or more drug-carrying polymeric carriers are connected to one PBRM. For example, the scaffold(e.g., a PBRM-polymer-drug conjugate) comprises a PBRM and one or more D-carrying polymeric earners connected to the PBRM, in which each of the D-carrying polymeric carrier independently is of Formula (Idd): POLYMER
Figure imgf000146_0001
Figure imgf000146_0002
wherein:
the PBRM has a molecular weight of greater than 40 kDa (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa);
. — (0)U-C(=0)-L^_LP2_ _
the terminal in attached to L denotes direct or indirect attachment of L to PBRM such that the D-carrying polymeric carrier is connected to the PBRM,
m is an integer from 1 to 300,
mi is an integer from 1 to 140,
m2 is an integer from 1 to 40,
m3 is an integer from 0 to 18,
m4 is an integer from 1 to 10; and
the sum of m, ml 5 m2, m3, and m4 ranges from 4 to 300;
provided that the total number of LP2 attached to the PBRM is 10 or less.
[00397] For example, in Formula (Idd), mi is an integer from 1 to about 120 (e.g., about 1 - 90) and/or m3 is an integer from 1 to about 10 (e.g., about 1 -8).
[00398] For example, when the hydroxyl polymeric earner has a molecular weight ranging from 2 kDa to 40 kDa, (e.g., about 6-20 kDa or about 8-15 kDa) , the number of drugs per hydroxyl polymeric carrier (e.g., m2) is an integer from 1 to about 40, (e.g., about 2-20 or about 2-15). This scaffold can be used, for example, for conjugating a PBRM having a molecular weight of 40 kDa or greater (e.g., 60 kDa or greater, 80 kDa or greater, 100 kDa or greater, 120 kDa or greater, 140 kDa or greater, 160 kDa or greater or 180 kDa or greater, or about 120-200 kDa, or about 140-180 kDa). In this embodiment the ratio of PBRM per hydroxyl polymeric carrier is between about 1 : 1 and about 1 : 10, between about 1 : 1 and about 1 :9, between about 1 : 1 and about 1 :8, between about 1 : 1 and aboutl :7, between about 1 : 1 and about 1 :6, between about 1 : 1 and about 1 :5, between about 1 : 1 and about 1 :4, between about 1 : 1 and about 1 :3, or between about 1 : 1 and about 1 :2.
[00399] For example, when the hydroxyl polymeric carrier has a molecular weight ranging from 2 kDa to 40 kDa, (e.g., about 6-20 kDa or about 8-15 kDa), the number of drugs per hydroxyl polymeric carrier (e.g., m2) is an integer from 1 to about 40, (e.g., about 1 : 10 or about 1 -15). This scaffold can be used, for example, for conjugating a PBRM having a molecular weight of 140 kDa to 180 kDa. In this embodiment the ratio of PBRM per hydroxyl polymeric carrier is between about 1 : 1 and about 1 : 10, between about 1 : 1 and about 1 :9, between about 1 : 1 and about 1 :8, between about 1 : 1 and about 1 :7, between about 1 : 1 and about 1 :6, between about 1 : 1 and about 1 :5, between about 1 : 1 and about 1 :4, between about 1 : 1 and about 1 :3, or between about 1 : 1 and about 1 :2.
[00400] PBRMs in this molecular weight range, include but are not limited to, for example, full length antibodies, such as, IgG, IgM.
[00401] For example, when the hydroxyl polymeric carrier has a molecular weight ranging from 2 kDa to 40 kDa, the number of drugs per hydroxyl polymeric carrier (e.g., m2) is an integer from 1 to about 40, (e.g., about 1 :20 or about 1 : 15). This scaffold can be used, for example, for conjugating a PBRM having a molecular weight of 60 kDa to 120 kDa. In this embodiment the ratio of PBRM per hydroxyl polymeric carrier is between about 1 :1 and about 1 : 10, between about 1 : 1 and about 1 :9, between about 1 : 1 and about 1 :8, between about 1 : 1 and aboutl :7, between about 1 : 1 and about 1 :6, between about 1 : 1 and about 1 :5, between about 1 : 1 and about 1 :4, between about 1 : 1 and about 1 :3, or between about 1 : 1 and about 1 :2.
[00402] PBRMs in this molecular weight range, include but are not limited to, for example, antibody fragments such as, for example Fab2, scFvSc and camelids.
[00403] In some embodiments, the protein-polymer drug conjugate is one of those characterized by Table 1 of Figure 1.
[00404] In some embodiment, the protein-polymer drug conjugate is one of those characterized by Table 2 of Figure 1. [00405] In some embodiments, the protein-polymer drug conjugate includes hydroxyl polymeric scaffold having a MW of up to 60 kDa (e.g., up to 50 kDa) and a drug to hydroxyl polymeric scaffold ratio of up to 50:1 (e.g., about 45: 1 , 40:1, or 35:1).
[00406] In some embodiments, the polymeric scaffold is conjugated with PBRMs by utilizing random lysine modification. In other embodiments, the polymeric scaffold is conjugated with PBRMs by utilizing cysteine-based bioconjugation strategy. See, e.g., WO2010100430 and US 7,595,292, the contents of which are hereby incorporated by reference in their entireties. In one embodiment, the polymeric scaffold conjugates with a PBRM (e.g., an antibody) via cysteines in the antibody hinge region. Without wishing to be bound by the theory, the resulting conjugate is stabilized through the formation of inter-chain bridge structures.
[00407] Accordingly, the invention also relates to a polymeric scaffold comprising at least two -G moieties connected to the polymeric scaffold, in which each -G is capable of conjugation to a thiol group from an amino acid (e.g., cysteine) in a PBRM so as to form a protein-polymer conjugate. In embodiments, -G is a maleimide group, a disulfide group, a thiol group, a triflate group, a tosylate group, an aziridine group, a 5-pydriyl functional group, a vinylsulfone group, a vinyl pyridine group, an alkyl halide group, an acrylate group or a methacrylate group.
[00408] In embodiments, one or more free thiol groups of a PBRM are produced by reducing a protein. The one or more free thiol groups of the PBRM then react with the at least two -G moieties contained in the polymer scaffold so as to conjugate the PBRM with the polymer scaffold.
[00409] In embodiments, the free thiol groups of the PBRM that are used for the conjugation are derived from a disulfide bridge of a native protein or a disulfide bridge of a protein complex consisting of two or more protein chains connected by the disulfide bridge. A disulfide bridge may be intrachain or interchain bridge. Alternatively, the free thiol groups of the PBRM are from cysteines or the unpaired thiol groups of the native protein that are not involved in inter or intra disulfide bridge formation.
[00410] Disulfide bonds can be reduced, for example, with dithiothreitol,
mercaptoethanol, tris-carboxyethylphosphine, dehydroascorbic acid, copper sulfate, using conventional methods. A protein can contain one or more disulfide bridges. Reduction to give free thiol groups can be controlled to reduce one or more specific disulfide bridges in a protein. Depending on the extent of disulfide reduction and the stoichiometry of the -G moieties on the polymeric scaffold polymeric, it is possible to conjugate one or more polymer scaffolds to the protein. Immobilized reducing agents may be used if it is desired to reduce less than the total number of disulfides, as can partial reduction using different reaction conditions or the addition of denaturants.
[00411] Advantages of conjugating a polymer to a protein via a thiol include, but are not limited to optimized efficacy, improved dose to dose consistency and homogeneity (as the number of conjugated polymer molecules per protein is the substantially the same for each protein molecule), specific conjugation directed to a specific residue or residues on each protein, and easier purification. Also, the protein-polymer conjugates via the thiol conjugation exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the unconjugated protein.
[00412] In one embodiment, the scaffold for conjugating to thiol groups in a PBRM is of
Formula (Ilia), which comprises:
Pol mer
Figure imgf000149_0001
-G to the backbone of hydroxyl polymeric carrier, m and m3 are as defined herein. For example, -G is connected to the polymer by a linker -L having the structure:
Figure imgf000149_0002
^ denoting direct or indirect attachment of LD1 to Gx.
[00414] For example, m is an integer from 1 to 2200.
[00415] For example, m3 is an integer from 2 to 20 (e.g., an integer from 2 to 10, or an integer from 2 to 6).
[00416] In another embodiment, the scaffold for conjugating to thiol groups in a PBRM is
Formula (Illb), which comprises:
Figure imgf000150_0001
(Illb).
[00417] The wavy line in Formula (Illb) above denotes direct or indirect attachment of -Gx to the backbone of hydroxyl polymeric carrier. For example, -Gx is connected to the
(0)u-C(=0)-LD-L½- polymeric scaffold by a linker -L having the structure: ^ with u and
LD1 defined as herein and ^ denoting direct or indirect attachment of LD1 to Gx. m, mj, and m3 are as defined herein.
[00418] For example, m is an integer from 1 to 2200.
[00419] For example, m3 is an integer from 2 to 20 (e.g., an integer from 2 to 10, or an integer from 2 to 6).
[00420] For example, mi is an integer from 1 to 660.
[00421] In yet another embodiment, the scaffold for conjugating to thiol groups in a PBRM is of Formula (IIIc), which comprises:
Figure imgf000150_0002
(IIIc).
[00422] The wavy line in Formula (IIIc) above denotes direct or indirect attachment of -G to the backbone of the hydroxyl polymeric carrier. For example, -G is connected to the (0)u-C(=0)-LDi- - polymeric scaffold by a linker -L having the structure: ς with u and
LD 1 defined as herein and ^ denoting direct or indirect attachment of LD1 to G . D, m, ml 5 m2, and m3 are as defined herein.
[00423] For example, m is an integer from 1 to 2200.
[00424] For example, m3 is an integer from 2 to 20 (e.g., an integer from 2 to 10, or an integer from 2 to 6).
[00425] For example, mi is an integer from 1 to 660.
[00426] For example, m2 is an integer from 1 to 300.
[00427] In some embodiments, the drug-polymer-PBRM conjugates, drug-polymer conjugates, drug carrying-polymeric scaffolds, or PBRM-carrying polymer scaffolds described herein each have a polydispersity index (PDI) of less than 1.5.
[00428] PBRM-drug-polymer conjugates, drug carrying-polymeric scaffolds, or PBRM- carrying polymer scaffolds can be purified (i.e., removal of residual unreacted drug, PBRM, or polymeric starting materials) by extensive diafiltration. If necessary, additional purification by size exclusion chromatography can be conducted to remove any aggregated PBRM-drug polymer conjugates. In general, the PBRM-drug polymer conjugates as purified typically contain < 5% aggregated PBRM-drug polymer conjugates as determined by SEC or SDS-PAGE; <1 % polymer-drug conjugate as determined by SEC and <2% unconjugated PBRM as determined by HPLC.
Synthetic Methods
[00429] According to the present invention, any available techniques can be used to make the inventive conjugates or compositions including them, and intermediates and components (e.g., carriers and modifiers) useful for making them.
Drugs and Drug derivatives
[00430] In certain embodiments, the drug may be modified before conjugation to the polymeric carrier. Schemes 1 and 2 are illustrative methods for modifying a Vinca alkaloid. Scheme 3 shows a method for modifying a non-natural camptothecin derivative. Scheme 4 shows a method for modifying auristatin F. More modification methods are described in US 2010/0305149, which is hereby incorporated by reference.
Scheme 1
Figure imgf000152_0001
[00431] Reaction of the C23 ester of a Vinca alkaloid with hydrazine followed by treatment with NaN02 results in an active azido ester. Reaction of the azido ester with an amino compound such as propanolamine or l-aminopropan-2-ol results in a Vinca alkaloid derivative with a functionalized hydroxyl which can be further derivatized with amino containing compounds, such as, for example, alanine or methyl alanine derivatives, for conjugation with polymers (see Scheme 1).
Scheme 2
Figure imgf000153_0001
[00432] Treatment of the hydroxyl derivative of the Vinca alkaloid with a protected amino containing tether such as t-butoxy esterified amino acid followed by TFA hydrolysis of the ester gives the triflate salt of the vinca alkaloid. (Scheme 2) Conjugation of the vinca alkaloid to functionalized polymers results in drug-polymer conjugates that can be further conjugated with a PBPvJVI or its derivative to result in protein-drug polymer conjugates.
[00433
Figure imgf000154_0001
,
SN38, is selectively protected by reacting the derivative with tert-butyldiphenylsilyl chloride (TBDPSiCl) in the presence of triethylamine. The 20-hydroxy group can be by reacted with t- butylcarbonyl-alanine to form the alanine derivative using the procedure described in Sapra, P. et ah, Clin. Cancer Res., 14: 1888-1896 (2008). Alternatively, other amino acids can be employed, e.g., glycine. The primary amine is unmasked by removing the Boc protecting group by treatment with trifluoroacetic acid, followed by removing the TBDPS protecting group with tetrabutylammonium fluoride (see Scheme 3). The resulting amino derivatized SN38 compound can be conjugated with a functionalized polymer to form a drug-polymer conjugate. Scheme 4
Figure imgf000155_0001
[00434] Treatment of auristatin F with a protected amino containing tether such as t- butoxy esterified 2-hydroxypropyl amine followed by HC1 hydrolysis of the ester gives the 2- hydroxylpropyl amino derivative of auristatin F (see Scheme 4). Conjugation of the auristatin F derivative to functionalized polymers results in drug-polymer conjugates that can be further conjugated with a PBRM or its derivative to result in protein- polymer-drug conjugates.
[00435] This invention also relates to a drug derivative so modified that it can be directly conjugated to a PBRM absent a polymeric carrier, and the drug-PBRM conjugates thereof. For example, the drug derivative is a com ound of Formula (XXII), wherein R47 comprises a
terminal maleimido group, i.e.,
Figure imgf000155_0002
(see, e.g., Example 31). Conjugates or Polymeric Scaffolds
[00436] The general methods of producing the conjugates or polymeric scaffolds of this invention have been described above. Schemes 5-10 below exemplify how the conjugates or polymeric scaffolds are synthesized. The variables (e.g., X, XD, Xp, LD1, and LP2 etc.) in these schemes have the same definitions as described herein unless otherwise specified. Each W is a function moiety that is capable of reacting with WD to form ZD-MD3 and each WP1 is a function moiety that is capable of reacting with Wp to form ZP-MP3. -XD-MDI-YD-MD2-WD and -XP-MP1- YP-MP2"WP may be different (such as in Schemes 5 and 5A) or the same (such as in Scheme 6). In some embodiments -XP-MP1-YP-MP2"WP is formed by further modification of -XD-MD1-YD- MD2-WD
Scheme 5
Figure imgf000156_0001
Scheme 5A
Figure imgf000157_0001
Figure imgf000157_0002
Scheme 6
Figure imgf000158_0001
[00437] The PBRM can be linked to the drug-polymer conjugate to form the protein-drug polymer conjugate using standard synthetic methods for protein conjugation, including, but not limited to, reactions based on reductive amination, Staudinger ligation, oxime formation, thiazolidine formation and the methods and reactions described herein.
[00438] Scheme 7 below shows the synthesis of a PBRM-drug-polymer conjugate in which the PBRM is linked to the drug polymer conjugate using click chemistry. Scheme 7
Figure imgf000159_0001
[00439] Scheme 8 below shows the synthesis of a PBRM-drug-polymer conjugate is which the PBRM is linked to the drug polymer conjugate by a Mannich reaction. Scheme 8
Figure imgf000160_0001
Figure imgf000160_0002
[00440] Scheme 9 below shows the synthesis of a PBRM-drug-polymer conjugate is which the PBRM is linked to the drug polymer conjugate by palladium catalyzed cross coupling. Scheme 9
Figure imgf000161_0001
[00441] In Schemes 7-9 above, the wavy bond indicates that PBRM is either connected to the functional modifier directly or via another moiety such as alkyl, cycloalkyl, aryl, etc.
[00442] Scheme 10 below shows a general synthetic scheme of making the polymeric scaffolds of the invention. The wavy bond ^ indicates direct or indirect connection between LD1 and D or LP2. The conjugates are formed in several steps: (1 ) the polymer, PHF is modified to contain a-(0)u-CO-LD ! moiety; (2) the polymer is then further modified so that it contains a Lp2 moiety that is capable of forming a covalent bond with a functional group of a PBRM; (3) the modified polymer, containing two different functional groups, is reacted with a functional group of a drug or its derivative (e.g., -D) to form a polymer-drug conjugate; (4) the PBRM is then reacted with the polymer-drug conjugate to form the protein-polymer-drug conjugate as depicted in the right side route in Scheme 10 below. In another embodiment the order of steps (2) and (3) can be reversed as depicted in the left side route in Scheme 10 below
[00443] The PBRM can be linked to the drug-polymer conjugate to form the protein-drug polymer conjugate using standard synthetic methods for protein conjugation, including, but not limited to, reactions based on reductive amination, Staudinger ligation, oxime formation, thiazolidine formation and the methods and reactions described herein.
Scheme 10
Figure imgf000162_0001
add PBRM
Figure imgf000163_0001
[00444] In yet another embodiment, steps (2) and (3) above are carried out simultaneously as depicted in Scheme 11 below.
Scheme 11
Polymer Polymer
OH
Figure imgf000164_0001
Polymer
Figure imgf000164_0002
add PBRM
Figure imgf000164_0003
Pharmaceutical Compositions
[00445] Also included are pharmaceutical compositions comprising one or more protein- polymer-drug conjugates as disclosed herein in an acceptable carrier, such as a stabilizer, buffer, and the like. The conjugates can be administered and introduced into a subject by standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral administration including intravenous, intra-arterial, subcutaneous, intraperitoneal or intramuscular injection or infusion or intracranial, e.g., intrathecal or intraventricular, administration. The conjugates can be formulated and used as sterile solutions and/or suspensions for injectable administration; lyophilized powders for reconstitution prior to injection/infusion; topical compositions; as tablets, capsules, or elixirs for oral administration; or suppositories for rectal administration, and the other compositions known in the art.
[00446] A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or subject, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, inhaled, transdermal, or by injection/infusion. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the drug is desirable for delivery). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect.
[00447] By "systemic administration" is meant in vivo systemic absorption or
accumulation of the modified polymer in the blood stream followed by distribution throughout the entire body. Administration routes that lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary, and intramuscular. Each of these administration routes exposes the modified polymers to an accessible diseased tissue. The rate of entry of an active agent into the circulation has been shown to be a function of molecular weight or size. The use of a conjugate of this invention can localize the drug delivery in certain cells, such as cancer cells via the specificity of PBRMs. [00448] A "pharmaceutically acceptable formulation" means a composition or formulation that allows for the effective distribution of the conjugates in the physical location most suitable for their desired activity. In one embodiment, effective delivery occurs before clearance by the reticuloendothelial system or the production of off-target binding which can result in reduced efficacy or toxicity. Non-limiting examples of agents suitable for formulation with the conjugates include: P-glycoprotein inhibitors (such as Pluronic P85), which can enhance entry of active agents into the CNS; biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation; and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver active agents across the blood brain barrier and can alter neuronal uptake mechanisms.
[00449] Also included herein are pharmaceutical compositions prepared for storage or administration, which include a pharmaceutically effective amount of the desired conjugates in a pharmaceutically acceptable carrier or diluent. Acceptable carriers, diluents, and/or excipients for therapeutic use are well known in the pharmaceutical art. For example, buffers,
preservatives, bulking agents, dispersants, stabilizers, dyes, can be provided. In addition, antioxidants and suspending agents can be used Examples of suitable carriers, diluents and/or excipients include, but are not limited to: (1) Dulbecco's phosphate buffered saline, pH about 6.5, which would contain about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose.
[00450] The term "pharmaceutically effective amount", as used herein, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Pharmaceutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician. In a preferred aspect, the disease or condition to can be treated via gene silencing.
[00451] For any conjugate, the pharmaceutically effective amount can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD5o (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD5o/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.
[00452] For example, a drug or its derivatives, drug-polymer conjugates or PBRM-drug- polymer conjugates can be evaluated for their ability to inhibit tumor growth in several cell lines using Cell titer Glo. Dose response curves can be generated using SoftMax Pro software and IC5o values can be determined from four-parameter curve fitting. Cell lines employed can include those which are the targets of the PBRM and a control cell line that is not the target of the PBRM contained in the test conjugates.
[00453] In one embodiment, the conjugates are formulated for parenteral administration by injection including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The conjugates can be administered parenterally in a sterile medium. The conjugate, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives, and buffering agents can be dissolved in the vehicle. The term "parenteral" as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous),
intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising conjugates and a pharmaceutically acceptable carrier. One or more of the conjugates can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients.
[00454] The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, a bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
[00455] The conjugates and compositions described herein may be administered in appropriate form, preferably parenterally, more preferably intravenously. For parenteral administration, the conjugates or compositions can be aqueous or nonaqueous sterile solutions, suspensions or emulsions. Propylene glycol, vegetable oils and injectable organic esters, such as ethyl oleate, can be used as the solvent or vehicle. The compositions can also contain adjuvants, emulsifiers or dispersants.
[00456] Dosage levels of the order of from between about 0.01 mg and about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (between about 0.05 mg and about 7 g per subject per day). In some embodiments, the dosage administered to a patient is between about 0.01 mg/kg to about 100 mg/kg of the subject's body weight. In some embodiments, the dosage administered to a patient is between about 0.01 mg/kg to about 15 mg/kg of the subject's body weight. In some embodiments, the dosage administered to a patient is between about 0.1 mg/kg and about 15 mg/kg of the subject's body weight. In some embodiments, the dosage administered to a patient is between about 0.1 mg/kg and about 20 mg/kg of the subject's body weight. In some embodiments, the dosage administered is between about 0.1 mg/kg to about 5 mg/kg or about 0.1 mg/kg to about 10 mg/kg of the subject's body weight. In some embodiments, the dosage administered is between about 1 mg/kg to about 15 mg/kg of the subject's body weight. In some embodiments, the dosage administered is between about 1 mg/kg to about 10 mg/kg of the subject's body weight. The amount of conjugate that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms can generally contain from between about 0.01 mg and about 100 mg; between about 0.01 mg and about 75 mg; or between about 0.01 mg and about 50 mg; or between about 0.01 mg and about 25 mg; of a conjugate.
[00457] For intravenous administration, the dosage levels can comprise from about 0.01 to about 200 mg of a conjugate per kg of the animal's body weight. In one aspect, the composition can include from about 1 to about 100 mg of a conjugate per kg of the animal's body weight. In another aspect, the amount administered will be in the range from about 0.1 to about 25 mg/kg of body weight of a compound.
[00458] In some embodiments, the conjugates can be administered are as follows. The conjugates can be given daily for about 5 days either as an i.v., bolus each day for about 5 days, or as a continuous infusion for about 5 days.
[00459] Alternatively, the conjugates can be administered once a week for six weeks or longer. As another alternative, the conjugates can be administered once every two or three weeks. Bolus doses are given in about 50 to about 400 ml of normal saline to which about 5 to about 10 ml of human serum albumin can be added. Continuous infusions are given in about 250 to about 500 ml of normal saline, to which about 25 to about 50 ml of human serum albumin can be added, per 24 hour period.
[00460] In some embodiments about one to about four weeks after treatment, the patient can receive a second course of treatment. Specific clinical protocols with regard to route of administration, excipients, diluents, dosages, and times can be determined by the skilled artisan as the clinical situation warrants.
[00461] It is understood that the specific dose level for a particular subject depends upon a variety of factors including the activity of the specific conjugate, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, combination with other active agents, and the severity of the particular disease undergoing therapy.
[00462] For administration to no n- human animals, the conjugates can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and drinking water so that the animal takes in a therapeutically appropriate quantity of the conjugates along with its diet. It can also be convenient to present the conjugates as a premix for addition to the feed or drinking water.
[00463] The conjugates can also be administered to a subject in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects. In some embodiment the conjugates are used in combination with chemotherapeutic agents, such as those disclosed in U.S. Patent No. 7,303,749. In other embodiments the chemotherapeutic agents, include, but are not limited to letrozole, oxaliplatin, docetaxel, 5-FU, lapatinib, capecitabine, leucovorin, erlotinib, pertuzumab, bevacizumab, and gemcitabine.
[00464] The present invention also provides pharmaceutical kits comprising one or more containers filled with one or more of the conjugates and/or compositions of the present invention, including, one or more chemotherapeutic agents. Such kits can also include, for example, other compounds and/or compositions, a device(s) for administering the compounds and/or compositions, and written instructions in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products.
Methods of use
Methods of Treating
[00465] In certain preferred embodiments of the invention, the protein-polymer-drug conjugate of the invention are used in methods of treating animals (preferably mammals, most preferably humans and includes males, females, infants, children and adults). In one
embodiment, the conjugates of the present invention may be used in a method of treating animals which comprises administering to the animal a biodegradable biocompatible conjugate of the invention. For example, conjugates in accordance with the invention can be administered in the form of soluble linear polymers, copolymers, conjugates, colloids, particles, gels, solid items, fibers, films, etc. Biodegradable biocompatible conjugates of this invention can be used as drug carriers and drug carrier components, in systems of controlled drug release, preparations for low- invasive surgical procedures, etc. Pharmaceutical formulations can be injectable, implantable, etc.
[00466] In yet another aspect, the invention provides a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject an efficient amount of at least one conjugate of the invention; wherein said conjugate releases one or more therapeutic agents upon biodegradation.
[00467] In another embodiment the conjugates can be administered in vitro, in vivo and/or ex vivo to treat patients and/or to modulate the growth of selected cell populations including, for example, cancer. In some embodiments, the particular types of cancers that can be treated with the conjugates include, but are not limited to: (1) solid tumors, including but not limited to fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma , endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophogeal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas,
cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer , small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma, multiforme astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma; (2) blood-borne cancers, including but not limited to acute lymphoblastic leukemia "ALL", acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia "AML", acute promyelocytic leukemia "APL", acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia , acute
myelomonocytic leukemia, acute nonlymphocyctic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia "CML", chronic lymphocytic leukemia "CLL", hairy cell leukemia, multiple myeloma, acute and chronic leukemias, e.g., lymphoblastic myelogenous and lymphocytic myelocytic leukemias; and (3) lymphomas such as Hodgkin's disease, non- Hodgkin's Lymphoma, Multiple myeloma, Waldenstrom's macroglobulinemia, Heavy chain disease, and Polycythemia vera.
[00468] In another embodiment the conjugates can be administered in vitro, in vivo and/or ex vivo to treat autoimmune diseases, such as systemic lupus, rheumatoid arthritis, psoriasis, and multiple sclerosis; graft rejections, such as renal transplant rejection, liver transplant rejection, lung transplant rejection, cardiac transplant rejection, and bone marrow transplant rejection; graft versus host disease; viral infections, such as CMV infection, HIV infection, and AIDS; and parasite infections, such as giardiasis, amoebiasis, schistosomiasis, and the like.
[00469] In certain embodiments the conjugates can also be used for the manufacture of a medicament useful for treating or lessening the severity of disorders, such as, characterized by abnormal growth of cells (e.g., cancer). [00470] In certain embodiments, the therapeutic agent is locally delivered to a specific target cell, tissue, or organ.
[00471] In certain embodiments, in practicing the method of the invention, the conjugate further comprises or is associated with a diagnostic label. In certain exemplary embodiments, the diagnostic label is selected from the group consisting of: radiopharmaceutical or radioactive isotopes for gamma scintigraphy and PET, contrast agent for Magnetic Resonance Imaging (MRI), contrast agent for computed tomography, contrast agent for X-ray imaging method, agent for ultrasound diagnostic method, agent for neutron activation, moiety which can reflect, scatter or affect X-rays, ultrasounds, radiowaves and microwaves and fluorophores. In certain exemplary embodiments, the conjugate is further monitored in vivo.
[00472] Examples of diagnostic labels include, but are not limited to, diagnostic radiopharmaceutical or radioactive isotopes for gamma scintigraphy and PET, contrast agent for Magnetic Resonance Imaging (MRI) (for example paramagnetic atoms and superparamagnetic nanocrystals), contrast agent for computed tomography, contrast agent for X-ray imaging method, agent for ultrasound diagnostic method, agent for neutron activation, and moiety which can reflect, scatter or affect X-rays, ultrasounds, radiowaves and microwaves, fluorophores in various optical procedures, etc. Diagnostic radiopharmaceuticals include γ-emitting
radionuclides, e.g. , indium- 1 1 1 , technetium-99m and iodine- 131, etc. Contrast agents for MRI (Magnetic Resonance Imaging) include magnetic compounds, e.g., paramagnetic ions, iron, manganese, gadolinium, lanthanides, organic paramagnetic moieties and superparamagnetic, ferromagnetic and antiferromagnetic compounds, e.g., iron oxide colloids, ferrite colloids, etc. Contrast agents for computed tomography and other X-ray based imaging methods include compounds absorbing X-rays, e.g., iodine, barium, etc. Contrast agents for ultrasound based methods include compounds which can absorb, reflect and scatter ultrasound waves, e.g., emulsions, crystals, gas bubbles, etc. Still other examples include substances useful for neutron activation, such as boron and gadolinium. Further, labels can be employed which can reflect, refract, scatter, or otherwise affect X-rays, ultrasound, radiowaves, microwaves and other rays useful in diagnostic procedures. Fluorescent labels can be used for photoimaging. In certain embodiments a modifier comprises a paramagnetic ion or group. [00473] In another aspect, the invention provides a method of treating a disease or disorder in a subject, comprising preparing an aqueous formulation of at least one conjugate of the invention and parenterally injecting said formulation in the subject.
[00474] In another aspect, the invention provides a method of treating a disease or disorder in a subject, comprising preparing an implant comprising at least one conjugate of the invention, and implanting said implant into the subject. In certain exemplary embodiments, the implant is a biodegradable gel matrix.
[00475] In another aspect, the invention provides a method for treating of an animal in need thereof, comprising administering a conjugate according to the methods described above.
[00476] In another aspect, the invention provides a method for eliciting an immune response in an animal, comprising administering a conjugate as in the methods described above.
[00477] In another aspect, the invention provides a method of diagnosing a disease in an animal, comprising steps of:
administering a conjugate as in the methods described above, wherein said conjugate comprises a detectable molecule; and
detecting the detectable molecule.
[00478] In certain exemplary embodiments, the step of detecting the detectable molecule is performed non-invasively. In certain exemplary embodiments, the step of detecting the detectable molecule is performed using suitable imaging equipment.
[00479] In one embodiment, a method for treating an animal comprises administering to the animal a biodegradable biocompatible conjugate of the invention as a packing for a surgical wound from which a tumor or growth has been removed. The biodegradable biocompatible conjugate packing will replace the tumor site during recovery and degrade and dissipate as the wound heals.
[00480] In certain embodiments, the conjugate is associated with a diagnostic label for in vivo monitoring.
[00481] The conjugates described above can be used for therapeutic, preventative, and analytical (diagnostic) treatment of animals. The conjugates are intended, generally, for parenteral administration, but in some cases may be administered by other routes.
[00482] In one embodiment, soluble or colloidal conjugates are administered
intravenously. In another embodiment, soluble or colloidal conjugates are administered via local (e.g., subcutaneous, intramuscular) injection. In another embodiment, solid conjugates (e.g., particles, implants, drug delivery systems) are administered via implantation or injection.
[00483] In another embodiment, conjugates comprising a detectable label are administered to study the patterns and dynamics of label distribution in animal body.
[00484] In certain embodiments, any one or more of the conjugates disclosed herein may be used in practicing any of the methods described above. In certain exemplary embodiments, the conjugate is a Trastuzumab-hydroxyl polymer-, Rituximab-hydroxyl polymer-, lintuzumab- hydroxyl polymer-, anti-5T4-hydroxyl polymer-, anti-mesothelin-hydroxyl polymer- or LHRH- hydroxyl polymer-drug conjugate.
[00485] Throughout the description, where compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously.
[00486] The synthetic processes of the invention can tolerate a wide variety of functional groups; therefore various substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester or prodrug thereof.
[00487] Drug compounds used for the conjugates of the present invention can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, J., March 's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition, John Wiley & Sons: New York, 2001 ; and Greene, T.W., Wuts, P.G. M., Protective Groups in Organic Synthesis, 3r edition, John Wiley & Sons: New York, 1999, incorporated by reference herein, are useful and recognized reference textbooks of organic synthesis known to those in the art. The following descriptions of synthetic methods are designed to illustrate, but not to limit, general procedures for the preparation of compounds of the present invention.
[00488] Conjugates of the present invention and the drug compounds included therein can be conveniently prepared by a variety of methods familiar to those skilled in the art. The conjugates or compounds of this invention with each of the formulae described herein may be prepared according to the following procedures from commercially available starting materials or starting materials which can be prepared using literature procedures. These procedures show the preparation of representative conjugates of this invention.
[00489] Conjugates designed, selected and/or optimized by methods described above, once produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the conjugates have biological activity. For example, the conjugates can be characterized by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.
[00490] Furthermore, high-throughput screening can be used to speed up analysis using such assays. As a result, it can be possible to rapidly screen the conjugate molecules described herein for activity, using techniques known in the art. General methodologies for performing high-throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No. 5,763,263. High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.
[00491] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an admission that any is pertinent prior art, nor does it constitute any admission as to the contents or date of the same. The invention having now been described by way of written description, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description and examples below are for purposes of illustration and not limitation of the claims that follow. EXAMPLES
Conjugates described herein can be prepared by the schemes generally outlined above and by methods described in the Examples below. The term "content" as used in certain examples below, unless otherwise specified, means the molar fraction of the polymer units that are substituted with the intended moiety, such as the linker, the drug molecule, or PBRM.
ABBREVIATIONS
[00492] The following abbreviations are used in the reaction schemes and synthetic examples, which follow. This list is not meant to be an all-inclusive list of abbreviations used in the application as additional standard abbreviations, which are readily understood by those skilled in the art of organic synthesis, can also be used in the synthetic schemes and examples.
Adoa 8-amino-3,6-dioxa-octanoic acid
AF HPA Auristatin F-hydroxypropylamide
AZD 8330 2-[(2-fluoro-4-iodophenyl)amino]-l ,6-dihydro-N-(2-hydroxyethoxy)-l ,5- dimethyl-6-oxo-3-pyridinecarboxamide
BOC tert-Butyloxycarbonyl
DIC N,N'-Diisopropylcarbodiimide
DIEA N,N-Diisopropylethylamine
DCM Dichloromethane
DMA Dimethylacetamide
DMAP 4-Dimethylaminopyridine
DMF Dimethylformamide
DMSO Dimethylsulfoxide
EDC l -Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
HATU 2-( 1 H-7- Azabenzotriazol- 1 -yl)- 1 , 1 ,3 ,3-tetramethyluronoium
hexafluorophosphate
HOBt Hydroxybenzotriazole
HPLC High pressure liquid chromatography
HPV Hydroxypropylvindesine
2HPV 2- Hydroxypropylvindesine
MCC (N-maleimidomethyl) 1 ,4-cyclohexyl carbamate M-(PEG),2 N-maleimido-PEG 12-propionamide
NHS 1 -Hydroxypyrrolidine-2,5-dione
NMP N-methyl-2-pyrrolidone
PABA p-Amino benzoic acid
PBS Phosphate buffered saline, 0.9 % NaCl
PHF poly(l-hydroxymethylethylene hydroxylmethylformal), or FLEXIMER®
PI- 103 3-[4-(4-morpholinyl)pyrido[3^2^4,5]furo[3,2-d]pyrimidin-2-yl]-phenol
PNP p-Nitrophenoxide
HPLC reverse-phase high performance liquid chromatography
SATA N- Succinimidy 1- S - acety lthioacetate
SEC Size exclusion chromatography
SMCC Succinimidyl-4-(/Y-maleimidomethyl)cyclohexane- 1 -carboxylate
TCEP Tris[2-carboxy ethyl] phosphine
TEA Triethylamine
TFA Trifluoroacetic acid
GENERAL INFORMATION
[00493] Peptides EC-l-Adoa-NH2 and LTVSPNY-Adoa-NH2 were purchased from CreoSalus, Louisville, Kentucky.
[00494] Linkers M-(PEG)12-NHS and S-Acetyl-(PEG)]2-NHS ester were purchased from Quanta Biodesign, Powell, Ohio.
[00495] Fmoc-Val-Cit-PABA-PNP, and auristatin F were purchased from Concortis Biosystems.
[00496] N-Boc-D-valine was purchased from Alfa Aesar.
[00497] Ispinesib was purchased from Shanghai Race Chemical Co.
[00498] AZD8330 and PI-103 kinase were purchased from Selleck.
[00499] HPLC purification was performed on a Phenomenex Gemini 5 μηι 1 10 A, 250 x
10 mm, 5 micron, semi-preparation column using the following solvent system: Solvent A: water
(0.1% TFA); Solvent B: CH3CN (0.1 % TFA).
[00500] Whenever possible the drug content of the conjugates was determined
spectro photometrically otherwise LC/MS was performed for quantitative determination of the drug content. For spectrophotometric determination HPV and 2 HPV were monitored at 310 nm; SN38 at 370 nm; ispinesib at 318 nm; PI- 103 at 330 nm and duocarmycin derivatives at 353 nm.
[00501] Protein content of the conjugates was determined spectrophotometrically at 280 nm.
[00502] The molecular weights of the polymer conjugates were determined by SEC with either polysaccharide or protein molecular weight standards. More specifically, for the polymer or polymer drug conjugates, polysaccharide molecular weights standard are used, and for protein-drug polymer conjugates, protein standards are used. Unless specifically indicated the reported polymer carrier molecular weight is the weight average molecular weight of hydroxyl polymer. The polymer and polymer conjugates synthesized/measured all had a polydispersity <2.
[00503] PBRM-drug polymer conjugates were isolated from residual unreacted drug polymer conjugates by extensive diafiltration. If necessary, additional purification by size exclusion chromatography was conducted to remove any aggregated PBRM-drug polymer conjugates. In general the PBRM-drug polymer conjugates typically contained < 5% aggregated PBRM-drug polymer conjugates as determined by SEC or SDS-PAGE; <1% free (unconjugated) drug as determined by SEC and <2% unconjugated PBRM as determined by HPLC.
[00504] Reduced or partially reduced antibodies were prepared using procedures described in the literature, see, for example, Francisco et al., Blood 102 (4): 1458-1465 (2003).
Example 1. Synthesis of Trastuzumab-MCC Derivative
Figure imgf000178_0001
[00505] Trastuzumab (10 mg) was dissolved in PBS buffer (1 ml, pH 7.0), then a solution of SMCC in DMSO (5 iL, 30 mg/ml) was added. The resulting solution was stirred at room temperature for 2 h. The trastuzumab-MCC was purified by gel filtration using a PBS equilibrated PD-10 column (90% yield). Analysis showed that on average 5 to 6 MCC groups were linked to one trastuzumab. [00506] Other PBRM-MCC derivatives, such as, MCC derivatives of cetuximab, rituximab, bevacizumab, nimotuzumab, gemtuzumab, alemtuzumab, lintuzumab, anti-5T4 or anti-mesothelin antibodies are synthesized with methods similar to the procedure described above.
Example 2. Synthesis of Trastuzumab-M-(PEG)i2 Derivative
Figure imgf000179_0001
[00507] Trastuzumab (10 mg) was dissolved in PBS buffer (1 ml, pH 7.0), then a solution of SM-(PEG)i2 in DMSO (4 μϋ, 100 mg/ml) was added. The resulting solution was stirred at room temperature for 2 h. Trastuzumab-M-(PEG)]2was purified by gel filtration using a PBS equilibrated PD-10 column (-90% yield). Analysis showed that on average 5 to 6 polyethylene groups were linked to one trastuzumab.
[00508] Other PBRM- M-(PEG)12 derivatives, such as, M-(PEG)I2 derivatives of cetuximab, rituximab, bevacizumab, nimotuzumab, gemtuzumab, alemtuzumab, lintuzumab, anti-5T4 or anti-mesothelin antibodies are synthesized with methods similar to the procedure described above.
Example 3. -PEG]2-SH
Figure imgf000179_0002
[00509] LHRH (10 mg) was dissolved in a mixture of acetonitrile: water (1 : 1 , 500 μί) and to it was added PEGi2-SATA stock solution (9.2 μί, 0.0025 mmol, 1.9 mg). The resulting mixture was stirred for 3 h at ambient temperature. The product was purified by RP-HPLC followed by lyophilization (60% yield).
[00510] Purified LHRH-PEG12-SH (2 mg) was dissolved in water (400 μί), pH was adjusted to 1 1.8 with TEA, and the mixture was stir for 40 min under argon and used in the next step.
Example 4. Synthesis of EC-l -Adoa-M-(PEG)i2
Figure imgf000180_0001
[00511] To a mixture of EC-l -Adoa-NH2 ( 10 mg, 4 15 μπιοΐ) in CH3CN/H20/DMSO (750 μί, 7:7: 1) was added M-(PEG)! 2-NHS (63 4.1 mg, 4.7 μιηοΐ) stock solution (0.064 mg/mL) in CH3CN. The pH was adjusted to 7.4 and then DMSO (50 μί) and NMP (50 μΓ) were added to make the mixture more homogenous. The mixture was stirred under argon overnight, protected from light. An additional aliquot (13 μί, 1 mg) of freshly prepared M-(PEG)i2-NHS stock (0.077 mg/mL) was added and the resulting mixture was stirred for 30 min. The crude product was purified by HPLC (Gradient: 10% solvent B to 90% solvent B over 25 min). The title compound eluted at 16 min. and was concentrated to give 2 mg of a colorless solid. ESI- MS calc for Ci46H209N2705oS2 801.1 (M + 4H+), found 802.1.
Ex mple 5. Synthesis of LTVSPNY- Adoa- PEG]2-Thioester
Figure imgf000181_0001
[00512] To a solution of LTVSPNY-Adoa-NH2 (10 mg, 10.7 μιηοΐ) in a mixture of CH3CN/H20 (500 μί, 1 : 1) was added (46 μΐ,, 20.8 μιηοΐ, 16.1 mg) of a freshly prepared stock solution of S-Acetyl-PEG12-NHS (350 mg/mL) in DMSO. The pH was adjusted to 6.5-7.0 and the reaction mixture stirred overnight. The pH was then adjusted to 7.5-8.0 and the reaction mixture was stirred for ~2 h. The crude product was purified by HPLC (Gradient: 10% solvent B to 70%) solvent B over 25 min) to afford, after concentration, 9 mg of the title compound as a colorless solid (51 % yield). ESI-MS calc for C78Hi26N9Na028S 845.9, found 845.9 (M + H+ + Na+).
Example 6. Synthesis of (S)-2HPV
Figure imgf000182_0001
(S)
[00513] Vinblastine desacetyl hydrazide (400 mg, 0.520 mmol, prepared as described in J. Med. Chem., 21 , 88-96, 1978) in MeOH (5 niL) was combined with IN HC1 (15 mL) at 0 °C, then sodium nitrite (93 mg, 1.353 mmol) was added in one portion. The reaction mixture was stirred for 12 min followed by pH adjustment to 7.6 at 0 °C with saturated NaHC03. The reaction mixture was extracted with DCM (3 X 50 ml) . The combined DCM fractions were washed with brine, dried over MgS04 and filtered through a pad of MgS04. The volume was reduced to 10 ml and 5 ml was used for coupling with (S)-l-aminopropan-2-ol.
[00514] (S)-l-aminopropan-2-ol (205 μΐ, 2.6 mmol) in anhydrous DCM (2 mL) was added drop wise to a cold stirred solution of vinblastine desacetyl diazide (prepared as described above) under argon. The reaction mixture was stirred at 0 °C for several hours and then brought to room temperature. LC/MS showed conversion to the title compound. The crude reaction mixture was applied directly to a CombiFlash column (40 g column) for purification
[00515] The CombiFlash column was conditioned with ethyl acetate (1% TEA).
Following sample injection the initial conditions were continued for 2 min followed by a gradient from 10% MeOH (1% TEA) to ethyl acetate (1% TEA) over 10 minutes and then held. The title compound eluted at ~ 12 minutes. The eluant was concentrated to obtain 96 mg (46% yield). m/z(+) 812.4.
Example 7. Synthesis of (R)-2H
Figure imgf000183_0001
[00516] The title compound was prepared as described in Example 6 except (R)-l - aminopropan-2-ol (205 μΐ, 2.6 mmol) was used instead of (S)-l -aminopropan-2-ol to give 97 mg (46% yield)
Example 8. Synthesis of (PI-103)-4-(2-aminoethyl)piperazine-l -carboxylate dihydrochloride
Figure imgf000183_0002
[00517] To a mixture of PI-103 (50 mg, 0.144 mmol) and TEA (60 iL, 0.431 mmol) in dry DMF (2.5 mL) was added 4-nitrophenyl chloroformate (35 mg, 0.172 mmol) and the resulting mixture was stirred at room temperature. After 45 min 2-piperazin- l -yl-ethyl-carbamic acid t-butyl ester (56 mg, 0.244 mmol) was added and the reaction mixture was then stirred overnight at room temperature followed by the removal of the solvent under high vacuum. The residue was dissolved in DCM (50 mL) and then washed successively with water (15 mL) and brine (15 mL). The organic phase was dried over Na2S04 and concentrated under vacuum. Crude product was purified on silica gel (4 g CombiFlash column, MeOH: DCM (0 % MeOH 1 -2 min followed by a gradient to 7 % MeOH over 15 min) to give the BOC-protected carbamate as a colorless film. ESI-MS calc for C31H38N706 604.3 (M + H+), found 604.3. [00518] To the purified BOC-protected carbamate was added DCM (5 mL) and 4 M HC1 in dioxane (5 mL). The mixture was stirred for 1 h at room temperature and then concentrated under vacuum. The deprotected PI- 103 product was dissolved in water and then lyophilized to afford the title compound as a pale yellow solid (69 mg, 83 % overall yield). ESI-MS calc for C26H30N7O4 504.2 (M + H+), found 504.2.
Example 9. Synthesis of PI-103)-4-aminobutylcarbamate hydrochloride
Figure imgf000184_0001
[00519] The title compound was prepared as described in Example 8 except the synthesis was conducted on a smaller scale with PI-103 (25 mg) and BOC-l,4-diaminobutane (23 mg, 0.122 mmol) was used instead of 2-piperazin-l-yl-ethyl-carbamic acid t-butyl ester to give the title compound (13 mg, 36 % overall yield). ESI-MS calc for C24H27N604 463.2 (M + H+), found 463.2.
Example 10. Synthesis of (PI-103)-4-aminobutylcarbonate hydrochloride
Figure imgf000184_0002
[00520] To an ice-cold solution of triphosgene (13.6 mg, 0.046 mmol) in dry THF (0.5 mL) was added a solution of r-butyl 4-hydroxybutylcarbamate (24.2 mg, 0.128 mmol) and TEA (18.1 μί, 0.13 mmol) in dry THF (1 mL) under argon. After stirring for 1 h at 0 °C, the crude chloroformate was slowly added to a solution of PI-103 (25 mg, 0.072 mmol) and TEA (15.1 \L, 0.108 mmol) in NMP (0.5 mL). After several minutes THF was removed under vacuum and NMP (0.5 mL) was added to make the mixture more homogenous. The resulting mixture was stirred overnight at room temperature. Additional chloroformate (from 45 mg BOC-alcohol, prepared as described above) and TEA (15 μί) were added and the reaction mixture was stirred for 40 min at which point LC/MS indicated 95% conversion to the desired product. The reaction mixture was diluted with DCM (150 mL) and then washed with water (2 x 50 mL) and brine (50 mL). The organic phase was dried over Na2S04 and concentrated under vacuum. The crude product was purified on silica gel (4 g CombiFlash column, EtOAc:Hex, 0% EtOAc 1 min, then gradient to 80% EtOAc over 16 min) to give 26 mg of a colorless film. Yield 64%. ESI-MS calc for C29H34N507 564.3 (M + H+), found 564.1.
[00521] The BOC-protected carbonate was dissolved in DCM (2 mL) and then treated with 4 M HC1 in dioxane (4 mL). The resulting mixture was stirred for 3.5 h and then
concentrated under vacuum. The deprotected carbonate was lyophilized from water:CH3CN to afford the title compound as a pale yellow solid (21.9 mg, 96% yield). ESI-MS calc for
C24H26N505 464.2 (M + H+), found 464.1.
Example 1 1. Synthesis of (PI-103)-(S)-2-amino-3-methylbutanoate hydrochloride
Figure imgf000185_0001
[00522] To a solution of PI- 103 (25 mg, 0.072 mmol) in NMP (-750 μΐ was added a mixture of HATU (32.7 mg, 0.086 mmol), DIEA (30.2 μΐ, 0.173 mmol), and BOC-Val-OH (0.086 mmol, 18.7 mmol) in NMP. The resulting mixture was stirred, protected from light, for 3 days at room temperature. A solution of BOC-Val-OH (15.6 mg, 0.072 mmol), HATU (27.4 mg, 0.072 mmol), and DIEA (25.1 \xL, 0.144 mmol) in NMP (200 \xl was then added. The reaction mixture was stirred for ~18 h at 50 °C and then DMAP (0.072 mmol, 8.8 mg) was added. The mixture was stirred for an additional 1.5 h at 50 °C followed by quenching the reaction with dilute acid. The reaction mixture was diluted with DCM and then washed with water (2 x 50 mL) and brine (50 raL). The BOC-protected valine ester was purified on silica gel (4 g
Combiflash column, EtOAc:Hex, 0% EtOAc hold for 1 min then a gradient to 50% EtOAc over 16 min).
[00523] The BOC-protected valine ester was dissolved in DCM (5 mL) and then treated with 4 M HC1 in dioxane (5 mL). The mixture was stirred for 6 h at room temperature and then concentrated to dryness under vacuum. The deprotected valine ester was lyophilized from water:CH3CN to afford the title compound as a pale yellow solid (13.6 mg, overall yield 39%). ESI-MS calc for C24H26N504 448.2 (M + H+), found 448.2.
Example 12. Synthesis of (AZD 8330)-(S)-2-aminopropanoate hydrochloride
Figure imgf000186_0001
[00524] To a solution of BOC-Ala-OH (61.5 mg, 0.325 mmol) in dry THF (1.5 mL) was added DIC (20.5 mg, 0.163 mmol). The resulting mixture was cooled to 0 °C under argon and stirred for 10-15 min. A mixture of AZD 8330 (50 mg, 0.108 mmol) and DMAP (1.3 mg, 0.0108 mmol) in dry THF (1.5 mL) was added and the reaction mixture was stirred for 1.5 h at room temperature protected from light. The reaction mixture was diluted with EtOAc and then washed with saturated NH4C1 followed by brine. The organic phase was dried over Na2S04 then concentrated under vacuum. The crude material was purified on silica gel (Combiflash column, acetone: DCM, 0% acetone hold for 1-2 min then gradient to 20% acetone) to afford 37 mg of a colorless solid. The solid was dissolved in DCM (5 mL) and then treated with 4 M HC1 in dioxane (10 mL). The mixture was stirred, protected from light, at room temperature for approximately 5 h. Solvent was removed under vacuum and the residue was lyophilized to afford the title compound as a pale orange solid (22.4 mg, 39% overall yield). Example 13. Synthesis of l-Aminopropan-2-yl-Auristatin F trifluoroacetate
Figure imgf000187_0001
[00525] To Auristatin F (150.0 mg, 0.201 mmol) and HOBt (32.6 mg, 0.241 mmol) in 5 mL dichloromethane was added diisopropylcarbodiimide (68.5 μΐ,, 0.442 mmol). The mixture was stirred at 0 °C for 10 minutes at which point a precipitate was observed. tert-Butyl-2- hydroxypropylcarbamate (881.0 mg, 5.03 mmol) in 2 mL dichloromethane was added. The reaction mixture was stirred at 45 °C in a sealed vial and the progress of the reaction monitored via LCMS. Additional HOBt (30.0 mg, 0.222 mmol) was added at 2.5 and 6 hours and the mixture stirred for 18 hours. Additional HOBt (54.3 mg, 0.402 mmol) and
diisopropylcarbodiimide (43.1 mg, 0.342 mmol) were added and the mixture stirred at 45 °C for an additional 9 hours at which time LCMS analysis showed complete disappearance of the starting material. The solvent was removed under reduced pressure and the residue dissolved in 3 mL DMF. The sample was purified via preparatory HPLC; (10-90 solvent B gradient over 10 minutes, eluting with 0.1%TFA/ Water, 0.1%TFA/CH3CN). The water was removed via lyophilization to give the title compound as a white solid.
[00526] l-(Tert-butoxycarbonylamino)propan-2-yl-auristatin F (150 mg, 0.166 mmol) was taken up in dichloromethane (5 mL) and 2,2,2-trifluoroacetic acid (0.256 mL, 3.32 mmol) was added. The mixture was stirred at 23 °C for 30 minutes at which time LC/MS indicated complete conversion. The solvent was reduced to 1 mL under reduced pressure. Dropwise addition of the solution to stirring diethyl ether gave the title compound (27.5 mg, 0.027 mmol. 16%) as a white solid which was collected via filtration. Example 14. Synthesis of RD-S 1 -BOC-amine
Figure imgf000188_0001
[00527] RD-S1 (48.5 mg, 0.055 mmol, prepared according to procedures described in WO
2008/138561) was taken up in CH2C12 (1 mL) and the solution cooled to 0 °C. EDC (0.127 mL, 0.82 mmol) and N,N-dimethylpyridin-4-amine (33.4 mg, 0.273 mmol) were added. The reaction mixture was stirred at 0 °C for 20 min and then t-butyl 2-hydroxypropylcarbamate (0.094 mL, 0.546 mmol) was added. The reaction mixture was allowed to warm to room temperature and stirred for 24 h. The sample was purified by preparative HPLC, eluting with 0.1 % TFA/CH3CN and 0.1% TF A/water, followed by lyophilization to give the title compound (20.3 mg, 40 % yield) as a beige solid.
Example 15. Synthesis of RD-S 1 -amine
Figure imgf000188_0002
[00528] RD-S 1 -BOC-Amine (20.3 mg, 0.022 mmol, prepared as described in Example 14) was taken up in CH2C12 (0.500 mL) and cooled to 0 UC. 2,2,2-Trifluoroacetic acid (200 μί, 2.61 mmol) was added dropwise, then stirred at room temperature for 30 min. The solvent was removed under reduced pressure. The resulting oil was taken up in CH2C12 followed by the addition of ether to give the title compound as a beige solid (18.1 mg, 100 % yield). Example 16. Synthesis of XMT-A2
Figure imgf000189_0001
X T-A2
[00529] To a solution of XMT-A1 (5.03 mg, 6.74 μπιοΐ) in DMF (33 μΐ at 0 °C under argon was added TEA (1.88 μΐ,, 0.013 mmol). The mixture was stirred for 5 min and then (2- (pyridine-2-yldisulfanyl)ethyl hydrazinecarboxylate (2.48 mg, 10.1 μπιοΐ) in DMF (20 μί) and HATU (3.85 mg, 10.1 μπιοΐ) were added. The reaction mixture was allowed to warm to room temperature, stirred for 2.5 h, diluted with a mixture of water (750 μί) and CH3CN (1 mL) and then purified by preparative HPLC eluting with 0.1 % TFA/CH3CN and 0.1 % TFA/water, followed by lyophilized to give the title compound (8.64 mg, 65.2 % yield) as a white solid.
Figure imgf000190_0001
[00530] XMT-A2 (11.9 mg, 0.012 mmol, prepared as described in Example 16) was dissolved in DMF (0.3 mL) and 11-aminoundecane-l-thiol hydrochloride (29.5 mg, 0.123 mmol) in DMF (0.3 mL) was added at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 2 days, diluted with water (2 mL) and purified by preparative HPLC, followed by lyophilization to give the title compound (6.02 mg, 46 % yield) as a white solid.
Example 18. Synthesis of Auristatin F-hydroxypropylamide (AF HP A)
Figure imgf000190_0002
[00531] Auristatin F (150 mg, 0.201 mmol), HATU (153.0 mg, 0.402 mmol), and diisopropylethylamine (108 Τ, 0.603 mmol) were taken up in DMF (5 mL) and 3-aminopropan- l-ol (45.9 μί, 0.603 mmol) was added. The mixture was stirred at 23 °C for 45 minutes at which time LCMS analysis showed complete disappearance of the starting material. Reduction of the volume to 1.4 mL under high vacuum followed by purification via preparative HPLC (10-90 solvent B gradient over 20 minutes eluting with 0.1%TFA/Water, 0.1%TFA/CH3CN) afforded the title compound as white solid (109 mg, 68 % yield). Example 19. Synth -Boc-L- Alanine
Figure imgf000191_0001
[00532] BOC-L-alanine (117.0 mg, 0.618 mmol) and DMAP (94.0 mg, 0.772 mmol) were taken up in dichloromethane and then diisopropylcarbodiimide (52.6 μί-, 0.340 mmol) was added. The reaction mixture was cooled to 0 °C and stirred for 10 minutes after which AF HPA (124 mg, 0.154 mmol, prepared as described in Example 18) was added. The reaction mixture was warmed to 23 °C and stirred for 18 hours. Purification via preparative HPLC followed by removal of the water via lyophilization afforded the title compound as beige solid (1 12 mg, 75 % yield).
Example 20. Synth -L-Alanine
Figure imgf000191_0002
[00533] AF HP A-Boc-L- Alanine (112 mg, 0.1 15 mmol, prepared as described in Example 19) was taken up in dichloromethane (3 mL) and excess trifluoroacetic acid was added. The mixture was stirred at 23 °C for 1 hour and the solvent removed under high vacuum. The resulting oil was taken up in dichloromethane (1.5 mL) and precipitation from diethyl ether (30 mL to give the title compound as white solid (96.2 mg, 85%). Example 21. Synthesis of Rituximab-MCC Derivative
Figure imgf000192_0001
[00534] The title compound was prepared as described in Example 1 except Rituximab was used instead of trastuzumab. Analysis showed that on average 5 to 6 MCC groups were linked to one Rituximab.
[00535] Other PBRM-MCC derivatives, such as, MCC derivatives of cetuximab, bevacizumab, nimotuzumab, gemtuzumab, alemtuzumab, lintuzumab, anti-5T4 or anti- mesothelin antibodies are synthesized with methods similar to the procedure described above
Example 22. Synthesis of Trastuzumab-Fab'
[00536] Trastuzumab-F(ab')2 was prepared from immobilized pepsin (15 mL settled gel) and trastuzumab (440 mg, 2.4 μπιοΐ) according to the manufacturer's (Pierce) instructions to give the title compound (265.2 mg, 92 % yield).
[00537] By substituting trastuzumab with other PBRMs, such as, for example, cetuximab, rituximab, bevacizumab, nimotuzumab, gemtuzumab, alemtuzumab, lintuzumab, anti-5T4 or anti-mesothelin antibodies in the procedure described above it is possible to synthesize other PBRM F(ab)'2 fragments.
[00538] To trastuzumab-F(ab')2 (3.44 mL, 0.325 μιτιοΐ of 10.4 mg/mL stock, prepared as described above) in PBS, pH 7.4 was added an aliquot (138 μί, 0.467 mg) of freshly prepared TCEP stock (3.38 mg/mL in Et3NHOAc buffer). The mixture was incubated 1 h at 37 °C. The reaction mixture was cooled to room temperature and then purified on a PD10 column which was preequilibrated with Et3NHOAc buffer to give trastuzumab-Fab', MW (SDS PAGE), about 50 to 55 kDa
Example 23. Synth -Hydroxypropylamide-Auristatin F
Figure imgf000192_0002
[00539] To an ice cold solution of auristatin F (50 mg, 0.067 mmol) in DMF (4 ml) was added HATU (51.0 mg, 0.134 mmol) and the resulting mixture was stirred cold for 20 mins. To this was added (S)-l-aminopropan-2-oI (10.07 mg, 0.134 mmol) followed by DIEA (0.035 ml, 0.201 mmol) and the mixture was stirred cold for 1 h and then overnight at room temperature. Purification via preparative HPLC followed by lyophilization gave the title compound as a white amorphous solid as the TFA salt (47 mg, 76% yield) M/z = 803.4.
Example 24. Synth -Hydroxypropylamide-Auristatin F
Figure imgf000193_0001
[00540] The title compound was prepared as described in Example 23 except (R)-l- aminopropan-2-ol (10.07 mg, 0.134 mmol) was used instead of (S)-l-aminopropan-2-ol. (49 mg, 80% yield) M/z = 803.4.
Example 25. Synthesis o -A4 proline ester
Figure imgf000193_0002
[00541] To an ice cold solution of (S)- 1 -(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid (2.79 mg, 0.013 mmol) in DMF (250 μΐ,) was added DIC (2.018 μΐ,, 0.013 mmol) and the resulting mixture was stirred for 15 mins and then added to a solution of XMT-A4 (5 mg, 6.48 μιηοΐ) and DMAP (2.374 mg, 0.019 mmol) in DMF (250 μΐ,). The reaction mixture was stirred cold and then at room temperature. After 4 h another aliquot of (S)-l-(tert-butoxycarbonyl) pyrrolidine-2-carboxylic acid (2.79 mg, 0.013 mmol), DIC (2.018 iL, 0.013 mmol) in 100 xL of DMF was added and the stirring was continued overnight at room temperature. The crude product was purified by HPLC followed by lyophilized to give the Boc-protected XMT-A4 as a white amorphous solid (4.4 mg, 63% yield). M/z = 969.4. [00542] To an ice cold solution of the Boc-protected XMT-A4 compound with 2,2,2- trifluoroacetic acid (1 : 1) (4.4 mg, 4.06 μπιοΐ) in DCM (300 μί was added TFA (31.3 μΐ, 0.406 mmol) and the resulting mixture was stirred cold for 1 h followed by stirring at room temperature for 1 h. The reaction mixture was concentrated, dissolved in acetonitrile and lyophilized to a give the title compound as a white solid (2.3 mg, 58% yield). M/z = 869.4.
Example 26. Synthesis of Auristatin F hydro xypropyl amide (AF HPA)
Figure imgf000194_0001
[00543] To a solution of auristatin F (100 mg, 0.134 mmol) in DCM (5 ml) cooled in an ice/salt bath was added DIC (0.052 ml, 0.335 mmol), tert-butyl 3-hydroxypropylcarbamate (1 17 mg, 0.670 mmol) and DMAP (82 mg, 0.670 mmol) and the resulting mixture was stirred cold for 2 h and then overnight at room temperature. The reaction mixture was purified by HPLC followed by lyophilized to give the tert-butyl carbamate protected title compound as a white amorphous solid (121 mg, 89% yield) M/z = 903.5.
[00544] To an ice cold solution of the tert-butyl carbamate protected title compound 2,2,2- trifluoroacetate (121 mg, 0.119 mmol) in DCM (4 ml) was added TFA (500 μΐ, 6.49 mmol) and the resulting mixture was stirred cold for 1 h and then at room temperature for 1 h. After removal of the excess TFA, the title compound was isolated by precipitation into ethyl ether as a white amorphous solid (109 mg, 93% yield); M/z = 803.4.
Example 27. Synthesis of XMT-A4 diaminobutyl carbamate
Figure imgf000195_0001
[00545] XMT-A4 ( 1 14 mg, 0.129 mmol), HOBt (39.4 mg, 0.257 mmol) and DMF (5 ml) were combined at room temperature with stirring. After 15 min phenylmethanol (69.6 mg, 0.643 mmol) and DMAP (47.2 mg, 0.386 mmol) were added. After 10 min DIC (0.030 ml, 0.193 mmol) was added. After 16 h at room temperature the crude reaction mixture was purified to give XMT-A4 benzyl ester as a white amorphous solid (60 mg, 47.8% yield). M/z = 862.5.
[00546] To a solution of XMT-A4 benzyl ester (23 mg, 0.024 mmol) in THF (4 ml) at room temperature was added HOBt (7.22 mg, 0.047 mmol), 4-nitrophenyl carbonochloridate (9.50 mg, 0.047 mmol), and triethylamine (0.033 ml, 0.236 mmol). The reaction was monitored by LC/MS or HPLC for the appearance of the p-nitrophenyl carbonate XMT-A4 intermediate. A second aliquot of HOBt (7.22 mg, 0.047 mmol), 4-nitrophenyl carbonochloridate (9.50 mg, 0.047 mmol) and triethylamine (0.033 ml, 0.236 mmol) was added. After 45 min, to the reaction mixture was added tert-butyl 4-aminobutylcarbamate (22.18 mg, 0.118 mmol) and triethylamine (0.033 ml, 0.236 mmol). After -30 minutes, the reaction mixture was purified to give XMT-A4 Boc-amino butylcarbamate benzyl ester as a white amorphous solid (17.5 mg, 62,4% yield). M/z = 1076.4. [00547] To an argon bubbled solution of XMT-A4 Boc-di amino butylcarbamate benzyl ester (17.5 mg, 0.015 mmol) in THF (2 niL) and ethanol (2.000 ml) was added palladium on carbon (1.564 mg, 0.015 mmol) followed by attachment of a balloon to the flask to deliver hydrogen (0.030 mg, 0.015 mmol). The reaction mixture was stirred vigorously until LC/MS or HPLC indicated that the reaction was complete. The crude reaction mixture was purified to give XMT-A4 Boc-amino butylcarbamate as a white amorphous solid (6.5 mg, 40.2% yield). M/z = 986.5
[00548] To an ice cold solution of XMT-A4 Boc-diamino butylcarbamate (6.5 mg, 5.91 μπιοΓ) in DCM (1 mL) was added TFA (0.455 μΐ, 5.91 μν οΐ) and the reaction mixture stirred cold for 1 h and then at room temperature for 1 h. After LC/MS or HPLC indicated that the reaction was complete the reaction mixture was concentrated and the residue taken up in acetonitrile and water with 0.1% TFA and then lyophilized to give the title compound as a white amorphous solid (5.2 mg, 88% yield) M/z = 886.3.
Example 28. Synthesis of XMT-A4 Valine ester
Figure imgf000196_0001
[00549] To an ice cold solution of N-Boc-D- valine (17.3 mg, 0.080 mmol) in DMF (500 μ ) was added DIC (1 1.28 μL, 0.072 mmol) and the resulting solution was stirred cold for 15 min, then it was added to a solution of XMT-A4 (30 mg, 0.034 mmol) and DMAP (13.27 mg, 0.109 mmol) in DMF (500 μΐ,). The resulting mixture was stirred cold for 15 min and then overnight at room temperature. The crude reaction mixture was purified to give XMT-A4 N- Boc-D-valine ester as a white amorphous solid (20 mg, 50% yield). M/z = 971.4. [00550] To an ice cold solution of XMT-A4 N-Boc-D-valine ester (20 mg, 0.018 mmol) and 2,2,2-trifluoroacetic acid (1 :1) In DCM (3 mL) was added TFA (0.284 ml, 3.69 mmol). The resulting mixture stirred cold for 1 h then at room temperature for 1 h, followed by purification to give the title compound (1 1 mg, 60% yield). M/z = 871.4.
Figure imgf000197_0001
[00551] Fmoc-Val-Cit-PABA-PNP (20.93 mg, 0.027 mmol), XMT-A4 dimethyl-diamino ethyl carbamate (22.75 mg, 0.023 mmol, prepared as described in Example 27 except tert-butyl methyl(2-methylamino)ethylcarbamate was used instead of tert-butyl 4-methylamino)butyl carbamate), m/z 886.4), 2,2,2-trifluoroacetic acid (1 :1) and HOBt (3.83 mg, 0.025 mmol) in DMF (2 mL) were stirred at room temperature under argon. To the reaction mixture was added triethylamine (0.016 ml, 0.1 14 mmol). After 16 h the crude reaction mixture was purified to give the title compound as to a white amorphous solid (17.5 mg, 54% yield). M/z = 1291.7. -A4-dimethyldiamino ethyl-PABA-Val Cit-Maleimide
Figure imgf000197_0002
[00552] XMT-A4 Dimethyl-diaminoethyl-PABA-Val Cit-NH2 ( 1 1.2 mg, 9.05 μηιοΐ, prepared as described in Example 29), 2,5-dioxopyrrolidin-l-yl 6-(2,5-dioxo-2,5-dihydro-lH- pyrrol-l-yl)hexanoate (5.58 mg, 0.018 mmol) and HOBt (2.77 mg, 0.018 mmol) in DMF (1 mL) were stirred at room temperature, followed by the addition of triethylamine (0.013 ml, 0.091 mmol). After 4 h the reaction mixture was purified to give the title compound as a white amorphous solid (6 mg, 46% yield). M/z = 1316.7.
Example 31. Synthesis of XMT-A4-dimethyldiamino ethyl-PABA-Val Cit-Maleimido-(S- Trastuzumab
Figure imgf000198_0001
[00553] To reduced trastuzumab (5 mg, prepared using the procedure described in Example 22) in triethylamine acetate buffer (1 mL, 50 mM, containing 1 mM EDTA, pH=7.0) was added XMT-A4-dimethyldiamino ethyl-PABA-Val Cit-Maleimide. After 18 h at room temperature the resulting conjugate was isolated and purified by diafitration (30% yield). The XMT-A4 to Trastuzumab ratio obtained was about 9:1 to about 13:1.
[00554] By substituting reduced rituximab in the procedure described above, XMT-A4- dimethyldiamino ethyl-PABA-Val Cit-Maleimido-S-rituximab was synthesized. The XMT-A4 to Rituximab ratio was about 6: 1 to about 1 1 : 1. [00555] Other protein-drug- conjugates are synthesized with methods similar to the procedure described above, involving other PBRM derivatives, such as, for example, reduced form of cetuximab, rituximab, bevacizumab, nimotuzumab, gemtuzumab, alemtuzumab, lintuzumab, anti-5T4 or anti-mesothelin antibodies as described in Example 6 above. Also PBRM-drug conjugates with varying ratios of drug to PBRM are obtained by varying the amount of PBRM and drug used in the Examples above.
Example 32. Synthesis of Ispinesib-PABA-Val-Cit-NH2
Figure imgf000199_0001
[00556] The title compound was prepared using the procedure described in Example 29. to give a white amorphous solid (75.4 mg, 75% yield). M/z = 922.3.
Example 33. Ispinesib-N-(acyloxyisopropyloxy)-Val-NH2
Figure imgf000199_0002
[00557] To an ice-cold solution of Ispinesib (100 mg) in dry THF (3 mL) was added DIEA (37.7 μί) followed by l -chloro-2-methylpropyl chloroformate (30.8 μί,). After the addition was complete, the reaction mixture was stirred at room temperature for 30 min under argon, then extracted with DCM (20 mL) and concentrated to give crude Ispinesib-N- (acyloxyisopropyloxy)-chloride as a racemic mixture. M/z 651.3.
[00558] To a solution of Ispinesib-N-(acyloxyisopropyloxy)-chloride in DMA (5 mL) was added Boc-Val-OCs salt (prepared by reacting Boc-(L)Val-OH (387 mg) with CsHC03) and the resulting mixture was stirred at room temperature. After 1.5 h, tetrabutylammonium iodide (14.3 mg) was added and the reaction mixture was stirred for an additional 3 h at 45 °C then purified to afford the partially pure Ispinesib-N-(acyloxyisopropyloxy)-Val-NH-Boc(160 mg). M/z 832.2.
[00559] To an ice-cold solution of partially pure Ispinesib-N-(acyloxyisopropyloxy)-Val- NH-Boc (160 mg) in DCM (5 mL) was added TFA (5 mL). The mixture was stirred for 2 h at 0 °C and then purified to give the title compound as a colorless solid (18.1 mg, 1 1% overall yield). M/z 732.3.
Example 34. Synthesis of Trastuzumab-Fab
[00560] Trastuzumab-Fab was prepared from immobilized papain (6.5 mL resin) and trastuzumab (192 mg) to give two Fab fragments and an Fc fragments. Purification resulted in Trastuzumab Fab (51.4 mg). MW (SDS PAGE), -45 kDa.
[00561] Other PBRM-Fab fragments, such as, Fab fragments of cetuximab, rituximab, bevacizumab, nimotuzumab, gemtuzumab, alemtuzumab, lintuzumab, anti-5T4 or anti- mesothelin antibodies are synthesized with methods similar to the procedure described above.
Example 35. Synthesis of hydroxyl polymer-drug-PBRM conjugates
[00562] With the drug derivatives and/or PBRMs from Examples 1 -34, hydroxyl polymer- drug-PBRM conjugates are synthesized with methods similar to the procedures described in U.S. Patent Application Nos. 13/493,899, filed June 1 1 , 2012 and 13/710,355, filed December 10, 2012.
Example 36. Cell viability assay for PBRM-drug polymer conjugates
[00563] PBRM-drug polymer conjugates are evaluated for their tumor viability using Cell Titer-Glo (Promega Corp). Cells are plated in black walled 96-well plate and allowed to adhere overnight at 37°C in a humidified atmosphere of 5% C02. HER2 expressing cells SKBR3, BT474, NCI-N87 and cells expressing low levels of HER2-MCF7 are plated at a density of 5,000 cells per well. The next day the medium is replaced with 50 iL fresh medium and 50 μΐ^ of 2x stocks of PBRM-drug polymer conjugate, drug polymer conjugate or drug is added to appropriate wells, mixed and incubated for 72 h. Cell Titer-Glo reagent is added to the wells at room temperature and the luminescent signal is measured after 10 min using a SpectraMax M5 plate reader (Molecular Devices). Dose response curves are generated using SoftMax Pro software. IC5o values are determined from four-parameter curve fitting.
Example 37. In vivo Efficacy, Pharmacokinetic and Biodistribution Studies
[00564] In order to evaluate the efficacy and pharmacokinetics of the protein drug conjugate mouse and rat subcutaneous and orthotopic xenograft models are used.
[00565] Test articles, along with appropriate controls are administered intravenously (IV) via tail- vein injection or intraperitoneally. To assess circulating levels of test article blood sample is collected at designated times via terminal cardiac-puncture. Samples are kept at room temperature for 30 min to coagulate, then centrifuged for 10 min at l ,000x g at 4 °C and immediately frozen at -80 °C. Total PBRM concentrations in serum samples are measured using ELISA. Circulating drug concentration (conjugated and free) is determined by LC/MS methods.
[00566] To assess efficacy of the PBRM-drug polymer conjugates the tumor size are measured using digital calipers. Tumor volume is calculated and used to determine the delay in tumor growth.
[00567] For the determination of drug biodistribution, tumor, and major organs such as, for example, liver, kidney, spleen, lung, heart, muscles, and brain are harvested, immediately frozen in liquid nitrogen, stored at -80 °C. PBRM and/or drug levels are determined in tissue homogenates by standard methods, such as, for example, ELISA or LC/MS /MS methods respectively.
Example 38. Tumor Growth Response to Administration of PBRM-drug polymer conjugates
[00568] Female CB-17 SCID mice are inoculated subcutaneously with NCI-N87 cells (n=10 for each group) or BT474 tumors (n=12 or n=10 for each group). Test compounds or vehicle are dosed IV as a single dose on day 1 ; once every week for 3 weeks on day 1 , day 8 and day 15 respectively; or once every week for 3 weeks on day 17, day 24 and day respectively. The auristatin compound polymer conjugate dose is determined such that it delivered the same amount of drug as that present in the highest dose of the corresponding PBRM-auristatin compound polymer conjugate is administered Tumor size is measured at several different time points using digital calipers. Tumor volume is calculated and is used to determine the delay in
3 3
tumor growth. Mice are sacrificed when tumors reach a size of 1000 mm , 800 mm , or 700 mm . Tumor volumes are reported as the mean ± SEM for each group.
Example 39. In vitro stability of PBRM-drug polymer conjugates
[00569] The in vitro stability of PBRM- drug polymer conjugates are evaluated by incubation of the PBRM- drug polymer conjugate in physiological saline or animal plasma at 37°C, pH 7.4. The rate of PBRM- drug polymer conjugate degradation is determined by monitoring the amount of drug released into the matrix by LC/MS analysis after isolation of released drug from the PBRM- drug polymer conjugate by liquid-liquid extraction.
Example 40. Ligand Binding Studies by BIAcore Surface Plasmon Resonance (SPR)
[00570] The kinetic binding of the PBRM- drug polymer conjugate to an immobilized receptor is determined by BIAcore SPR. The binding constants for the PBRM in the PBRM- drug-conjugate and PBRM alone are determined using standard BIAcore procedures.
Example 41. Mouse Plasma PK and Tissue Distribution after Administration of PBRM- drug polymer conjugates
[00571] The plasma PK stability and the tissue distribution of PBRM- drug-conjugate is determined after administration of PBRM- drug-conjugate in female CB-17 SCID mice with NCI-N87 tumors (n=3). The conjugated drug concentrations are determined by LC/MS analysis. The concentration of the drug-PBRM-conjugate is estimated from the conjugated drug data. Total PBRM concentration is determined by ELISA.
INCORPORATION BY REFERENCE
[00572] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.
EQUIVALENTS
[00573] The invention can be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

Claims

CLAIMS What is claimed is:
1. A polymeric scaffold useful to conjugate with a protein based recognition- molecule (PBRM), the scaffold comprising a linear, branched or cyclic polymer having one or
Dl
(0)u-C(=0)-Lui- -D
more -OH groups connected to the olymer, one or more ζ connected to the polymer, and one or more
Figure imgf000204_0001
connected to the polymer, wherein: the polymer is a hydroxyl polymer having a molecular weight ranging from 2 kDa to 300 kDa and the polymer is not a polyacetal or a polyketal,
each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa;
LDI is a carbonyl-containing moiety;
(0)u-C(=0)-L Dl
each occurrence of in
(0)u-C(=0)-LD-L -D
ζ independently is a first linker that contains a biodegradable bond so that when the bond is broken, D is released in an active form for its intended therapeutic effect; in which each u independently is an integer 0 or 1 , and the ^ in (0)u-C(=0)-LDi- -D
between L and D denotes direct or indirect attachment of D to L ; and each occurrence of
Figure imgf000204_0002
independently is a second linker not yet connected to PBRM, in which LP2 is a moiety containing a functional group that is capable of forming a covalent bond with a functional roup of a PBRM, each u independently is an integer
0 or 1 , and the ς in
Figure imgf000204_0003
denotes direct or indirect attachment of LP2 to LD1, and each occurrence of the second linker is distinct from each occurrence of the first linker.
2. The polymeric scaffold of claim 1 being of Formula (Ibb): Pol mer
OH
Figure imgf000205_0001
(Ibb),
wherein:
m is an integer from 1 to 2200,
mi is an integer from 1 to 660,
m2 is an integer from 1 to 300,
m3 is an integer from 1 to 110, and
the sum of m, mi, m2 and m3 ranges from 4 to about 2200.
3. The scaffold of claim 1, further comprising a PBRM connected to the poly carrier via L .
4. The scaffold of claim 4, being of Formula (Icc):
Figure imgf000205_0002
(Icc), wherei
Figure imgf000206_0001
between LR and PBRM denotes direct or indirect attachment of PBRM to LP2,
each occurrence of PBRM independently has a molecular weight of less than 200 kDa; m is an integer from 1 to 2200,
mi is an integer from 1 to 660,
m2 is an integer from 1 to 300,
m3 is an integer from 0 to 110,
m4 is an integer from 1 to 60; and
the sum of m, mi, m2, m3 and m4 ranges from 4 to 2200.
5. The scaffold of claim 3, wherein the scaffold comprises one or more D-carrying polymeric carriers, each independently having Formula (Idd), connected to the PBRM:
Figure imgf000206_0002
(Idd),
wherein:
the PBRM has a molecular weight of greater than 40 kDa;
Figure imgf000206_0003
the terminal attached to L denotes direct or indirect attachment of L to PBRM such that the D-carrying polymeric carrier is connected to the PBRM,
m is an integer from 1 to 300,
mi is an integer from 1 to 140, ni2 is an integer from 1 to 40,
m3 is an integer from 0 to 18,
m4 is an integer from 1 to 10; and
the sum of m, m1 ; m2, m3, and m4 ranges from 4 to 300;
provided that the total number of Lp2 attached to the PBRM is 10 or less.
6. The scaffold of any one of claims 1-5, wherein LD1 comprises— X-(CH2)V- C(=0)— with X directly connected to the carbonyl group of -(0)U-C(=0), in which X is CH2, O, or NH, and v is an integer from 1 to 6.
7. The scaffold of any one of claims 1-6, wherein u is 0 when the one or more -OH groups are the hydroxyl groups of one or more -COOH of the polymer and u is 1 when the one or more -OH groups are not the hydroxyl groups of one or more -COOH.
8. The scaffold of any one of claims 1-7, wherein the scaffold has a molecular weight ranging from 2 kDa to 40 kDa when the PBRM has a molecular weight of greater than 40 kDa or a molecular weight ranging from 20 kDa to 300 kDa when the PBRM has a molecular weight of less than 200 kDa.
PCT/US2013/074703 2012-12-12 2013-12-12 Hydroxy-polmer-drug-protein conjugates WO2014093640A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13814764.0A EP2931316B1 (en) 2012-12-12 2013-12-12 Hydroxyl-polymer-drug-protein conjugates
US14/651,640 US9872918B2 (en) 2012-12-12 2013-12-12 Hydroxyl-polymer-drug-protein conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736483P 2012-12-12 2012-12-12
US61/736,483 2012-12-12

Publications (1)

Publication Number Publication Date
WO2014093640A1 true WO2014093640A1 (en) 2014-06-19

Family

ID=49885466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/074703 WO2014093640A1 (en) 2012-12-12 2013-12-12 Hydroxy-polmer-drug-protein conjugates

Country Status (3)

Country Link
US (1) US9872918B2 (en)
EP (1) EP2931316B1 (en)
WO (1) WO2014093640A1 (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016094505A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
WO2016094509A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
WO2016096610A1 (en) * 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
WO2016207098A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
WO2016207094A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
WO2016207103A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
WO2016207104A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
WO2016207089A1 (en) * 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
WO2016207090A3 (en) * 2015-06-23 2017-02-16 Bayer Pharma Aktiengesellschaft Targeted conjugates of ksp inhibitors
WO2017095805A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017201204A1 (en) 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017214301A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214233A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214462A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214458A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214282A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214339A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2018075692A2 (en) 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
US10011657B2 (en) 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
US10322192B2 (en) 2016-03-02 2019-06-18 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
WO2019229701A2 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
WO2019234136A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2020232399A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Compositions comprising hdac inhibitors and retinoids
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
WO2021026409A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
WO2021091953A1 (en) 2019-11-05 2021-05-14 Regeneron Pharmaceuticals, Inc. N-terminal scfv multispecific binding molecules
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2021178896A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
US11174318B2 (en) 2016-12-22 2021-11-16 Università Degli Studi Magna Graecia Catanzaro Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US11478554B2 (en) 2016-12-21 2022-10-25 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCS) having enzymatically cleavable groups
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
US11759527B2 (en) 2021-01-20 2023-09-19 Abbvie Inc. Anti-EGFR antibody-drug conjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
AU2014331645C1 (en) * 2013-10-11 2020-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
KR102087850B1 (en) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
US9808528B2 (en) 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
BR112018012524A2 (en) 2015-12-21 2018-12-11 Bristol Myers Squibb Co variant antibodies for site-specific conjugation
US10543285B2 (en) * 2016-04-15 2020-01-28 The Penn State Researh Foundation Compositions and methods for targeted delivery of therapeutic and/or diagnostic agents
AU2023239982A1 (en) * 2022-03-21 2024-09-19 Primelink Biotherapeutics (Shenzhen) Co., Ltd Polymer-drug conjugates

Citations (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4294757A (en) 1979-01-31 1981-10-13 Takeda Chemical Industries, Ltd 20-O-Acylmaytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4322348A (en) 1979-06-05 1982-03-30 Takeda Chemical Industries, Ltd. Maytansinoids
US4331598A (en) 1979-09-19 1982-05-25 Takeda Chemical Industries, Ltd. Maytansinoids
US4362663A (en) 1979-09-21 1982-12-07 Takeda Chemical Industries, Ltd. Maytansinoid compound
US4364866A (en) 1979-09-21 1982-12-21 Takeda Chemical Industries, Ltd. Maytansinoids
US4371533A (en) 1980-10-08 1983-02-01 Takeda Chemical Industries, Ltd. 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof
US4424219A (en) 1981-05-20 1984-01-03 Takeda Chemical Industries, Ltd. 9-Thiomaytansinoids and their pharmaceutical compositions and use
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0354787A1 (en) 1988-08-12 1990-02-14 Fujisawa Pharmaceutical Co., Ltd. Oxaspiro[2,5]octane derivative
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5070092A (en) 1989-07-03 1991-12-03 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives related to dc-88a compound
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5101038A (en) 1988-12-28 1992-03-31 Kyowa Hakko Kogyo Co., Ltd. Novel substance dc 113 and production thereof
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5475092A (en) 1992-03-25 1995-12-12 Immunogen Inc. Cell binding agent conjugates of analogues and derivatives of CC-1065
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5595499A (en) 1993-10-06 1997-01-21 The Whitaker Corporation Coaxial connector having improved locking mechanism
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
WO1997019086A1 (en) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone derivatives, preparation and use
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1998008849A1 (en) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Method for producing epothilones, and intermediate products obtained during the production process
WO1998013375A1 (en) 1996-09-23 1998-04-02 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Compounds with antimycotic and cytostatic effect, preparation method, agent containing these compounds and dsm 11 092
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
WO1998022461A1 (en) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
WO1998025929A1 (en) 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1998038192A1 (en) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones with a modified side chain
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO1999002514A2 (en) 1997-07-08 1999-01-21 Bristol-Myers Squibb Company Epothilone derivatives
WO1999003848A1 (en) 1997-07-16 1999-01-28 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
WO1999007692A2 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
WO1999027890A2 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999028324A1 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
WO1999061432A1 (en) 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6239104B1 (en) 1997-02-25 2001-05-29 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6340701B1 (en) 1999-11-24 2002-01-22 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6548530B1 (en) 1995-10-03 2003-04-15 The Scripps Research Institute CBI analogs of CC-1065 and the duocarmycins
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
US6603812B1 (en) 1998-08-17 2003-08-05 Linear Technology Corporation Hardware implementation of a decimating finite impulse response filter
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6630579B2 (en) 1999-12-29 2003-10-07 Immunogen Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6660742B2 (en) 2000-09-19 2003-12-09 Taiho Pharmaceutical Co. Ltd. Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins
WO2004005269A1 (en) 2002-07-09 2004-01-15 Morphochem Ag Komb Chemie Method for producing substituted thiazol-2-yl methyl esters
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6747021B2 (en) 2000-10-02 2004-06-08 Eli Lilly And Company Cryptophycin compound
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
WO2005023294A2 (en) * 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system
WO2005081711A2 (en) 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6989450B2 (en) 2000-10-13 2006-01-24 The University Of Mississippi Synthesis of epothilones and related analogs
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008138561A1 (en) 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2009012958A2 (en) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
WO2009026177A1 (en) 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
US7553816B2 (en) 2001-09-24 2009-06-30 Seattle Genetics, Inc. p-amidobenzylethers in drug delivery agents
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
US7595292B2 (en) 2003-07-11 2009-09-29 Polytherics Limited Conjugated biological molecules and their preparation
WO2009134279A1 (en) 2007-07-20 2009-11-05 The Regents Of The University Of California Tubulysin d analogues
US20100004784A1 (en) 2006-09-29 2010-01-07 Electronics & Telecommunications Research Institute Apparatus and method for effectively transmitting image through stereo vision processing in intelligent service robot system
US20100048490A1 (en) 2007-03-14 2010-02-25 Iontcho Radoslavov Vlahov Binding ligand linked drug delivery conjugates of tubulysins
WO2010033733A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
WO2010034724A1 (en) 2008-09-25 2010-04-01 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
US7754885B2 (en) 2002-11-21 2010-07-13 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Tubulysins, method for producing the same and tubulysin preparations
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
US20100305149A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal Drug Conjugates Comprising Variable Rate-Releasing Linkers
WO2011017249A1 (en) 2009-08-03 2011-02-10 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20110070248A1 (en) 2009-09-24 2011-03-24 Seattle Genetics, Inc. Dr5 ligand drug conjugates
WO2011057805A1 (en) 2009-11-12 2011-05-19 R&D Biopharmaceuticals Gmbh Tubulin inhibitors
WO2011120053A1 (en) * 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20120321583A1 (en) 2011-06-10 2012-12-20 Mersana Therapeutics, Inc. Protein-Polymer-Drug Conjugates
US20130101546A1 (en) 2011-06-10 2013-04-25 Mersana Therapeutics, Inc. Protein-Polymer-Drug Conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4490369B2 (en) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション Maleamic acid polymer derivatives and biological complexes thereof
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
TW201042257A (en) 2009-05-26 2010-12-01 Baxter Int Detection of antibody that binds to water soluble polymer-modified polypeptides
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
KR102087850B1 (en) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 Protein-Polymer-Drug Conjugates
US9808528B2 (en) 2014-06-18 2017-11-07 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof

Patent Citations (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4361650A (en) 1978-03-24 1982-11-30 Takeda Chemical Industries, Ltd. Fermentation process of preparing demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4294757A (en) 1979-01-31 1981-10-13 Takeda Chemical Industries, Ltd 20-O-Acylmaytansinoids
US4322348A (en) 1979-06-05 1982-03-30 Takeda Chemical Industries, Ltd. Maytansinoids
US4331598A (en) 1979-09-19 1982-05-25 Takeda Chemical Industries, Ltd. Maytansinoids
US4362663A (en) 1979-09-21 1982-12-07 Takeda Chemical Industries, Ltd. Maytansinoid compound
US4364866A (en) 1979-09-21 1982-12-21 Takeda Chemical Industries, Ltd. Maytansinoids
US4371533A (en) 1980-10-08 1983-02-01 Takeda Chemical Industries, Ltd. 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4424219A (en) 1981-05-20 1984-01-03 Takeda Chemical Industries, Ltd. 9-Thiomaytansinoids and their pharmaceutical compositions and use
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5767293A (en) 1988-08-12 1998-06-16 Fujisawa Pharmaceutical Co., Ltd. Oxaspiro 2,5! octane derivative
EP0354787A1 (en) 1988-08-12 1990-02-14 Fujisawa Pharmaceutical Co., Ltd. Oxaspiro[2,5]octane derivative
US5789405A (en) 1988-08-12 1998-08-04 Fujisawa Pharmaceutical Co., Ltd. Oxaspiro(2,5)octane derivative
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5101038A (en) 1988-12-28 1992-03-31 Kyowa Hakko Kogyo Co., Ltd. Novel substance dc 113 and production thereof
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5070092A (en) 1989-07-03 1991-12-03 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives related to dc-88a compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5416064A (en) 1989-10-25 1995-05-16 Immunogen, Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5475092A (en) 1992-03-25 1995-12-12 Immunogen Inc. Cell binding agent conjugates of analogues and derivatives of CC-1065
US5846545A (en) 1992-03-25 1998-12-08 Immunogen, Inc. Targeted delivery of cyclopropylbenzindole-containing cytotoxic drugs
US5585499A (en) 1992-03-25 1996-12-17 Immunogen Inc. Cyclopropylbenzindole-containing cytotoxic drugs
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US6124431A (en) 1993-10-01 2000-09-26 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US5595499A (en) 1993-10-06 1997-01-21 The Whitaker Corporation Coaxial connector having improved locking mechanism
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5665860A (en) 1994-08-01 1997-09-09 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6548530B1 (en) 1995-10-03 2003-04-15 The Scripps Research Institute CBI analogs of CC-1065 and the duocarmycins
WO1997019086A1 (en) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone derivatives, preparation and use
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6043372A (en) 1996-08-30 2000-03-28 Novartis Ag Intermediates in the process for preparing epothilones
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
WO1998008849A1 (en) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Method for producing epothilones, and intermediate products obtained during the production process
WO1998013375A1 (en) 1996-09-23 1998-04-02 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Compounds with antimycotic and cytostatic effect, preparation method, agent containing these compounds and dsm 11 092
WO1998022461A1 (en) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO1998025929A1 (en) 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs
US6239104B1 (en) 1997-02-25 2001-05-29 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
WO1998038192A1 (en) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilones with a modified side chain
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
US6566541B2 (en) 1997-06-09 2003-05-20 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase (MetAP2) inhibitors and uses thereof
WO1999002514A2 (en) 1997-07-08 1999-01-21 Bristol-Myers Squibb Company Epothilone derivatives
WO1999003848A1 (en) 1997-07-16 1999-01-28 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
WO1999007692A2 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
WO1999027890A2 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999028324A1 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
WO1999061432A1 (en) 1998-05-12 1999-12-02 Biochem Pharma Inc. Fumagillin analogs and their use as angiogenesis inhibitors
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
US6603812B1 (en) 1998-08-17 2003-08-05 Linear Technology Corporation Hardware implementation of a decimating finite impulse response filter
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6436931B1 (en) 1999-11-24 2002-08-20 Immunogen Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6372738B2 (en) 1999-11-24 2002-04-16 Immunogen Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6340701B1 (en) 1999-11-24 2002-01-22 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US6630579B2 (en) 1999-12-29 2003-10-07 Immunogen Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
USRE39151E1 (en) 2000-08-18 2006-06-27 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6660742B2 (en) 2000-09-19 2003-12-09 Taiho Pharmaceutical Co. Ltd. Compositions and methods of the use thereof achiral analogues of CC-1065 and the duocarmycins
US6747021B2 (en) 2000-10-02 2004-06-08 Eli Lilly And Company Cryptophycin compound
US6989450B2 (en) 2000-10-13 2006-01-24 The University Of Mississippi Synthesis of epothilones and related analogs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7553816B2 (en) 2001-09-24 2009-06-30 Seattle Genetics, Inc. p-amidobenzylethers in drug delivery agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US7049316B2 (en) 2002-04-05 2006-05-23 Immunogen Inc. Prodrugs of CC-1065 analogs
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6586618B1 (en) 2002-04-05 2003-07-01 Immunogen Inc. CC-1065 analog synthesis
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
WO2004005269A1 (en) 2002-07-09 2004-01-15 Morphochem Ag Komb Chemie Method for producing substituted thiazol-2-yl methyl esters
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
WO2004010957A2 (en) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7754885B2 (en) 2002-11-21 2010-07-13 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Tubulysins, method for producing the same and tubulysin preparations
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7595292B2 (en) 2003-07-11 2009-09-29 Polytherics Limited Conjugated biological molecules and their preparation
WO2005023294A2 (en) * 2003-09-05 2005-03-17 The General Hospital Corporation Polyacetal drug conjugates as release system
WO2005081711A2 (en) 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20100004784A1 (en) 2006-09-29 2010-01-07 Electronics & Telecommunications Research Institute Apparatus and method for effectively transmitting image through stereo vision processing in intelligent service robot system
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20100048490A1 (en) 2007-03-14 2010-02-25 Iontcho Radoslavov Vlahov Binding ligand linked drug delivery conjugates of tubulysins
WO2008138561A1 (en) 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2009134279A1 (en) 2007-07-20 2009-11-05 The Regents Of The University Of California Tubulysin d analogues
US20110021568A1 (en) 2007-07-20 2011-01-27 The Regents Of The University Of California Tubulysin d analogues
WO2009012958A2 (en) 2007-07-20 2009-01-29 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
WO2009026177A1 (en) 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
US20100240701A1 (en) 2007-10-25 2010-09-23 Endocyte, Inc. Tubulysins and processes for preparing
US20110020343A1 (en) 2008-03-18 2011-01-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010033733A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
WO2010034724A1 (en) 2008-09-25 2010-04-01 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
US20100305149A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal Drug Conjugates Comprising Variable Rate-Releasing Linkers
WO2011017249A1 (en) 2009-08-03 2011-02-10 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US20110070248A1 (en) 2009-09-24 2011-03-24 Seattle Genetics, Inc. Dr5 ligand drug conjugates
WO2011057805A1 (en) 2009-11-12 2011-05-19 R&D Biopharmaceuticals Gmbh Tubulin inhibitors
WO2011120053A1 (en) * 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20120321583A1 (en) 2011-06-10 2012-12-20 Mersana Therapeutics, Inc. Protein-Polymer-Drug Conjugates
US20130101546A1 (en) 2011-06-10 2013-04-25 Mersana Therapeutics, Inc. Protein-Polymer-Drug Conjugates

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
AKINORI NOGUCHI ET AL: "PREPARATION AND PROPERTIES OF THE IMMUNOCONJUGATE COMPOSED OF ANTI-HUMAN COLON CANCER MONOCLONAL ANTIBODY AND MITOMYCIN C-DEXTRAN CONJUGATE1", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 3, no. 2, 1 March 1992 (1992-03-01), pages 132 - 137, XP000262170, ISSN: 1043-1802, DOI: 10.1021/BC00014A007 *
AXEL KLEEMANN; JURGEN ENGEL: "Pharmaceutical Substances: Syntheses, Patents, Applications", 1999, THIEME MEDICAL PUBLISHING
BIOORG. MED. CHEM., vol. 11, 2003, pages 5051
BIOORG. MED. CHEM., vol. 14, 2004, pages 91
CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 - 131
DENNY, EXP. OPIN. THER. PATENTS., vol. 10, no. 4, 2000, pages 459 - 474
DEVLIN: "High Throughput Screening", 1998, MARCEL DEKKER
FRANCISCO ET AL., BLOOD, vol. 102, no. 4, 2003, pages 1458 - 1465
GREENE, T.W. AND WUTS, P.G.,: "Protective Groups in Organic Synthesis Third Ed.", 1999, JOHN WILEY & SONS
GREENE, T.W.; WUTS, P.G. M.: "Protective Groups in Organic Synthesis, 3rd edition,", 1999, JOHN WILEY & SONS
J. MED. CHEM., vol. 21, 1978, pages 88 - 96
J. MED. CHEM., vol. 23, 1980, pages 554
J. MED. CHEM., vol. 29, 1986, pages 2358 - 2363
J. MED. CHEM., vol. 30, 1987, pages 1774
J. MED. CHEM., vol. 49, 2006, pages 5645
J. ORG. CHEM., vol. 69, 2004, pages 357
J.ORG. CHEM., vol. 70, 2005, pages 6870
JENSEN K D ET AL: "Cytoplasmic delivery and nuclear targeting of synthetic macromolecules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 87, no. 1-3, 21 February 2003 (2003-02-21), pages 89 - 105, XP004412749, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(02)00352-8 *
KROP ET AL., J. CLIN. ONCOL., vol. 28, 2010, pages 2698 - 2704
LI ET AL., TET LETTS., vol. 50, 2009, pages 2932 - 2935
LIU ET AL., SCIENCE, vol. 282, 1998, pages 1324 - 1327
NATE LARSON ET AL: "Polymeric Conjugates for Drug Delivery", CHEMISTRY OF MATERIALS, vol. 24, no. 5, 13 March 2012 (2012-03-13), pages 840 - 853, XP055103531, ISSN: 0897-4756, DOI: 10.1021/cm2031569 *
RICART, A. D.; TOLCHER, A. W., NATURE CLINICAL PRACTICE, vol. 4, 2007, pages 245 - 255
RIHOVA B ET AL: "Clinical implications of N-(2-hydroxypropyl)methacrylamide copolymers", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, NL, vol. 4, no. 5, 1 October 2003 (2003-10-01), pages 311 - 322, XP008124188, ISSN: 1389-2010, DOI: 10.2174/1389201033489711 *
RODESCHINI ET AL., J ORG. CHEM., vol. 69, 2004, pages 357 - 373
SAPRA, P. ET AL., CLIN. CANCER RES., vol. 14, 2008, pages 1888 - 1896
SMITH, M. B.; MARCH, J.: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition,", 2001, JOHN WILEY & SONS
SUSAN BUDAVARI ET AL.,: "Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", 1996, CRC PRESS
TET. LETT., vol. 40, 1999, pages 4797
ULBRICH K ET AL: "HPMA copolymers with pH-controlled release of doxorubicin - In vitro cytotoxicity and in vivo antitumor activity", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 87, no. 1-3, 21 February 2003 (2003-02-21), pages 33 - 47, XP004412737, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(02)00348-6 *

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
US10308713B2 (en) 2014-10-31 2019-06-04 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
US10011657B2 (en) 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
EP3735990A1 (en) 2014-12-09 2020-11-11 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
WO2016094505A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
WO2016094509A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
WO2016096610A1 (en) * 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
US11123439B2 (en) 2015-06-22 2021-09-21 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups
AU2016282723B2 (en) * 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
WO2016207089A1 (en) * 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN114917361A (en) * 2015-06-22 2022-08-19 拜耳医药股份有限公司 Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups
IL256394A (en) * 2015-06-22 2018-04-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN108025084A (en) * 2015-06-22 2018-05-11 拜耳医药股份有限公司 Antibody drug conjugate with enzyme cleavable moiety（ADC）With antibody prodrug conjugate（APDC）
US10973923B2 (en) 2015-06-23 2021-04-13 Bayer Pharma Aktiengesellschaft Site specific homogeneous with KSP inhibitors
US11806404B2 (en) 2015-06-23 2023-11-07 Bayer Pharma Aktiengesellschaft Site specific homogeneous with KSP inhibitors
JP2018524313A (en) * 2015-06-23 2018-08-30 バイエル ファーマ アクチエンゲゼルシャフト Antibody-drug complex of kinesin spindle protein (KSP) inhibitor with anti-B7H3 antibody
US10744205B2 (en) 2015-06-23 2020-08-18 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies
JP2018524314A (en) * 2015-06-23 2018-08-30 バイエル ファーマ アクチエンゲゼルシャフト Antibody-drug complex of kinesin spindle protein (KSP) inhibitor with anti-B7H3 antibody
WO2016207090A3 (en) * 2015-06-23 2017-02-16 Bayer Pharma Aktiengesellschaft Targeted conjugates of ksp inhibitors
WO2016207104A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
WO2016207103A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
CN107921288A (en) * 2015-06-23 2018-04-17 拜耳医药股份有限公司 The targeting conjugate of KSP inhibitor
US11071788B2 (en) 2015-06-23 2021-07-27 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
WO2016207094A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
CN108025086A (en) * 2015-06-23 2018-05-11 拜耳制药股份公司 Antibody-active agent conjugates (ADC) of KSP inhibitors and anti-B7H 3 antibodies
WO2016207098A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
WO2017095805A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US11045480B2 (en) 2015-11-30 2021-06-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US10188660B2 (en) 2015-11-30 2019-01-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
US10195209B2 (en) 2015-11-30 2019-02-05 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
US11510910B2 (en) 2016-02-23 2022-11-29 Tva (Abc), Llc HSP90 targeted conjugates and particles and formulations thereof
US10322192B2 (en) 2016-03-02 2019-06-18 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US10548986B2 (en) 2016-03-02 2020-02-04 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
EP4233909A2 (en) 2016-05-17 2023-08-30 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use
EP3804765A1 (en) 2016-05-17 2021-04-14 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use
EP3626273A1 (en) 2016-05-17 2020-03-25 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use
WO2017201204A1 (en) 2016-05-17 2017-11-23 Abbvie Biotherapeutics Inc. ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017214282A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214339A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP4364754A2 (en) 2016-06-08 2024-05-08 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214301A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
US10640563B2 (en) 2016-06-08 2020-05-05 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
EP4104865A1 (en) 2016-06-08 2022-12-21 AbbVie Inc. Anti-egfr antibody drug conjugates
WO2017214233A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2017214462A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214458A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3888689A1 (en) 2016-06-08 2021-10-06 AbbVie Inc. Anti-egfr antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
US11643469B2 (en) 2016-06-15 2023-05-09 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
US11001636B2 (en) 2016-06-15 2021-05-11 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
WO2018075692A2 (en) 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
US11660351B2 (en) 2016-12-21 2023-05-30 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
US11478554B2 (en) 2016-12-21 2022-10-25 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCS) having enzymatically cleavable groups
US11965033B2 (en) 2016-12-22 2024-04-23 Università Degli Studi Magna Graecia Catanzaro Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43
US11174318B2 (en) 2016-12-22 2021-11-16 Università Degli Studi Magna Graecia Catanzaro Monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43
WO2019229701A2 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
WO2019234136A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
WO2020232399A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Compositions comprising hdac inhibitors and retinoids
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
WO2021026409A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
WO2021091953A1 (en) 2019-11-05 2021-05-14 Regeneron Pharmaceuticals, Inc. N-terminal scfv multispecific binding molecules
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2021178896A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
US11759527B2 (en) 2021-01-20 2023-09-19 Abbvie Inc. Anti-EGFR antibody-drug conjugates
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Also Published As

Publication number Publication date
EP2931316A1 (en) 2015-10-21
EP2931316B1 (en) 2019-02-20
US20150306240A1 (en) 2015-10-29
US9872918B2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
US20210106690A1 (en) Protein-polymer-drug conjugates
US10537645B2 (en) Protein-polymer-drug conjugates
EP2931316B1 (en) Hydroxyl-polymer-drug-protein conjugates
EP2928504B1 (en) Protein-polymer-drug conjugates
EP3054991B1 (en) Protein-polymer-drug conjugates
EP3054992B1 (en) Protein-polymer-drug conjugates
AU2012267447A1 (en) Protein-polymer-drug conjugates
US20180243427A1 (en) Tubulysin compounds and conjugates thereof
US20170119896A1 (en) Terminally modified polymers and conjugates thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13814764

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14651640

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013814764

Country of ref document: EP